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ABSTRACT 
Liver Disease is a rapidly rising cause of mortality and morbidity in the United Kingdom.  There is an 
urgent need for new therapies for liver disease, given that the only curative treatment is liver 
transplantation which is limited by organ availability.  A potential role of bone marrow stem cells as a 
novel therapy for liver disease has been proposed although understanding of the mechanisms 
involved in mediating both the anti fibrotic effect and the trafficking of cells to the liver are limited.  
In this thesis I have investigated the beneficial effect of a purified population of haematopoietic stem 
cells(HSC) in liver injury and studied mechanisms by which their effect may be optimised.  Firstly I 
confirmed the increased mobilisation and recruitment of HSC to the injured liver and demonstrated a 
significant anti fibrotic effect of repeated injections of HSC in   a murine model of liver injury.  
Observations from these studies suggested that stimulation of endogenous repair is the mechanism 
responsible.  Sphingosine 1-phosphate (S1P) has bee shown to mediate egress of HSC  from 
peripheral tissue into draining lymphatics, I have shown increased levels of S1P in both the blood and 
liver during liver injury, mediated by upregulation of sphingosine kinase 1.  The S1P receptor 
modulator FTY720 increased the hepatic accumulation of HSC during liver injury without altering HSC 
recruitment to the liver, suggesting reduced egress of HSC.  Ultimately I demonstrated that 
administration of FTY720 increased the hepatic retention of injected HSC  which was associated with 
an enhanced anti fibrotic action.  These studies provide encouraging evidence for the use of HSC in 
clinical studies and propose a mechanism by which the effect of this rare population of cells may be 
optimised. 
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1 INTRODUCTION 
 
1.1 Overview 
In the introduction to this thesis I will begin by describing the urgent need for new 
treatments for chronic liver disease given the rapidly rising mortality from end stage liver 
disease and the limitations of the currently available therapies.   I describe the 
characteristics of the liver, the changes that occur in liver disease and the current evidence 
for the reversibility of liver scarring.  I introduce the concept of using bone marrow derived 
stem cells to treat liver disease and discuss the studies to date that support the beneficial 
effect of such therapy and the proposed mechanisms underlying this.  I outline the 
characteristics of haematopoietic stem cells and our understanding of the mechanisms of 
tissue homing, concluding by discussing  trafficking of HSC and  the effect of modulation of 
sphingosine 1-phosphate signalling. 
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1.2 The Need for new therapies for Liver Disease 
The incidence of chronic liver disease is rapidly rising both in the United Kingdom and 
worldwide.  In the United Kingdom it is the fifth most common cause of death, and whilst 
the mortality from the leading causes of death (such as heart disease, stroke and cancer) has 
continued to fall over the past forty years, deaths from liver disease continue to rise at an 
alarming rate (Fig 1.1).  The average age of death from liver disease is 59 years compared 
with between 72 and 84 years for other leading causes of death.  The increase in cases of 
chronic liver disease is driven by the sharply rising rates of obesity and diabetes contributing 
to non alcoholic fatty liver disease, increases in alcohol related liver disease particularly 
amongst younger age groups than in the past and a rise in the number of cases of chronic 
hepatitis C infection(Leon et al. 2006; UK Chief Medical Officer 2012). 
At present there are no established treatments for end stage liver disease other than 
replacement of the damaged organ through liver transplantation.  The major limitation of 
liver transplantation remains supply of donor organs, whilst the need for transplantation 
continues to increase year on year the number of suitable donor livers for transplantation 
has not risen to meet demand.  Each year only 50-60% of patients on the liver transplant 
waiting list receive a transplant, with significant numbers of patients dying or deteriorating 
whilst on the waiting list(NHS Blood and Transplant 2012).   Liver transplantation carries 
significant peri-operative risk, so not all patients with end stage liver disease can be 
considered for a transplant particularly those who are older or who have other medical 
problems.  Post operatively transplant recipients are at increased risk of kidney disease, 
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heart disease and the complications of taking immunosuppressant medications (Lucey et al. 
2013). 
The current management of chronic liver disease is predominantly aimed at preventing and 
treating the complications, such as ascites and variceal bleeding (D'Amico et al. 2006).  
Whilst the management of the complications of liver disease has improved over time 
(Garcia-Pagan et al. 2008), it remains the case that there are no effective treatments that 
can reverse the underlying liver damage. 
Given the rapid rise in liver disease and the lack of widespread effective treatments there is 
clearly an urgent need for newer therapies for liver disease, that can prevent or reverse the 
progression of chronic liver disease and provide an alternative to liver transplantation. 
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Figure 1.1  Rising Mortality from Liver Disease 
Change in mortality from 1971 to 2008 in the six commonest causes of death in the United 
Kingdom (Reproduced from Health Service Quarterly (Office for National Statistics, Winter 
2008)) 
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1.3 Liver Disease 
1.3.1 The Normal Liver 
The liver is the largest solid organ in the body and is vital to both maintaining homeostasis 
and responding at times of stress.  It is crucial to several hundred vital metabolic functions 
including the synthesis and excretion of bile acids, glucose metabolism through 
glycogenolysis and gluconeogenesis, metabolism of nitrogenous waste products, cholesterol 
metabolism, plasma protein synthesis and steroid hormone metabolism.  Additionally the 
liver has vital roles in clearing toxins from the bloodstream and regulating the immune 
system(Dooley 2011). 
The liver is closely associated with the gastrointestinal tract and possesses a unique dual 
blood supply whereby approximately 80% of blood enters the liver through the portal vein 
and 20% through the hepatic artery (Fig1.2A).    The portal vein drains blood from the GI 
tract, spleen and pancreas and supplies low pressure venous blood which is high in nutrient 
and toxin content and low in oxygen content.  The hepatic artery arises from the celiac axis 
and supplies high pressure oxygenated blood.  After entering the liver, these vessels divide 
into smaller branches until the terminal branches come together at portal tracts where the 
blood is mixed and enters the hepatic sinusoids.   Blood drains from the sinusoids into 
central venules which come together to form the hepatic veins which drain into the inferior 
vena cava(Fig 1.2B)(Dooley 2011). 
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Figure 1.2  Anatomy of the Human Liver 
Diagrammatic representation of the macroscopic and microscopic anatomy of the human 
liver, indicating (A)blood supply, (B)lobule structure and (C)sinusoidal anatomy (Reproduced 
from Anatomy & Physiology,OpenStax-CNX6/19/2013 http://cnx.org/content/col11496/1.6) 
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The liver produces approx 25-50% of the lymph flowing through the thoracic duct 
(Barrowman et al. 1984; Barrowman 1991) and in common with many other organs the 
lymphatic vessels are responsible for both tissue drainage and immunological control 
(Ohtani et al. 2008; Othani 2008).  The hepatic sinusoids are the predominant source of 
hepatic lymph fluid. Fluid within the space of Disse passes through channels of interstitial 
space, between sinusoidal endothelial cells and hepatocytes and enters the interstitial space 
of either the portal tract or the sublobular veins.  Fluid and migrating cells within this 
interstitial space enter prelymphatic and then lymphatic vessels(Ohtani et al. 2003; Ohtani et 
al. 2008).  Increased portal lymph flow has been observed in patients with liver 
disease(Ludwig et al. 1968; Witte et al. 1969) and up to 30-fold increases in lymph flow have 
been demonstrated in cirrhotic rats, which correlated well with portal pressure (Barrowman 
et al. 1984). 
The hepatic sinusoids represent the functional units of the liver and consist of 
interconnecting plates of hepatocytes lined on the basolateral surface by specialised 
fenestrated endothelial cells; this creates the space of Disse which allows direct contact 
between sinusoidal blood and hepatocytes.  At the apical surface of the hepatocytes, bile 
canaliculi are formed which drain into terminal branches of the biliary tree lined by 
specialised epithelial cells called cholangiocytes.  These bile ductules drain into larger ducts 
and eventually into the common hepatic duct leaving the liver and draining into the common 
bile duct (Fig1.2C)(Dooley 2011). 
Hepatocytes make up about 80% of the total liver volume and large, polygonal cells.  High 
numbers of mitochondria mean that they are the key metabolic cell within the liver and are 
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responsible for the vast majority of the functions of the liver.  The fenestrations of the 
sinusoidal endothelium  ensure that the basal surface of hepatocytes can be in direct contact  
with blood containing nutrients and toxins in the space of Disse, and microvilli on the surface 
membrane increase the surface area available for exchange of solutes(Fig 1.3A)(Dooley 
2011). 
Hepatic sinusoidal endothelial cells are characterised by the presence of open fenestrations 
and the absence of tight junctions between cells, thus allowing the entry of blood into the 
space of Disse and direct contact with hepatocytes (Fig1.3A).  Functionally these cells 
possess the ability to endocytose waste products and toxins and to upregulate surface 
adhesion molecules at times of injury or inflammation to enhance cellular recruitment to the 
liver (Smedsrod et al. 1994; Lalor et al. 2002; Edwards et al. 2005). 
Kuppfer cells are liver resident macrophage present in the space of Disse in association with 
the endothelial cells (Fig1.3A).  Their function is to phagocytose bacteria and cellular debris 
from sinusoidal blood and also regulate hepatic inflammation and regeneration through 
production and secretion of soluble mediators such as cytokines and chemokines (Matsuoka 
et al. 1990; Duffield 2003; Fallowfield et al. 2007). 
Hepatic stellate cells possess intracytoplasmic stores of vitamin A and retinoids, and are 
located within the space of Disse where they regulate turnover of the extra cellular matrix 
(Fig1.3A).  During liver injury these cells become activated and transdifferentiate into 
fibrogenic cells called hepatic myofibroblasts.  The specific role of these cells in the 
pathogenesis of liver disease will be further discussed(Matsuoka et al. 1990; Friedman 2008; 
Henderson et al. 2008). 
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The liver of a mouse is proportionally larger than that of a human, comprising approximately 
6% of total body weight compared with approximately 2% in a human.   It is made up of 4 
anatomically distinct lobes – medial, left, caudate and right which is subdivided into cranial 
and caudal segments.   The mouse liver possess the same dual blood supply as the human 
liver, together with a biliary drainage system to the intestine and a gall bladder(Hollander et 
al. 1987). 
The microscopic appearances of the murine liver are similar to that of human liver.  Portal 
areas containing a portal vein branch, hepatic artery branch and a  bile ductule can be 
identified, with hepatocytes arranged in plates radiating from central venules towards the 
portal areas and separated by sinusoidal capillaries demonstrating the same lobular 
arrangement as seen in humans(Hollander et al. 1987). The cellular composition of the 
mouse liver is also similar to that of humans with hepatocytes comprising approximately 
55% of total cell numbers, Kuppfer cells 18%, Hepatic Stellate cells 8% and liver sinusoidal 
endothelial cells 22% (Baratta et al. 2009). 
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1.3.2 Pathophysiology of Hepatic Fibrosis and Cirrhosis 
The development of hepatic fibrosis and cirrhosis represents the common end result of 
chronic liver injury regardless of the underlying aetiology.  Examples of injurious agents 
resulting in repeated hepatocyte damage include the toxic effects of excessive alcohol 
consumption, chronic viral infection or sustained auto immune injury.  The 
pathophysiological process of cirrhosis is common to all causes of chronic liver disease and 
results in (i) a disordered scarred hepatic architecture with associated intrahepatic 
resistance (portal hypertension) leading to the clinical manifestations of varices, ascites and 
encephalopathy and (ii) loss of hepatocyte mass resulting in failure of hepatic synthetic 
function(D'Amico et al. 2006). 
Hepatic injury results in the release of inflammatory mediators (such as reactive oxygen 
species and Transforming Growth Factor β)(Parola et al. 2001) from necrotic and apoptotic 
hepatocytes, cholangiocytes  and endothelial cells (Jaeschke 2002),this results in the 
activation of liver resident cells of the innate immune system and recruitment of additional 
inflammatory cells, such as macrophages and neutrophils via upregulation of adhesion 
molecules on sinusoidal endothelial cells and secretion of pro inflammatory and pro fibrotic 
cytokines (including TGFβ, IL-1β, Platelet Derived Growth Factor, CCL2)(Friedman 2008; 
Ramachandran et al. 2012).  Pro fibrogenic cytokines released by apoptotic hepatocytes, 
activated kupffer cells and recruited inflammatory cells promote activation of hepatic 
stellate cells into activated hepatic myofibroblasts which is associated with loss of vitamin A 
stores and expression of αSMA(Friedman 2008; Friedman 2008; Ramachandran et al. 2012).   
Activation results in the acquisition of key properties which contribute to fibrogenesis – 
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most importantly a direct contribution to hepatic fibrosis through increased production and 
secretion of collagens I,III and IV (Fig1.3B)(Schuppan 1990; Bataller et al. 2005).  This 
increased collagen production is accompanied by increased expression of tissue inhibitors of 
metalloproteinases (TIMPs), enzymes which are responsible for the breakdown of 
components of the extracellular matrix (ECM) under normal circumstances, the resulting 
effect of this is a shift in the balance between TIMP and matrix metalloproteinases (MMPs) 
in favour of ECM accumulation(Bataller et al. 2005; Friedman 2008).  Increases in ECM 
further promote hepatic stellate cell activation, survival and proliferation.  Activated 
myofibroblasts secrete inflammatory and fibrogenic cytokines and chemokines (such as 
PDGF, MCP1, IP10 and VEGF) which further promote the proliferation and migration of 
myofibroblasts and other inflammatory cells which results in an amplification of the 
fibrogenic process (Fig 1.3B)(Bataller et al. 2005).  The deposition of collagen and 
accumulation of ECM results in the development of bridging fibrosis and eventually fibrous 
septae and regenerative hepatic nodules which distort the hepatic parenchyma and disrupt 
hepatic blood flow(Friedman 2008).  This results in the development of portal hypertension 
which underlies the clinical complications of ascites, varices and encephalopathy, and 
ultimately hepatic synthetic failure(D'Amico et al. 2006). 
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Figure 1.3 Changes in the Hepatic Architecture in Liver Fibrosis 
(A) Architecture of normal liver demonstrating structural relationship between hepatocytes 
and sinusoidal endothelial cells creating the space of Disse containing hepatic stellate cells 
and normal sinusoidal lumen. (B) During liver injury inflammatory lymphocytes, apoptotic 
hepatocytes and activated Kupffer cells release fibrogenic mediators resulting in phenotypic 
activation of  hepatic stellate cells to fibrogenic myofibroblasts resulting in deposition of 
ECM, capilliarisation of the sinusoidal lumen and increased resistance to luminal blood flow. 
(Reproduced from Bataller et al, J Clin Invest. 2005;115(2):209-218) 
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1.3.3 Reversibility of Hepatic Fibrosis and Cirrhosis 
Historically the progression of hepatic fibrosis to cirrhosis was thought to be a relentless 
unidirectional process, however it is now recognised that this is not the case and that there 
is evidence from both animal models and humans that hepatic fibrosis is a reversible process 
with both progression and resolution possible.  Clinical trials of new drugs for the treatment 
of chronic hepatitis B (HBV) and C (HCV) have demonstrated resolution of fibrosis in large 
numbers of patients in liver biopsies taken before and after treatment(Ellis et al. 2012).  
Furthermore treatment or removal of the toxic insult has been shown to improve hepatic 
fibrosis in alcohol related liver disease(Pares et al. 1986), autoimmune hepatitis(Dufour et al. 
1997), biliary obstruction (Hammel et al. 2001)and non alcoholic fatty liver disease(Ellis et al. 
2012).  Reports of the reversibility of fully established cirrhosis have been less frequent, but 
in one series of 113 patients with cirrhosis due to either chronic HCV, chronic HBV or 
autoimmune hepatitis 12.4% of patients showed regression of cirrhosis after treatment with 
antiviral or immunosuppressive medications (Serpaggi et al. 2006).   In an experimental 
rodent model using carbon tetrachloride to induce liver injury, fibrosis which had developed 
after 8 weeks treatment resolved almost completely after withdrawal of the injury.  After 12 
weeks injury cirrhosis had developed, which only partially resolved after removal of 
injury(Issa et al. 2004). 
The resolution of hepatic fibrosis is dependent upon two key processes, the degradation of 
collagenous scar tissue and a reduction in activated hepatic myofibroblasts through 
apoptosis(Iredale et al. 1998) or reversion to a quiescent stellate cell phenotype(Kisseleva et 
al. 2012).   
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Macrophages have been shown to play a critical role in the progression and resolution of 
hepatic fibrosis, and both pro- and anti- fibrotic macrophage phenotypes have been 
described (Ramachandran et al. 2012).  Duffield and colleagues used a CD11b-DTR 
transgenic mouse model which allowed selective depletion of macrophages at different 
timepoints during the progression and resolution of hepatic fibrosis.  They were able to 
demonstrate that depletion of macrophages during the progression of fibrosis resulted in 
lower levels of fibrosis and reduced numbers of activated myofibroblasts, but that  
macrophage depletion during resolution of fibrosis impaired the recovery of fibrosis(Duffield 
et al. 2005).   During the progression of hepatic fibrosis direct cellular contact between 
collagen I in the ECM and activated myofibroblasts promotes myofibroblast survival(Bataller 
et al. 2005). Direct contact between macrophages and myofibroblasts may result in 
myofibroblast apoptosis, as pro apoptotic signals (such as MMP-9, TRAIL and NGF) are also 
released from infiltrating macrophages or regenerating hepatocytes(Elsharkawy et al. 2005; 
Iredale 2008).  During resolution of fibrosis, macrophages within the liver  are derived from 
both liver specific Kupffer cells and circulating cells from the bone marrow (Duffield et al. 
2005)and are localised to areas of hepatic scar(Duffield et al. 2005; Fallowfield et al. 2007).  
Fallowfield et al demonstrated that these scar associated macrophages express both MMP-9 
and MMP-13 capable of degrading collagenous fibrotic scar tissue, and showed failure of 
resolution of fibrosis in MMP-13 deficient mice(Fallowfield et al. 2007).  Tissue inhibitor of 
metalloproteinase-1 (TIMP-1) acts to both inhibit the collagenolytic activity of MMP (Iredale 
et al. 1992; Iredale et al. 1996)and to prevent myofibroblast apoptosis(Elsharkawy et al. 
2005), which during the progression of fibrosis results in an accumulation of ECM fibrotic 
scar tissue.  During resolution of fibrosis levels of TIMP-1 and -2 are significantly lower 
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resulting in  a change in the balance between TIMP and MMP and a net degradation  of ECM 
scar tissue and an increased tendency towards myofibroblast apoptosis(Iredale et al. 1998; 
Issa et al. 2004). 
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1.4 Bone Marrow Stem Cells 
Adult bone marrow contains two major populations of stem cells, Haematopoietic Stem Cells 
and Mesenchymal Stem Cells.  Haematopoietic stem cells provide continual renewal and 
replacement of all blood cell lineages whilst Mesenchymal stem cells differentiate into cells 
of three lineages constituting skeletal tissue – fat, cartilage and bone. 
1.4.1 Haematopoietic Stem Cells 
Haematopoietic Stem Cells (HSC) were first described over 50 years ago(Till et al. 1961) and 
since then have become the most widely studied stem cell and have also been used 
extensively in clinical practice as part of the treatment for haematologic malignancies 
(Gratwohl et al. 2010).  HSC possess the typical properties of a stem cell – self renewal and 
potency.  They have the ability to differentiate into mature cells committed along specific 
lineages and are responsible for the continual replenishment of the constituent cellular 
components of the blood (Fig 1.4).  The ability for self renewal ensures one or both progeny 
retain the potential of the parent cell, thus ensuring a lifelong stem cell 
population(Siminovitch et al. 1963).  HSC reside within the bone marrow niche and can be 
subdivided into a smaller quiescent population in the endosteal region of the bone marrow 
(long term repopulating HSC) and a more frequently occurring, active, cell cycling population 
associated with the vascular endothelium of the bone marrow (short term repopulating 
HSC)(Kiel et al. 2005).  Although the bone marrow represents the primary niche for HSC, 
sites of other niches have been shown to include organs such as the liver, spleen and 
skin(O'Malley 2007; Miyata et al. 2008). 
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Haematopoietic multipotent progenitor cells represent the first descendant progeny of true 
HSC, and although lacking in the ability to self renew maintain the potential to differentiate 
into cells of all haematopoietic lineages.  Studies of both the therapeutic effects of HSC and 
the mechanisms involved in the trafficking of HSC have tended to use populations of cells 
enriched for both haematopoietic stem cells and haematopoietic progenitor cells rather 
than studying purely HSC which are present at very low frequency within the bone marrow 
(Muller-Sieburg et al. 1986; Mazo et al. 2011). 
HSC can be identified and isolated based upon cell surface marker expression, vital dye 
staining ability (eg Hoescht) and performance in functional cell assays(Purton et al. 2007).  In 
humans, surface expression of CD34 or CD133 have been used to identify populations of 
cells enriched for HSC (Civin et al. 1984).  In mice expression of the c-kit and sca-1 surface 
markers together with the absence of expression of lineage specific markers represent a 
population of cells enriched with both HSC and haematopoietic multipotent progenitor cells 
(Fig 1.4) (Wognum et al. 2003).  Further discrimination into long term repopulating HSC, 
short term repopulating HSC and HPC can be made according to expression of Flt3 and 
CD34(Wognum et al. 2003).   
Stem cell antigen 1 (sca-1) is a phosphatidylinositol- anchored protein, a member of the 
lymphocyte antigen 6 family(Lai et al. 1998) which identifies early haematopoietic stem and 
progenitor cells(Spangrude et al. 1988).  Sca-1 is found predominantly on undifferentiated 
cells but also regulates the activation of T- and B-cells (Rock et al. 1989).  c-kit, also known as 
Stem Cell Factor receptor or CD117, is a cytokine receptor found on haematopoietic stem 
cells but also on mast cells, thymocytes and common myeloid progenitor cells (Edling et al. 
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2007).  The binding of SCF to the receptor results in dimerisation and activation of intrinsic 
tyrosine kinase activity which phosphorylates signal transduction molecules controlling cell 
survival, proliferation and differentiation(Yarden et al. 1987; Edling et al. 2007). Lineage 
specific markers used to eliminate differentiated cells include Ter119 for erythroid cells, CD5, 
CD8a and CD45R for lymphoid cells and, Gr-1 and CD11b for myeloid cells. 
Identification using surface markers can have limitations, for example it has been shown that 
sca-1 can be upregulated on non-stem cells during inflammation(Malek et al. 1989; Purton et 
al. 2007).  The test of true HSC is the ability to reconstitute haematopoiesis in serial 
transplantation assays, ensuring that transplanted cells possess both self renewal and full 
haematopoietic potential, whilst colony forming cell (CFC) assays can be used as a test of 
haematopoietic potential alone (Purton et al. 2007; Mazo et al. 2011). 
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Figure 1.4 Differentiation of Haematopoietic Stem Cells 
Differentiation of long term repopulating HSC (LT-HSC) to short term repopulating HSC (ST-
HSC) and multipotent progenitors (MPP) is associated with progressive loss of self renewal 
capability, and in mice these populations of cells are defined by expression of c-kit and sca-1 
and absence of lineage marker expression (red box).  Mulitpotent progenitors differentiate 
into committed myeloid (CMP) or lymphoid progenitors (CLP) and eventually to terminally 
differentiated mature cells of the haematopoietic system. (Reproduced from Larsson and 
Karlsson, Oncogene 2005;24:5676-5692) 
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1.5 Bone Marrow Stem Cell Therapy for Liver Disease 
1.5.1 Contribution of the Bone Marrow to Liver Repair and Regeneration 
The first reports of the contribution of the bone marrow to liver regeneration came from 
Petersen and colleagues who performed sex mis-matched bone marrow transplants in mice 
undergoing liver injury(Petersen et al. 1999). In addition to the use of carbon 
tetrachloride(CCl4) to induce liver injury, mice also received 2-Acetyl-Aminofluorene(2-AAF) 
to suppress endogenous hepatocyte proliferation (which would be the expected mechanism 
of regeneration following CCl4 injury).  Notably, they demonstrated the presence of donor 
(bone marrow) derived hepatocytes in the livers of transplanted animals(Petersen et al. 
1999).  This was subsequently corroborated by other groups who infused wild type bone 
marrow into  fumarylacetoacetate hydrolase deficient mice (FAH-/-) mice. In this model 
transplanted wild-type BM cells were able to generate FAH-expressing hepatocytes and 
improve the liver function and survival of the FAH deficient mice(Petersen et al. 1999; 
Lagasse et al. 2000; Theise et al. 2000; Wang et al. 2003).   
In contrast to these initial reports suggesting that bone marrow cells made a significant 
contribution to the hepatocyte population of the liver, Wagers et al demonstrated that in 
irradiated mice receiving  GFP tagged, single stem cell transplants, detection of donor-
derived hepatocytes was an extremely rare event despite full reconstitution of the bone 
marrow by GFP positive cells(Wagers et al. 2002), whilst subsequently other studies have 
also shown a negligible contribution of BM cells to hepatocyte repopulation (Kanazawa et al. 
2003; Li et al. 2012).   
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In the absence of a significant survival advantage, such as in metabolic liver disease, it is 
likely that the contribution of bone marrow derived cells to the hepatocyte population is 
limited and unlikely to be of significant clinical relevance.   
The progression of liver disease not only results in liver failure due to hepatocyte death but 
also in the deposition of fibrous matrix leading to the development of cirrhosis resulting in 
portal hypertension and its clinical complications.   To investigate the contribution of bone 
marrow derived cells to the development of hepatic fibrosis, Forbes and colleagues 
examined fibrotic liver tissue from a) male patients who had received a liver transplant from 
a female donor and b) a female patient who had received a bone marrow transplant from a 
male donor.   Y-chromosome positive cells with a myofibroblast phenotype (αSMA+, 
vimentin+, CD45-) were observed within the fibrotic livers suggesting that scar forming cells 
in liver fibrosis may originate from the bone marrow(Forbes et al. 2004).  A subsequent 
animal study utilising sex mismatched bone marrow transplants also observed bone marrow 
derived hepatic stellate cells and myofibroblasts in the livers of mice with hepatic 
fibrosis(Russo et al. 2006).   
In contrast however, Higashiyama et al transplanted bone marrow from transgenic mice 
with a collagen reporter (GFP or luciferase) into wild type mice and induced liver fibrosis 
with carbon tetrachloride or bile duct ligation and found no significant contribution of BM to 
myofibroblasts in the fibrotic livers of the recipients(Higashiyama et al. 2009).  A further 
study also failed to find any significant number of BM derived cells amongst the 
myofibroblast population of fibrotic livers(Paredes et al. 2012).   
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Further evidence for the role of bone marrow cells in the response to liver injury is 
suggested by the significant mobilisation of cells from the bone marrow into the circulation 
following regenerative stimuli such as hepatic resection or transplantation(De Silvestro et al. 
2004; Lemoli et al. 2006; Gehling et al. 2010), and during acute or chronic liver 
injury(Ghanem et al. 2012; Wan et al. 2013).   Kollet and colleagues demonstrated 
mobilisation and homing of human CD34+ bone marrow cells to the liver in the NOD/SCID 
mouse during carbon tetrachloride induced chronic liver injury.  A similar finding was 
observed following direct hepatic injection of the cytokine SDF-1, which is upregulated in 
liver injury, and which was abrogated by a CXCR4 neutralising antibody(Kollet et al. 2003). 
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1.5.2 The Anti Fibrotic potential of Bone Marrow Stem Cells in Liver Disease 
The observation that bone marrow may contribute to hepatic repair and regeneration lead 
to further study of the therapeutic benefits of bone marrow derived cells in liver injury.  
Sakaida and colleagues infused GFP+ bone marrow into mice with CCl4 induced chronic liver 
injury and demonstrated a significant reduction in liver fibrosis and improvement in serum 
albumin levels.  No clear mechanism or cell type responsible for this effect was determined 
but an increase in hepatic MMP9 expression was observed(Sakaida et al. 2004). Rather than 
infuse bone marrow cells into mice with liver injury, Yannaki et al administered GCSF to 
mobilise bone marrow cells into the circulation.  Using sex mismatched bone marrow 
transplants and CCl4 to induce either acute or chronic liver injury, they demonstrated that 
administration of GCSF reduced the severity of the liver injury and improved survival but 
that this was mediated through stimulation of endogenous repair mechanisms rather than 
engraftment and differentiation of bone marrow derived cells(Yannaki et al. 2005).  
However, the evidence for a beneficial effect of bone marrow cells in liver injury is not 
consistent, Quintanilha et al infused bone marrow cells into rats with chronic CCl4 liver injury 
and failed to show any improvement in fibrosis either during or after the onset of 
injury(Quintanilha et al. 2008).  Furthermore, in a recent study Thomas et al showed that in 
mice with chronic liver injury, infusions of unsorted whole bone marrow cells worsened 
hepatic fibrosis(Thomas et al. 2011).  Bone marrow contains a heterogeneous population of 
cells, including both haematopoietic and mesenchymal stem cells, progenitor cells at varying 
stages of differentiation and mature, fully differentiated cells therefore the varying 
outcomes seen in these studies is perhaps not surprising.  Despite the lack of clarity 
regarding the beneficial effects of bone marrow cells, and in particular the cell type 
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responsible for these effects, attempts have been made to optimise the performance of 
bone marrow cell infusion to improve hepatic injury.  Bone marrow cells cultured in serum 
free media for 14 days reduced liver fibrosis and improved serum albumin in a CCl4  model of 
liver injury, although the infused cells consisted mainly of cultured macrophages and 
mesenchymal stem cells(Iwamoto et al. 2013).  A further study of cultured bone marrow 
cells found that after passage two, 94% of the cells were mesenchymal stem cells and 
infusion of these cells resulted in a significant reduction in hepatic fibrosis(Tanimoto et al. 
2013). Splenectomy followed by bone marrow cell infusion in mice with chronic liver injury 
resulted in higher numbers of cells within the liver and an improved therapeutic 
effect(Iwamoto et al. 2012).  Interestingly when bone marrow cells for infusion were 
harvested from animals with chronic liver injury, no beneficial effect on liver injury was 
observed(Mannheimer et al. 2011).  This observation may be of particular relevance given 
that clinical studies to date have used autologous cells in patients with chronic liver disease. 
Cho et al examined the beneficial effects of three different approaches, G-CSF injection 
alone to mobilise bone marrow cells, infusion of bone marrow derived mononuclear cells 
and infusion of purified haematopoietic stem cells.  In this study there were significant 
reductions in hepatic fibrosis with similar benefits seen with both mononuclear cells and 
haematopoietic stem cells, whilst GCSF injections alone resulted in a significant but less 
marked reduction(Cho et al. 2011).  
Mesenchymal stem cells (MSC) infused into mice with chronic liver injury resulted in a 
reduction in liver fibrosis although very few cells were seen to engraft the injured 
liver(Rabani et al. 2010).  Zhao and colleagues examined the effects of MSC in rats with CCl4 
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induced chronic liver injury and found a significant reduction in mortality and hepatic fibrosis 
compared with controls.  Repeatedly infusing mesenchymal stem cells on 3 occasions gave 
rise to an improvement in survival and fibrosis when compared with a single injection of 
cells(Miryounesi et al. 2013). 
The relative beneficial effects of MSC and HSC on hepatic fibrosis in a chronic carbon 
tetrachloride model of liver injury in mice were compared in a study by Li and colleagues. 
They found that both survival and fibrosis improved in the MSC and HSC groups when 
compared with controls but that the effect of MSC was greater than that of HSC(Li et al. 
2013).  The authors proposed a synergistic effect for the two cell types, although 
administration of MSC alone was significantly better than a combined infusion of HSC and 
MSC. This study also confirmed a previous finding that MSC engraft the injured liver with a 
greater frequency than either purified HSC or bone marrow mononuclear cells(Cho et al. 
2009; Li et al. 2013). 
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1.5.3 Proposed Mechanisms responsible for the anti fibrotic effect 
Despite mounting evidence for the beneficial effects of bone marrow derived stem cells, the 
mechanisms by which these effects are mediated remain poorly understood and have not 
been well addressed in studies to date.   Initial reports suggesting that transdifferentiation of 
stem cells to hepatocytes was the predominant mechanism have largely been discounted as 
the frequency of hepatocyte production is extremely low and unlikely to account for the 
benefits observed.  Reports of transdifferentiation are variable and seem more likely to 
occur following infusion of unsorted bone marrow cells rather than more defined 
populations. 
The concept of bone marrow derived stem cells exerting a stimulatory effect on endogenous 
repair mechanisms is gaining increasing popularity as a likely mechanism. This is best 
described as a paracrine effect, which is defined as the ability of a cell to generate signals 
inducing changes in nearby cells.  In chronic liver injury the endogenous repair mechanisms 
are impaired by the inhibitory effect of scar tissue and replicative senescence following 
repeated injury(Fassett et al. 2003; Trak-Smayra et al. 2004).  
The anti-fibrotic effect of bone marrow derived stem cells has been reported to be 
accompanied by significant upregulation of matrix metalloproteinases in the injured liver, 
predominantly MMP-9 but also MMP-2 and MMP-13(Rabani et al. 2010; Roderfeld et al. 
2012; Iwamoto et al. 2013).  This has been observed following infusions of both HSC and 
MSC and reported to persist for up to 20 weeks following cell infusion(Roderfeld et al. 2012).  
Although increased MMP expression may mediate the anti fibrotic effect, the cellular source 
remains unclear.  Some have reported that increases in MMP-9 in the liver is derived from 
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donor cells(Sakaida et al. 2004; Higashiyama et al. 2007), whilst others have demonstrated 
MMP-9 derived from increased numbers of endogenous mononuclear cells recruited into 
the liver following cell infusion(Thomas et al. 2011; de Oliveira et al. 2012).   
The stimulatory effect of cytokines and growth factors released by infused cells may result in 
increased hepatocyte proliferation and stimulate hepatic progenitor cells whilst also 
reducing inflammatory cell infiltration.   Administration of GCSF, a cytokine produced by 
bone marrow derived stem cells, during liver injury resulted in the proliferation of 
endogenous hepatocytes rather than the production of new hepatocytes from bone marrow 
derived cells recruited to the liver(Yannaki et al. 2005). Increased levels of GCSF within the 
liver have been demonstrated following bone marrow cell infusion(Mizunaga et al. 2012), 
and increases in HGF and VEGF following cell infusion further suggest a beneficial role in 
hepatocyte proliferation and angiogenesis in improving liver injury(Asano et al. 2007; 
Nakamura et al. 2007).  Exogenously administered IL-10 has been shown to reduce fibrosis in 
an animal model and serum IL-10 levels have been reported to increase following cell 
infusion(Huang et al. 2006; de Freitas Souza et al. 2012).  Alterations in the infiltration of 
endogenous cells in the liver following cell infusion include a reduction in inflammatory 
cells(de Oliveira et al. 2012) and increases in reparative macrophage populations(Thomas et 
al. 2011).  Macrophages recruited into the liver may exert a direct anti fibrotic effect and 
also stimulate hepatic progenitor cell proliferation(Ramachandran et al. 2012; Bird et al. 
2013). 
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1.5.4 Clinical Studies of Bone Marrow Stem Cells in Liver Disease 
Although some considerable uncertainty remains in the pre-clinical work regarding the 
nature of the effect of bone marrow derived stem cell therapy, the most efficacious cell 
population and the exact mechanism of action, clinical trials of bone marrow derived stem 
cell therapy have moved forward rapidly since the first reports in 2005 (Fig 1.5).  Am Esch 
and colleagues reported the use of autologous CD133+ HSC in patients without intrinsic liver 
disease undergoing hepatic resection for predominantly metastatic disease.  The low 
residual liver volume in these patients (after a putative resection) would have precluded 
immediate surgery. All patients underwent selective portal vein embolisation to stimulate 
growth of the non occluded liver segments, followed by portal venous infusion of either 
autologous CD133+ HSC or saline control.  Strikingly they found that liver volume increased 
significantly quicker in patients who had received cells  compared with controls and surgery 
could be performed sooner in that group(am Esch et al. 2005; Furst et al. 2007).  This work 
has subsequently been replicated in a larger study with similar findings and, more 
importantly, improved long term survival in patients receiving infusion of stem cells with 
portal vein embolisation (am Esch et al. 2012). 
The initial reports of the use of BM derived stem cells in patients with chronic liver disease 
took alternative approaches to the method of cell isolation and route of delivery.   One study 
administered GCSF to patients with cirrhosis and collected bone marrow cells mobilised into 
the blood, isolated CD34+ HSC and infused these cells via the hepatic artery(Gordon et al. 
2006).  Alternatively, the investigators in another study directly harvested bone marrow cells 
from the iliac crest under general anaesthesia, selected out mononuclear bone marrow cells  
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Fig 1.5 Clinical Studies of Bone Marrow Stem Cells for Liver Disease  
Summary of published studies of mesenchymal stem cells, bone marrow derived cells and 
haematopoietic stem cells, indicating type of stem cell injected, number of patients included 
and information on outcomes following infusion. (Reproduced from Zhang and Wang, J 
Hepatology 2013;59(1):183-85) 
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and infused these cells via the portal vein(Terai et al. 2006).  Whilst both studies involved 
only small numbers of patients, 5 and 9 respectively, and lacked control participants, they 
demonstrated that this form of therapy appeared safe and feasible.  Clinical outcomes were 
reported in both studies and showed reduced serum bilirubin and improved serum albumin 
two months following cell infusion in the first study(Gordon et al. 2006) and improved serum 
albumin and Child Pugh score at six months in the second(Terai et al. 2006). These two initial 
studies highlight the significant number of variables involved in comparing these and 
subsequent studies.   Further small scale, uncontrolled studies have included variation in the 
patients enrolled (aetiology and severity of liver disease), the method of cell harvest (direct 
bone marrow aspiration or peripheral blood leukophereis), the type and number of cells 
infused (various populations from unsorted mononuclear cells to purified CD133+ HSC) and 
the route of cell infusion (hepatic artery, portal vein or peripheral vein)(Yannaki et al. 2006; 
Lyra et al. 2007; Mohamadnejad et al. 2007; Levicar et al. 2008; Pai et al. 2008; Lyra et al. 
2010).  The aim of many of these studies was to determine safety and feasibility and in that 
sense the outcomes were promising, however the size and nature of many of these 
subsequent studies meant that meaningful conclusions on clinical outcomes could not be 
made (Fig 1.5). 
In more recent small controlled trials Lyra and colleagues demonstrated significant 
improvements in liver function one year following infusion of bone marrow mononuclear 
cells into the hepatic artery when compared with untreated control patients(Lyra et al. 
2010). Ismail and colleagues examined the role of infusion of bone marrow mononuclear 
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cells prior to liver resection in cirrhotic patients with hepatocellular carcinoma and showed 
improved outcomes three months post operatively compared with patients undergoing 
resection alone(Ismail et al. 2010). 
Human studies of BM stem cell therapy have predominantly used either unsorted 
mononuclear cell preparations (consisting of cells of haematopoietic lineages) or cell 
populations enriched for HSC (eg CD34+ or CD133+).  The harvest and ex vivo isolation of HSC 
is a well established technique used extensively for the preparation of auto- or allo- grafts in 
patients with haematological malignancy.  The techniques used are well validated and 
processes conform to guidelines and standards for preparation of clinical grade 
products(Sutherland et al. 1996).  MSC represent a more heterogeneous population of cells 
than HSC and their isolation requires more intensive manipulation ex vivo, meaning that 
studies of these cells are more challenging to perform.  The reported studies of MSC have 
included differences in the variables previously discussed but also in the techniques used to 
define and isolate the cells. 
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1.6 Sphingosine 1-phosphate 
Sphingosine 1-phosphate (S1P), named in 1884 after the Greek mythological creature the 
Sphinx because of its enigmatic nature(Thudichum 1884) , is a bioactive sphingolipid 
metabolite derived from sphingomyelin via the sphingomyelinase pathway.   Sphingolipids 
are structural components of plasma membranes designed to protect the cell surface.  Initial 
reports described the role of S1P in regulating cell growth and suppressing apoptosis 
(Hannun et al. 2008), however further investigations have revealed its role as a intra-and 
extra-cellular signalling mediator involved in multiple cellular processes including cell growth 
and survival, regulation of cell motility and invasion, angiogenesis and vascular maturation, 
lymphocyte trafficking and immune regulation(Spiegel et al. 1993; Rivera et al. 2007). There 
is also evidence that S1P is important in the pathophysiology of diseases such as cancer, 
allergy, atherosclerosis and auto immune disease(Maceyka et al. 2012). Mechanisms by 
which S1P exerts its action include alterations in subcellular localisation, cellular import and 
export, protein binding and variation in receptor expression on target cells(Rosen et al. 
2009) (Olivera et al. 2013).  
1.6.1 Metabolism of S1P 
The ability of S1P to act as a cell signalling molecule relies on the generation of a S1P 
concentration gradient across cell membranes and between body compartments.  S1P has a 
short half life of only 15 minutes(Venkataraman et al. 2008) and its concentration in cells, 
tissues and fluids is governed by the balance between synthesis and degradation or export.  
Enzymes responsible for the synthesis of S1P are Sphingosine Kinase 1 and 2 and for the 
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reversible and irreversible degradation of S1P are Sphingosine Phophastase and Sphingosine 
Lyase respectively (Fig 1.6) (Takabe et al. 2008; Maceyka et al. 2012). 
Sphingosine kinase 1 and 2 (SphK1,2) catalyse the ATP dependent phosphorylation of 
sphingosine (an 18 carbon aliphatic amino alcohol breakdown product of sphingomyelin 
present in cell membranes (Rivera et al. 2008)).  SphK1 and SphK2 contain 5 conserved 
domains(Pyne et al. 2009) but differ in enzymatic activity, substrate preference, subcellular 
location and tissue distribution. (Liu et al. 2002; Pitson 2011).  SphK1 preferentially 
phosphorylates sphingosine and SphK2 is less selective and phosphorylates a larger number 
of substrates, including FTY 720 (Kharel et al. 2005; Don et al. 2007).  There is evidence of 
redundancy between the two enzymes as single SphK1 or SPhK2 knock out mice retain 
normal serum S1P levels and normal phenotype, whereas double knock out mice are 
embryonically lethal due to defects in the vascular system that are incompatible with life 
(Allende et al. 2004; Mizugishi et al. 2005; Takabe et al. 2008).  It has been proposed that 
SphK1 predominantly synthesizes S1P destined for cellular export and SphK2 generates S1P 
for use as an intracellular messenger(Johnson et al. 2002; Sensken et al. 2010; Olivera et al. 
2013) as the concentration of S1P in the blood of the SphK2 knock out mouse is higher than 
wild type mice due to increased cellular export after synthesis by SphK1(Olivera et al. 2013).  
S1P synthesis and secretion can be upregulated following exposure to a variety of cytokines 
and growth factors, including TNFα, LPS, PDGF and VEGF, resulting in translocation of SphK1 
to the cell membrane and increased enzymatic activity (Pitson et al. 2003; Pitson et al. 2005; 
Stahelin et al. 2005; Takabe et al. 2008). 
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Figure 1.6 Metabolism of Sphingosine 1-phosphate 
(Reproduced from Spiegel and Milsiten Nature Rev Mol Cell Biol 2003;4:397-407) 
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Sphingosine lyase (SphL) is a pyridoxal phosphate dependent enzyme present in the 
endoplasmic reticulum(Pyne et al. 2009; Olivera et al. 2013) which catalyses the irreversible 
degradation of S1P to hexadecanal and phosphoethanolamine (Bandhuvula et al. 2007).   It 
is present in a wide variety of cells and tissues (Bektas et al. 2010) but is absent from 
platelets and erythrocytes (Yatomi et al. 1997; Ito et al. 2007).  The S1P concentration in the 
serum and tissues of the SphL knock out mouse is up to 100 fold higher than wild type 
mice(Vogel et al. 2009; Bektas et al. 2010), demonstrating the importance of the enzyme in 
regulating S1P levels.  Sphingosine phosphatase(SphP) is also present in the endoplasmic 
reticulum and catalyses the reversible dephosphorylation of S1P back to 
sphingosine(Mandala et al. 1998; Le Stunff et al. 2002). 
The concentration of S1P within the blood is in the micromolar range and lower within the 
lymph.  Tissue concentrations have been harder to accurately determine within the 
literature and have been estimated in the low nanomolar or picomolar range (Schwab et al. 
2005; Pappu et al. 2007).  These significant differences result in the formation of an S1P 
gradient between tissue (including lymphoid tissue) with a low S1P concentration and blood 
and lymph with high S1P concentrations(Pappu et al. 2007; Olivera et al. 2013).   The 
difference is partly as a result of the differential cellular expression of sphingosine lyase, this 
enzyme is present in the majority of tissue resident cells and degrades tissue S1P to maintain 
low S1P levels (Stoffel 1970), whereas platelets and erythrocytes lack sphingosine lyase and 
therefore generate high S1P levels in the blood and lymph through the unopposed synthesis 
of S1P by sphingosine kinase (Ito et al. 2007).  Maintaining low tissue levels of S1P means 
that small, acute changes in S1P levels can result in alterations to cell behaviour mediated by 
S1P receptor signalling – Schwab and colleagues demonstrated a pivotal role for the S1P 
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gradient in lymphocyte trafficking.  Pharmacological inhibition of sphingosine lyase resulted 
in a significant elevation of the S1P concentration within lymphoid tissue which abolished 
the gradient between tissue and lymph and blocked the egress of lymphocytes from 
lymphoid tissue(Schwab et al. 2005). 
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1.6.2 Cellular Sources of S1P 
Whilst synthesis and degradation of S1P occurs in most mammalian cells and S1P acts as an 
intracellular signalling molecule, the generation of S1P gradients relies on the cellular 
synthesis and export from cells that are ‘net producers’ of S1P. 
Many of the cells within peripheral blood contribute to the production of S1P present at high 
levels within the blood.   Erythrocytes have been shown to be the main cellular source of S1P 
within the vasculature(Hanel et al. 2007; Pappu et al. 2007) and generate approximately half 
of the total blood S1P concentration (Ito et al. 2007). Erythrocytes have high sphingosine 
kinase activity (Yang et al. 1999; Camerer et al. 2009) and lack sphingosine lyase (Ito et al. 
2007). The release of S1P from erythrocytes occurs in a continuous, time dependent fashion 
and is not dependent upon cellular activation(Yang et al. 1999).  S1P release from 
erythrocytes is regulated by the ABCC family of membrane transporter proteins and 
transported in the plasma bound to albumin or high density lipoprotein (Takabe et al. 2008; 
Kobayashi et al. 2009).  Supporting evidence for  the major role of erythrocytes in S1P 
production have been the observations of a correlation in humans between the red blood 
cell concentration and S1P concentration (Ohkawa et al. 2008) and of lower S1P levels in the 
blood of anaemic patients than normal controls (Bode et al. 2010). 
Yatomi and colleagues demonstrated high levels of SphK activity and absence of SphL activity 
within mature platelets, resulting in high levels of storage of S1P(Yatomi et al. 1997).  In 
contrast to erythrocytes, the release of S1P from platelets is not continual but is dependent 
upon activation by a variety of platelet stimuli including thrombin, TPA (a protein kinase C 
activator) and collagen (Yatomi et al. 1997; Yang et al. 1999; Kobayashi et al. 2009).   The NF-
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E2 (a transcription factor required for normal platelet formation(Shivdasani et al. 1995)) 
knockout mouse lacks circulating platelets yet maintains normal blood S1P levels (Pappu et 
al. 2007) It has been proposed that platelets do not contribute significantly to circulating 
levels of S1P under conditions of normal homeostasis, but that in response to tissue injury or 
inflammation activated platelets release stored S1P(Kim et al. 2009; Olivera et al. 2013).  
Yang et al have shown that cell preparations of neutrophils and mononuclear cells (mainly 
lymphocytes) possess potent sphingosine kinase activity and that uptake and conversion of 
radiolabelled sphingosine to S1P in vitro occurred rapidly and with similar efficiency to both 
platelets and erythrocytes.  The synthesis and release of S1P from both neutrophils and 
mononuclear cells was also independent of cellular stimulation or activation(Yang et al. 
1999). 
The role of endothelial cells in the maintenance of S1P gradients is vital as they are a direct 
barrier between varying concentrations of S1P (Olivera et al. 2013).  Their unique structure 
and location means these cells can generate S1P to be exported into blood or lymph via the 
luminal surface or into tissue via the parenchymal surface.  Endothelial cells have been 
shown to express all the enzymes responsible for S1P metabolism providing them with 
another regulatory role, for example activation of endothelial cells by exposure to shear 
stress resulted in upregulation of SphK and down regulation of SphL and SphP with the net 
effect being the increased secretion of S1P (Venkataraman et al. 2008).   Venkataraman and 
colleagues showed that SphK1 knockout mice have lower blood S1P levels than wild type 
mice, however injection of SphK1 expressing adenoviral particles resulted in SphK1 
expression in liver sinusoidal endothelium and restored blood S1P levels back to those of 
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wild type mice(Venkataraman et al. 2008).  Pappu et al transplanted bone marrow cells from 
SphK 1/2 knock out  fetal mice into irradiated wild type mice and despite the blood cells in 
these mice not having the ability to produce S1P, the blood concentration of S1P remained 
adequate(Pappu et al. 2007). Recently Fukuhara et al have elucidated that the membrane 
protein Spns2 is responsible for the extracellular secretion of S1P (Fukuhara et al. 2012). 
They showed that spns2 knock out mice have lower blood S1P concentration than wild type, 
and that  an endothelial cell specific knock out mouse had low blood S1P concentration 
despite adequate production and secretion by blood cells, concluding that production and 
secretion of S1P by endothelial cells is responsible for a significant proportion of the blood 
S1P concentration(Fukuhara et al. 2012). 
 
 
 
 
 
 
 
 
 
1.6.3 S1P Receptor Signalling 
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S1P is currently recognised to act as both an intracellular and extracellular signalling 
molecule, however until recently it was thought to be solely an intracellular messenger 
(Zhang et al. 1991; Olivera et al. 1993; Fyrst et al. 2010).  Cell stimulation by growth factors 
and cytokines (Xia et al. 1998; Xia et al. 1999) increases intracellular sphingosine kinase 
activity resulting in increased intracellular S1P concentrations, however the intracellular 
signalling target for S1P remains unclear(Sanchez et al. 2004; Blaho et al. 2014).  
 In 1998 Lee and colleagues recognised that S1P was the ligand for the orphan receptor 
Endothelial Differentiation Gene 1 (EDG1) resulting in its reclassification as Sphingosine 1 
Phosphate Receptor 1 (S1P1) (Lee et al. 1998).  Further members of the EDG family were 
subsequently found to bind S1P with high affinity and renamed as S1P2 (EDG5), S1P3 
(EDG3), S1P4 (EDG6) and S1P5 (EDG8)(Chun et al. 2002).  All five S1P receptors  structurally 
consist of an NH2 terminus and seven transmembrane domains with hydrophilic intracellular 
and extracellular loops(Sanchez et al. 2004).Extracellular binding of S1P to surface receptors 
results in activation of intracellular signalling pathways mediated by G protein 
coupling(Takabe et al. 2008; Blaho et al. 2014). 
The wide variety of diverse physiological functions regulated by S1P are all mediated through 
S1P receptor signalling(Sanchez et al. 2004).  This is achieved by variable expression of 
receptor subtypes, differential levels of expression and differential G protein coupling across 
different cells and tissues(Sanchez et al. 2004).  For example amongst haematopoietic cells, 
S1P1 is widely expressed (Rivera et al. 2008)whilst S1P4 is found on T lymphocytes(Wang et 
al. 2005), S1P2 on mast cells and macrophages(Kurashima et al. 2007), S1P5 on NK 
cells(Jenne et al. 2009)  and S1P3 and S1P5 on dendritic cells (Czeloth et al. 2005).   Whilst 
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S1P1 is crucial for immune cell migration(Matloubian et al. 2004), its role in mediating 
functions such as angiogenesis and vascular tone is revealed by the observation that the 
S1P1-/- knockout mouse is embryonically lethal due to failure of blood vessel formation (Liu 
et al. 2000). 
The role of S1P receptors in regulating cell migration and trafficking has been well studied, 
particularly in cells of the immune system(Schwab et al. 2007).  S1P1 signalling controls 
egress of T and B cells from secondary lymphoid organs and egress of thymocytes from the 
thymus (Matloubian et al. 2004; Allende et al. 2008).  Mobilisation of both antibody 
secreting plasma cells from the spleen and B cells from Peyers patches  to the blood is also 
dependent on S1P1(Gohda et al. 2008; Kunisawa et al. 2008). In contrast, NK cell migration 
from bone marrow into the blood is regulated by S1P5(Walzer et al. 2007).  As previously 
discussed the role of S1P1 in controlling the egress of HSC from peripheral tissues into 
draining lymphatics has been recently described(Massberg et al. 2007). 
Expression of S1P receptors by haematopoietic stem cells has been described as variable on 
human CD34+ HSC, with S1P1 the only consistently expressed receptor in a study by Kimura 
et al (Kimura et al. 2004)whilst Massberg demonstrated expression of S1P1-4 on murine HSC 
(Massberg et al. 2007). Migration of HSC to S1P in vitro is similar in both human and murine 
cells with a dose dependent response(Kimura et al. 2004; Massberg et al. 2007; Ratajczak et 
al. 2010) however at high concentrations of S1P, migration is inhibited.  The exact 
mechanism behind these observations is not clear but it has been postulated that exposure 
to S1P results in downregulation of S1P1 thus impairing migration(Rivera et al. 2008), 
alternatively at higher concentrations of S1P, receptor signalling is mediated by S1P2 which 
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exerts an inhibitory effect on cell migration(Ratajczak et al. 2010).  More recently the 
observation that S1P is a chemokine for HSC has lead to further investigation into its role in 
HSC mobilisation and trafficking.  There is growing evidence that S1P has a role in HSC 
mobilisation from the bone marrow into peripheral blood (Ratajczak et al. 2010; Golan et al. 
2012; Juarez et al. 2012).  Golan and colleagues demonstrated that the mobilising cytokine 
GCSF alters S1P levels within the blood thus promoting mobilisation (Golan et al. 2012)and 
Ratacjzak showed that the increase in S1P following GCSF administration was due to 
complement activation with membrane attack complex mediated erythrocyte lysis(Ratajczak 
et al. 2010).  Juarez et al showed that S1P signalling alone did not promote mobilisation but 
that an S1P receptor agonist together with a CXCR4 antagonist resulted in effective HSC 
mobilisation without the need for GCSF(Juarez et al. 2012).  
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1.6.4 S1P Receptor Agonists/Antagonists 
FTY720 was the first described modulator of S1P receptors, and was first used as an 
immunosuppressive agent (Brinkmann et al. 2002; Mandala et al. 2002).   FTY720 is 
phosphorylated in vivo by sphingosine kinase 2 to form FTY720-phosphate (FTY720-P) (Billich 
et al. 2003; Don et al. 2007),  which is structurally similar to S1P(Sanchez et al. 2004).   
FTY720 is an agonist at S1P1, 3, 4 and 5 as it binds and activates these receptors, however 
subsequent irreversible downregulation and ubiquitin dependent proteosomal degradation 
of S1P1 renders cells unresponsive to S1P (Oo et al. 2007).  In this way FTY720 acts as a 
functional antagonist to S1P receptors (Fig 1.7). 
Administration of FTY720 induces a rapid and reversible lymphopenia (Mandala et al. 2002), 
with lymphocytes sequestered into secondary lymphoid organs (Schwab et al. 2005).  It does 
not induce any directly toxic effects on lymphocytes nor affect the total numbers of 
lymphocytes within the body making  it an excellent potential immunosuppressive drug 
(Brinkmann et al. 2002).  In vivo, FTY720 significantly improved outcomes in mice with 
experimental autoimmune encephalitis and has shown excellent promise (as the drug 
Fingolimod) in clinical trials for patients with multiple sclerosis (Brinkmann et al. 2010).  
 W146 is a competitive antagonist specific for the S1P1 receptor(Sanna et al. 2006).  In 
contrast to FTY720, which induces S1P receptor internalisation and degradation rendering 
cells unresponsive to S1P, W146 directly blocks the effects of both S1P and FTY720 at the 
S1P1 receptor (Fig 1.7)(Tarrason et al. 2011). In vivo, W146 induces a peripheral 
lymphopenia in mice through sequestration of lymphocytes in lymph nodes(Tarrason et al. 
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2011) and also causes vascular capillary leakage, particularly in the lungs resulting in lung 
oedema (Sanna et al. 2006). 
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Fig 1.7 Mechanism of Action of S1P Receptor Agonists and Antagonists 
(A) S1P activates S1P1 resulting in receptor internalisation, down stream G protein coupled 
signalling and subsequent surface recycling.  (B) FTY720-P acts as a functional antagonist 
through internalisation and ubiquitin dependent degradation of S1P1 without downstream 
signalling or surface recycling, rendering cells unresponsive to S1P. (C) W146 is a competitive 
antagonist specific for S1P1, blocking activation of S1P1 by S1P. (Adapted from Obintata and 
Hla, Chemistry and Biology 2012;19:1080-81) 
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1.7 Haematopoietic Stem Cell Trafficking 
1.7.1 HSC Mobilisation and Recruitment 
The trafficking of HSC between different body compartments and organs occurs initially 
during the embryonic development of haematopoesis(Mazo et al. 2011).   HSC are initially 
found within the fetal liver, which is the predominant site of fetal haematopoiesis, 
subsequently colonisation of the thymus and spleen occurs(Djaldetti et al. 1972; Jenkinson 
et al. 2006).  The bone marrow is the primary site of adult haematopoiesis and is colonised 
by HSC derived from the fetal liver prior to birth, at which point fetal liver HSC become 
quiescent and do not significantly contribute to haematopoiesis (Christensen et al. 2004; 
Bowie et al. 2006). 
Wright and colleagues described the continuous exchange of HSC between the bone marrow 
and peripheral blood and estimated that approximately 400 single HSC were present in the 
peripheral blood of a mouse at any one time (Wright et al. 2001).  HSC have also been 
detected in various organs other than the bone marrow including the liver, lungs, 
gastrointestinal tract, kidney, thymus and skin(Wright et al. 2001; Sackstein 2004; Massberg 
et al. 2007; Zlotoff et al. 2011).  Following systemic injection HSC were largely undetectable 
within the peripheral blood and were distributed widely in varying organs, with only 1-2% of 
the injected cells detectable in the bone marrow and 4% within the peripheral blood at 6 
minutes after injection compared with 7% in the liver and 12% in the lungs (Wright et al. 
2001). 
HSC reside mainly in specialised niches within the bone marrow where cytokines, 
chemokines and growth factors control cell proliferation, differentiation, self renewal and 
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survival(Adams et al. 2006; Officer 2012) thus maintaining a regenerative pool of HSC in  a 
quiescent state (Fortunel et al. 2003). 
 The presence of HSC in peripheral blood has been demonstrated and that there is a 
constant exchange of HSC between the BM and the peripheral circulation(Wright et al. 2001; 
Massberg et al. 2007) with approximately 400 HSC in the murine peripheral circulation at 
any one time (Wright et al. 2001).   Circulating HSC re-engraft the BM in the absence of 
either myelosuppression or inflammation and is important in maintaining haematopoietic 
homeostasis(Wright et al. 2001).   
The ongoing exchange of HSC between blood, bone marrow and other organs is an 
important homeostatic mechanism under normal physiological conditions (Mazo et al. 
2011). Furthermore it has been shown in various animal models that tissue injury and 
inflammation increase trafficking of HSC to the injured tissue where differentiation into 
effector cells can occur(Kollet et al. 2003; Massberg et al. 2007; Si et al. 2010).  The cellular 
and molecular mechanisms responsible for regulating this trafficking have provoked much 
investigation given the potential role of HSC as a cellular therapy for tissue injury, including 
liver disease. 
Autologous or allogenic HSC transplantation following myeloablative therapy in patients 
with haematological malignancy have been in routine clinical use for some time(Gratwohl et 
al. 2010). The success of bone marrow transplantation is dependent upon the effective 
homing of infused HSC from the blood to the bone marrow . The mechanisms regulating the 
homing of cells to the bone marrow have therefore been well studied and follow a sequence 
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of molecular events similar to the well established model of lymphocyte recruitment(Lalor et 
al. 2002; Shetty et al. 2008). 
Circulating HSC enter the bone marrow via a series of adhesion steps prior to entry into the 
bone marrow (Springer 1994; Mazo et al. 2011) similar to those involved in the recruitment 
of lymphocytes to the liver– the ‘multi step adhesion cascade’(Fig 1.8)(Ley et al. 2007; Shetty 
et al. 2008).   The first step involves the slowing and tethering of fast moving cells from the 
circulation to the vascular endothelium, achieved by the interaction between adhesion 
molecules expressed on the vascular endothelium with ligands on the cell surface.  Bone 
marrow endothelium uniquely expresses P-selectin, E-selectin and VCAM-1, which are not 
found on other endothelial cells under physiological conditions and  the ligands for these 
adhesion molecules PSGL-1 and VLA α4β1 respectively are expressed on the surface of HSC 
(Feuerer et al. 2004; Katayama et al. 2004).  The interaction between CD44 on the cell 
surface of HSC and its ligand hyaluronate, a glycosaminoglycan present in the connective 
tissue of the bone marrow is also responsible for initiating the slowing and rolling of fast 
moving HSC from the circulation(Vermeulen et al. 1998; Avigdor et al. 2004).  Slowly rolling 
cells receive an activation signal from the chemokine CXCL12, which acts via the G-protein 
coupled chemokine receptor CXCR4 and triggers conformational change and cytoskeletal 
rearrangement resulting in firm adhesion to the endothelium. (Cyster 1999; Peled et al. 
1999). Adherent cells then transmigrate across the endothelium along a chemotactic 
gradient of CXCL12 which is constitutively expressed at high levels in the bone marrow 
(Peled et al. 1999; Hillyer et al. 2003). 
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The mechanisms regulating the trafficking of HSC to organs other than the bone marrow 
have not been as well studied and are not yet well understood.  The role of the interaction 
between VCAM1 and α4β1 in the recruitment of HSC to the liver has been studied.  
Kavanagh and colleagues used an ischaemia reperfusion model of liver injury to stimulate 
recruitment of HSC to the liver and showed that in common with the bone marrow the 
interaction of VCAM with α4β1 is vital for HSC recruitment and that blockade of this 
signalling significantly impaired HSC recruitment, however HSC recruitment was not 
impeded by the blockade of CD44 or CD18(Kavanagh et al. 2010).  The VCAM1 α4β1 
interaction has also been shown to be an important mechanism for the recruitment of HSC 
to the heart but does not have a role in recruitment to the gastrointestinal tract or spleen 
(Papayannopoulou et al. 1995; Mazo et al. 2011). It is likely that recruitment of HSC to 
extramedullary organs is mediated by mechanisms similar to those in the bone marrow, but 
also involving organ specific mechanisms that are not yet completely understood.  
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Fig 1.8  Recruitment of HSC from Blood into Bone Marrow 
Fast moving circulating HSC are tethered to the endothelium by P- and E- selectins binding to 
ligands expressed on HSC (PSGL-1 and CD44).  Tethered, slowly rolling HSC are activated by 
CXCL12 thorugh CXCR4 signalling, inducing a conformational change in á4â1resulting in 
increased affinity for VCAM-1 and mediating firm adhesion to the endothelium. Adherent 
HSC then transmigrate across the vessel wall along a chemotactic gradient of CXCL12. 
(Reproduced from Mazo et al Trends in Immunology (2011) 32;10:493-503) 
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1.7.2 Chemokine Receptor Signalling 
Chemokines are a 8-12kDa heparin-binding cytokines, all with the ability to induce directed 
chemotaxis to specific sites and all possessing amino acid residues in conserved locations 
that are vital to maintaining their tertiary structure.  The Chemokine family can be classified 
into four groups based upon the spacing of their first two cysteine residues – in CC 
chemokines the cysteine residues are adjacent, in CXC chemokines the residues are 
separated by a single amino acid residue, CX3CL1 is the only chemokine with three amino 
acids separating the cysteine residues and XCL1 and XCL2 lack two adjacent cysteine 
residues.(Wright et al. 2002; Oo et al. 2010; Bachelerie et al. 2014). 
Chemokines may also be described as either  ‘inflammatory’ or ‘homeostatic/constitutive’ 
depending on whether they are induced by inflammation (eg CXCL6,7,8 :neutrophil 
migration) or constitutively expressed and responsible for homeostatic immune regulation 
(eg CXCL12 :HSC homing to BM)(Bachelerie et al. 2014). 
Chemokines are crucial for lymphocyte recruitment to the liver and patterns of chemokine 
expression within the liver have been well studied.  CCL3-5 are strongly expressed in vascular 
endothelium within portal tracts particularly in immune mediated liver disease but also at 
low levels in normal liver(Goddard et al. 2001; Oo et al. 2010).   CXCL9, CXCL10 and CXCL11 
are present at high levels on sinusoidal endothelium in the injured liver (viral, autoimmune 
disease) and at low levels in normal liver (Shields et al. 1999; Harvey et al. 2003).   These 
chemokines are also secreted by other liver cells including hepatocytes, cholangiocytes and 
hepatic stellate cells, and are presented on sinusoidal endothelium(Oo et al. 2010).   
Transcytosis allows chemokines produced by underlying hepatocytes or stellate cells to be 
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transported from the basolateral to the luminal surface of the endothelium, and chemokines 
secreted by cholangiocytes can be retained in the proteoglycan rich endothelial 
glycocalyx(Curbishley et al. 2005). The differences in injury induced chemokine expression 
may reflect a mechanism by which localised lymphocyte recruitment occurs(Oo et al. 2010). 
Kollet and colleagues examined the role of CXCR4 in the recruitment of HSC to the liver, 
using NOD/SCID mice with acute and chronic carbon tetrachloride liver injury they 
demonstrated that blocking CXCR4 reduced homing and engraftment of human CD34+ HSC.  
Localised hepatic injections of CXCL12 acted to increase homing, mediated via CXCR4(Kollet 
et al. 2003).  Liver injury was associated with increase hepatic CXCL12 levels and MMP-9 
expression.   MMP-9 has been shown to upregulate CXCR4 expression on bone marrow 
cells(Kollet et al. 2003; Kawai et al. 2012) and in MMP-9 knock out mice limited recruitment 
of HSC to the liver was observed (Kawai et al. 2012).  MMP-9 degraded bone marrow 
CXCL12, promoting HSC mobilisation and synergistically enhanced CXCL12 directed migration 
in vitro(Jin et al. 2008). CXCR4 has been shown to present, albeit at low levels on the surface 
of murine HSC (Sasaki et al. 2009). 
Injury or inflammation stimulates recruitment of HSC to the site of injury(Dalakas et al. 2005; 
Badami et al. 2007), which corresponds with upregulation of CXCL12)(Stumm et al. 2002; 
Kollet et al. 2003).    CXCL12 is the predominant chemoattractant for HSC mediated via 
CXCR4 expresssion (Wright et al. 2001; Wright et al. 2002), and is widely expressed in many 
tissues including the liver(Shirozu et al. 1995; Imai et al. 1999; Goddard et al. 2001).  It has 
been shown that irradiation or chemotherapy results in a localised increase in bone marrow 
CXCL12 expression (Ponomaryov et al. 2000) and Kollet and colleagues investigated its 
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potential role as a stress signal for HSC mediating recruitment to injured or inflamed tissues 
(Kollet et al. 2003). They found an increase in membrane bound CXCL12 in carbon 
tetrachloride liver injury and that the increase in CXCL12 promoted homing of HSC to the 
liver, furthermore blocking CXCL12/CXCR4 interactions abolished recruitment of HSC to the 
liver.  HSC recruited to the liver were localised to areas rich in CXCL12 in a similar fashion to 
that seen in the CXCL12 rich endosteal region of bone marrow(Weiss et al. 1991; Kollet et al. 
2003).   They also demonstrated the role of interactions between matrix metalloproteinases 
2 and 9, and the cytokines Stem Cell Factor (SCF) and Hepatocyte Growth Factor (HGF) in 
HSC recruitment during liver injury.  Increased MMP2 and 9 expression resulted in shedding 
of membrane bound SCF which in turn increased CXCR4 expression on HSC, whilst HGF 
expression induced cytoskeletal rearrangement and increased motility of HSC(Kollet et al. 
2003). 
Si and colleagues demonstrated the expression of CCR2 on HSC and confirmed their 
migration to the ligand CCL2 in vitro.  Following APAP induced acute liver injury, significant 
numbers of HSC were recruited into the livers of wild type mice, however this effect was not 
seen in CCR2 knockout mice.  Infusion of HSC derived from the bone marrow of wild type 
mice significantly improved hepatic injury, but no improvement was seen following infusion 
of HSC from CCR2 knockout mice(Si et al. 2010).  CCR2 knockout mice display higher levels of 
hepatic necrosis following APAP induced injury (Hogaboam et al. 2000).   Macrophages with 
the reparative M2 phenotype were absent from CCR2 knockout mice with liver injury (Holt 
et al. 2008)and in contrast to wild type mice, HSC from CCR2 knock out mice did not 
differentiate into macrophages of a reparative phenotype(Si et al. 2010).  
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1.7.3 HSC Recirculation 
The continual exchange of HSC between the peripheral blood and bone marrow  has been 
long recognised (Goodman et al. 1962) and more recently it has been shown that bone 
marrow derived HSC are present in organs other than the bone marrow(Wright et al. 2001). 
Until recently the mechanisms by which HSC recirculate between bone marrow and other 
tissues was not well understood.  Massberg and colleagues investigated whether HSC 
undergo a similar recirculation to that of lymphocytes, whereby lymphocytes egress from 
organs via draining lymphatics and return to the peripheral blood circulation via the thoracic 
duct(von Andrian et al. 2000; Massberg et al. 2007).  They were able to demonstrate the 
presence of bone marrow derived HSC within the thoracic duct lymph but that in contrast to 
lymphocytes, egress from tissues was directly into the lymph and did not require homing to 
lymph nodes to enter the lymphatic circulation(von Andrian et al. 2000; Massberg et al. 
2007).  Through the use of pairs of parabiotic mice, including a GFP expressing mouse, HSC 
chimerism was detected within organs outside the bone marrow and within the thoracic 
duct lymph, demonstrating continual recirculation.  After separation of the pararbiotic pairs, 
HSC chimerism within the blood reduced immediately whilst a similar reduction was 
observed within the lymphatic fluid 36 hours later, inferring from this that the dwell time of 
HSC within organs is about 36 hours or more(Massberg et al. 2007).   
Sphingosine 1-phosphate is a bioactive lipid signalling molecule that has been shown to 
regulate the egress of lymphocytes into efferent lymphatics, mediated by S1P receptor 1 
signalling (Rosen et al. 2005; Schwab et al. 2005; Massberg et al. 2006).  Massberg and 
colleagues blocked the action of S1P receptors by the administration of FTY720 which 
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resulted in a dramatic reduction in HSC within the lymphatic fluid, a similar effect was seen 
with S1P1 specific blockade using SEW2871.  The reduction on HSC was seen within 6 hours 
of FTY720 administration and was accompanied by a reduction in the numbers of HSC within 
the peripheral blood, however the authors concluded that as they had shown the dwell time 
of HSC within tissues to be 36 hours or more that the reduction in HSC in the lymph was as a 
consequence of reduced tissue egress rather than reduced tissue entry (Fig 1.9).  This finding 
was supported by the observation that after 7 days of FTY720 administration increased 
numbers of HSC could be found within various organs other than the bone marrow and 
numbers of HSC within the bone marrow remained constant(Massberg et al. 2007). 
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Figure 1.9  Recirculation of Haematopoietic Stem Cells 
Schematic model illustrating the trafficking of migratory HSPCs under physiological 
conditions and during inflammation (Reproduced from Massberg et al Cell 2007;131(5):994-
1008) 
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1.8 Aims of this project 
There is a clear need for new therapies for liver disease, particularly those which may halt or 
reverse the progressive nature of hepatic fibrosis and cirrhosis. Adult bone marrow stem 
cells represent a promising therapeutic option but clarity on the specific cell types that may 
be of benefit is lacking and information on the mechanisms mediating these beneficial 
effects remains sparse.  The mechanisms controlling the trafficking of stem cells to 
peripheral tissues such as the liver are not completely understood with emerging evidence 
that the bioactive lipid Sphingosine 1-phosphate is a key regulator.  A greater understanding 
of the trafficking of stem cells may help optimise and improve their beneficial effect. 
Therefore, the aims of this project are: 
i) To determine whether repeated peripheral injections of a purified population 
of haematopoietic stem cells (c-kit+, sca-1+ lineage -) improve hepatic fibrosis 
in a carbon tetrachloride model of chronic liver injury, and through the use 
CD45 congenic mice determine the fate of injected cells 
ii) To determine the alterations that occur in S1P concentrations in blood, 
lymph, liver and bone marrow in a murine model of chronic liver injury and 
determine changes in expression of the enzymes responsible for S1P synthesis 
and degradation that occur in both murine and human chronic liver injury  
iii) To determine whether increased numbers of HSC are mobilised from the 
bone marrow and recruited to the liver during chronic liver injury using bone 
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marrow transplantation between CD45 congenic mice to identify bone 
marrow derived cells 
iv) To determine whether modulation of S1P receptor signalling by FTY720, a 
functional S1P receptor antagonist, increases the accumulation of HSC within 
the injured liver and, using intravital microscopy investigate the effects of 
FTY720 on HSC recruitment to the injured liver 
v) To determine whether administration of FTY720 leads to an increase in the 
number of injected HSC within the livers of mice with chronic carbon 
tetrachloride induced liver injury, and whether administration of FTY720 in 
conjunction with repeated peripheral injections of purified HSC augments 
their anti fibrotic effect
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2 EXPERIMENTAL METHODS 
 
2.1 Animal Experiments 
All animal experiments performed were conducted in accordance with the Animals(Scientific 
Procedures) Act 1986 under a Project Licence held by Dr. Phil Newsome (PPL 40/3201).  
Some animals were transferred to a Project Licence held by Dr. Neena Kalia (PPL40/2749) for 
Intravital Microscopy.  Approval of the University of Birmingham Ethics Committee was also 
obtained.   
All animals were housed in an approved animal facility (Biomedical Services Unit, University 
of Birmingham) under conditions of 12 hour light/dark cycles and with unlimited access to 
food and water. 
Wild type, inbred C57/BL6 mice were supplied directly to the Biomedical Services Unit by 
Harlan UK and used for cell isolation at 6-8 weeks of age and for experimental procedures at 
8 weeks of age.  
The BoyJ mouse(B6.SJL-Ptprca Pep3b/BoyJ) is a congenic C57/BL6 mice expressing  the 
differential pan leukocyte marker Ptprca (CD45.1).  Wild type inbred C57/BL6 express the 
Ptprcb (CD45.2) allele.  BoyJ mice were supplied from a colony held by Prof Jon Frampton 
maintained in the Biomedical Services Unit and used for experimental procedures at 8 weeks 
of age. 
At the completion of experimental procedures mice were euthanased under terminal 
inhalational anaesthesia (3% Isoflurane) allowing blood sampling via cardiac puncture to be 
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performed prior to death.  Mice used for cell isolation were euthanased using cervical 
dislocation as approved under Schedule1 of the Animals(Scientific Procedures) Act. 
 
2.2 Human Tissue  
Human liver tissue was obtained from  patients of the Liver Transplant Unit at the Queen 
Elizabeth Hospital Birmingham in accordance with approval granted by the Local Research 
Ethics Committee and as regulated by the Human Tissue Act.   Diseased liver tissue samples 
were obtained from explanted livers removed from patients undergoing liver transplantation 
and normal liver samples were obtained from donor liver tissue not required for 
transplantation.   
 
2.3 HPC7 Cell Culture  
The HPC-7 cell line was obtained from Dr Neena Kalia (University of Birmingham) having 
originally been a gift from Prof Leif Carlsson (University of Umea, Sweden). HPC-7 is a 
haematopoietic progenitor cell line derived from murine embryoinic stem cells transduced 
with LHX2 (Pinto et al. 1998, Pinto et al. 2002). LHX2 is a LIM homeodomain protein 
regulating cell division and differentiation.  HPC-7 express transcription factors and surface 
markers characteristic of haematopoietic progenitor cells. Multilineage differentiation 
capacity is maintained and culture and expansion of HPC-7 cells has been shown not to 
affect progenitor properties (Pinto et al. 1998, Dasse et al. 2012). 
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HPC-7 cells were cultured in StemPro Serum Free Media 34 (SFM-34) (Invitrogen) 
supplemented with 50U/ml Penicillin (Gibco), 50U/ml Streptomycin (Gibco), 2mM Glutamine 
(Gibco) and 100ng/ml recombinant murine Stem Cell Factor (SCF)(Invitrogen).  HPC-7 cell 
proliferation is dependent upon SCF and upon maintenance in culture (37oC, 5%CO2) at a 
density of between 0.8 and 1.5 x106 cells /ml. 
Cell counts were performed by staining with 0.4% Trypan blue solution (in a 4:1 ratio) to 
exclude dead cells and viable cells counted using a standard Neubauer haemocytometer. 
 
2.4 Isolation of Cells from Bone Marrow 
8-12 week old male C57/BL6 mice were euthanased by an approved Home Office Schedule 1 
method and both femurs and both tibias removed.   After removal of muscle and other soft 
tissue, the epiphyses of each bone were gently removed and the bone flushed through with 
cold Dulbecco’s Modified Essential Medium (DMEM) supplemented with 10% Fetal Calf 
Serum (FCS), 50U/ml Penicillin, 50U/ml Streptomycin, and 2mM Glutamine using a 26-gauge 
needle and 1ml syringe.  The extracted bone marrow cells were filtered through a 70um cell 
strainer (BD Biosciences) followed by wash in Phosphate Buffered Saline (PBS) + 1% FCS and 
centrifugation at 2000rpm for 5 minutes, cells were resuspended in ACK Red Cell Lysis Buffer 
(Sigma) for 10 minutes at room temperature followed by a further wash in PBS + 1% FCS and 
centrifugation at 2000rpm for 5 minutes.    
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2.5 Isolation of Cells from Tissue Samples 
After euthanasia organs were removed and washed thoroughly in PBS.   Livers, Kidneys and 
Lungs were directly injected throughout with 2mg/ml Collagenase IV in DMEM/10% FCS 
followed by mincing using a scalpel.  The tissue suspension was then incubated at 37oC for 
40 minutes with continuous gentle agitation.   The suspension was then washed through a 
coarse (250µm) mesh and a fine (50µm) mesh using  Roswell Park Memorial Institute (RPMI) 
media  to obtain a cell suspension, this was centrifuged at 2000rpm for 5 minutes and the 
pellet resuspended in RPMI (Liver 20ml, Kidney/Lung 10mls).   A working dilution of Optiprep 
(Sigma) at 1.09g/ml was obtained by mixing neat Optiprep with PBS in a 4:11 ratio.  In a 15ml 
conical tube 5ml of cell suspension was layered carefully over 5ml of Optiprep solution, this 
was centrifuged at 1050g for 25 minutes at 4oC with no brake applied to the centrifuge.   
Mononuclear cells were carefully aspirated from the interface between Optiprep and media, 
washed in PBS, centrifuged at 2000rpm for 5 minutes and the resulting cells used in further 
experiments. 
 
2.6 Isolation of Cells from Peripheral Blood 
Mice were anaesthetised using 3% Isoflurane and venesected via cardiac puncture to obtain 
0.5-1.0 ml peripheral blood, followed by euthanasia by an approved Home Office Schedule 1 
method.  The volume of blood obtained was recorded and collected into tubes containing 
ethylenediaminetetraacetic acid (EDTA, BD Biosciences).   ACK Red Cell Lysis Buffer was 
added to the sample at 10 times the volume of blood, vortexed and incubated at room 
temperature until the resulting suspension became transparent indicating lysis of 
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erythrocytes.   The suspension was then three times washed in PBS and centrifuged at 
2000rpm for 5 minutes.  The resulting leukocyte pellet was then used for further 
experiments. 
 
2.7 Flow Cytometry and Cell Sorting  
Cells isolated using the described techniques were resuspended in PBS + 1%FCS and purified 
anti-mouse CD16/32 antibody (ebioscience) added at 1:25 dilution to block non specific Fc-
receptor binding and incubated on ice for 20 minutes.  After a further wash in PBS + 1%FCS 
and centrifugation, cells were resuspended in PBS+1%FCS for antibody staining.  Antibodies 
used are listed in Table 2.1.  Tubes were incubated on ice for 30 minutes then washed and 
centrifuged.  Cells were resuspended in PBS + 1%FCS and passed through a 50µm filter 
immediately prior to  analysis or cell sorting. 
Analysis of extracellular surface markers using directly conjugated antibodies was performed 
as described above.  Analysis of intracellular targets using unconjugated antibodies was 
performed with the following procedure.  After completion of labelling with extracellular 
antibodies cells were resuspended in CytoFix solution (BD Biosciences) for 20 minutes at 
room temperature followed by washing in PermWash solution (BD Biosciences) and 
centrifugation at 2000rpm for 5 minutes.  Cells were resuspended in PermWash solution and 
staining with the relevant intracellular antibodies (Table 2.1) was performed for 30 minutes 
on ice, followed by wash in PermWash and centrifugation.  After resuspending the cells in 
PermWash solution, Goat Serum (Sigma) at a dilution of 1:20 was added to the staining 
tubes for 20 minutes on ice to prevent non specific binding of the secondary fluorochrome 
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conjugated antibody. Secondary antibody (Table 2.1) was added for 30 minutes on ice 
followed by washing in PermWash solution, centrifugation and resuspension in PBS+1%FCS 
for analysis by flow cytometry. 
Cells sorting was performed using a MoFloCell Sorter(Dako Cytomation) running Summit 5.2 
software.  The gating strategy used and a representative analysis of the sort purity is 
outlined in figure 2.1.   Cells to be used for PCR analysis were sorted directly into 350ul RLT 
lysis buffer (Qiagen) ready for RNA extraction and cells to be used for experimental 
injections were sorted into PBS and used immediately. 
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Figure 2.1 Isolation of c-kit+ sca1+ lineage- cells 
 
Bone marrow cells were obtained from donor mice following dissection of the tibia and 
femurs by flushing the marrow cavity with DMEM + 10%FCS.  Cells were treated with red cell 
lysis buffer and filtered prior to labelling with fluorescently conjugated antibodies to lineage 
specific markers (CD11b, CD8a, CD5, Ter119, Gr-1, B220), c-kit and sca-1.  Cells were isolated 
by initially excluding dead cells and debris on a forward scatter – side scatter plot (A) and 
excluding doublets of cells on a forward scatter – pulse width plot (B).  The lineage negative 
population was determined (C) and plotted according to expression of c-kit and sca-1 surface 
markers (D).  HSC were defined as c-kit+, sca-1+ and lineage marker negative (‘KSL’) and 
represented 0.05% of the total bone marrow cell population.   The purity of the isolated cells 
was then checked by determining lineage marker, c-kit and sca-1 expression on a sample of 
isolated cells (E).  
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Isolation of c-kit+ sca1+ lineage- cells
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Table 2.1 Antibodies used for Flow Cytometry 
Antibody Conjugate Origin Target Isotype Catalogue 
number 
Manufacturer Concentration 
Used 
Isotype Control FITC Rat Mouse IgG2a 11-4321-82 eBioscience 1:50 
Isotype Control FITC Rat Mouse IgG2b 11-4031-82 eBioscience 1:50 
Isotype Control APC Rat Mouse IgG2a 17-4210-82 eBioscience 1:50 
Isotype Control Pacific Blue Rat Mouse IgG2b 400627 BioLegend 1:50 
Isotype Control PE Rat Mouse IgG2a 12-4210-82 eBioscience 1:50 
Isotype Control PE Rat Mouse IgG2b 12-4211-82 eBioscience 1:50 
Isotype Control PE Hamster Mouse IgG 12-4112-82 eBioscience 1:50 
Isotype Control PE Rat Mouse IgG2a IC006P RnD Biosytems 1:20 
Isotype Control APC Rat  Mouse IgG2 17-4321-81 eBioscience 1:50 
Isotype Control PE Rat Mouse IgG1 12-4031-82 eBioscience 1:50 
Isotype Control Alexa 647 Rat Mouse IgG 400526 Biolegend 1:50 
Isotype Control - Rabbit Mouse IgG sc-3888 Santa Cruz Biotech 1:100 
Anti-CD11b FITC Rat Mouse IgG2b 11-6112-82 eBioscience 1:50 
Anti-CD5 FITC Rat Mouse IgG2a 11-6051-82 eBioscience 1:50 
Anti-CD8a FITC Rat Mouse IgG2a 11-0081-82 eBioscience 1:50 
Anti-Ter119 FITC Rat Mouse IgG2b 11-5921-82 eBioscience 1:50 
Anti-CD45R FITC Rat Mouse IgG2a 11-0452-82 eBioscience 1:50 
Anti-Gr-1 FITC Rat Mouse IgG2b 11-5931-82 eBioscience 1:50 
Anti-CD117 (c-kit) PE Rat Mouse IgG2b 15-1171-82 eBioscience 1:50 
Anti-CD117 (c-kit) Pacific Blue Rat Mouse IgG2b 105820 BioLegend 1:50 
Anti-CD117 (c-kit) APC-Cy7 Rat Mouse IgG2b 25-1171-82 eBioscience 1:50 
Anti-Sca1 APC Rat Mouse IgG2a 17-5981-82 eBioscience 1:50 
Anti-CD127 (IL-7Ra) PE Rat Mouse IgG2b 12-1271-81 eBioscience 1:50 
Anti-EDG1 (S1P1) PE Rat Mouse IgG2a FAB7089T RnD Biosytems 1:20 
Anti-EDG1(S1P1) - Rabbit Mouse IgG sc-25489 Santa Cruz Biotech 1:100 
Anti-CD45 PE Rat Mouse IgG2b 12-0451-81 eBioscience 1:50 
Anti-CD45.1 PE Mouse Mouse IgG2b 12-0453-81 eBioscience 1:50 
Anti-CD45.2 APC Mouse Mouse IgG2 17-0454-81 eBioscience 1:50 
Anti-CD146 PE Rat Mouse IgG1 12-1469-81 eBioscience 1:50 
Anti-CCR2 PE Rat Mouse IgG2b FAB5538P RnD Systems 1:10 
Anti-CCR4 PE Rat Mouse IgG2a 12-1949-80 eBioscience 1:50 
Anti-CCR7 PE Rat Mouse IgG2a 12-1971-80 eBioscience 1:50 
Anti-CCR9 PE Rat Mouse IgG2b 12-1991-80 eBioscience 1:50 
Anti-CXCR2 Alexa 647 Rat Mouse IgG 129101 Biolegend 1:50 
Anti-CXCR3 PE Hamster Mouse IgG 12-1831-80 eBioscience 1:50 
Anti-CXCR4 PE Rat Mouse IgG2b 12-9991-80 eBioscience 1:50 
Anti-CD16/32 
Purified 
- Rat Mouse  14-0161-82 eBioscience 1:50 
Secondary PE Donkey Rabbit IgG 12-4739-81 eBioscience 1:200 
LIVE/DEAD Cell Stain Yellow - - - L34959 Invitrogen 1:200 
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2.8  Isolation of Liver Cells 
Single cell suspensions of digested murine livers were prepared as previously described using 
collagenase digestion (Section 2.5).  The resulting cell suspension was centrifuged slowly at 
30g for 3 minutes to obtain a hepatocyte pellet which was resuspended in 350µl RLT buffer 
for RNA extraction.  The remaining supernatant was used for isolation of liver sinusoidal 
endothelial cells. 
To isolate liver sinusoidal endothelial cells the supernatant was centrifuged at 2000rpm for 5 
minutes and resuspended in 20ml PBS + 1% FCS.   In a 50ml tube 20ml of 23% Percoll was 
layered carefully onto 20ml of 50% Percoll to maintain a distinct interface between the two 
concentrations, on to this 10ml of the cell suspension was carefully added and the tubes 
centrifuged at 1300g for 10 minutes with no brake applied.  The cells suspended at the 
interface between the Percoll concentrations were removed by manual pipetting and 
resuspended in PBS + 1% FCS, centrifuged at 2000rpm for 5 minutes and resuspended in 
270µl PBS + 1% FCS and 30µl of anti-CD146 magnetic microbeads (Miltenyi Biotec).  This was 
left to incubate for 20 minutes on ice followed by centrifugation at 2000rpm for 5 minutes 
and resuspended in 1ml PBS.  Magnetically activated cell sorting (MACS, Miltenyi Biotec) MS 
columns were placed into MACS magnets and primed with 500µl PBS, 500µl aliquots of the 
magnetically labelled cell suspension were added to each column and washed through three 
times with 500µl PBS.  The MACS MS columns were then removed from the magnets, and 
flushed through with 1ml PBS.  The resulting cell suspension was collected, centrifuged at 
2000rpm for 5 minutes ensuring all supernatant was removed and resuspended in RPMI 
media for culture or 350µl RLT lysis buffer for RNA extraction. 
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2.9  Isolation of Peripheral Blood Mononuclear Cells 
A working dilution of Optiprep (Sigma) at 1.09g/ml was obtained by mixing neat Optiprep 
with PBS in a 4:11 ratio.  In a 15ml conical tube 5ml of peripheral blood cell suspension was 
layered carefully over 5ml of Optiprep solution, this was centrifuged at 1050g for 25 minutes 
at 4oC with no brake applied to the centrifuge.   Mononuclear cells were carefully aspirated 
from the interface between Optiprep and media, washed in PBS and centrifuged at 2000rpm 
for 5 minutes and the resulting cells resuspended in 350µl RLT buffer for RNA extraction. 
 
2.10 Colony Forming Unit Assay 
Quantification of the number of colony forming cells in cell populations was performed by 
culture of cells in semi solid methylcellulose based media.   The media used was Methocult 
GF (StemCell Technologies, M3434) containing cytokines stimulating growth of myeloid cell 
colonies (CFU-GM, CFU-G, CFU-M, CFU-GEMM).  The Methocult GF media contains 1% 
methylcellulose in IMDM, 15% fetal bovine serum, 1% bovine serum albumin, 10µg/ml 
recombinant human Insulin, 200µg/ml human Transferrin, 0.1mM 2-mercaptoethanol, 
50ng/ml recombinant murine Stem Cell Factor, 10ng/ml recombinant murine IL-3, 10ng/ml 
recombinant human IL-6, 3U/ml recombinant human Erythropoietin and 2mM Glutamine. 
Cell populations under investigation were prepared as previously described and 
resuspended in IMDM at a concentration ten fold higher than required in the assay.  0.3ml of 
cell suspension was added to 3mls of thawed Methocult GF media, vortexed well and left to 
stand for 5 minutes to allow air bubbles to dissipate.  Using a blunt ended needle attached 
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to a 2ml syringe, 1.1ml of the cell containing media was added to a 35mm sterile petri dish 
and distributed evenly by gentle rotation.  Assays were incubated at 37oC 5%CO2 inside 
100mm petri dishes together with a separate 35mm petri dish containing 3ml sterile water 
to prevent dessication of the media.  Incubation proceeded for 10-12 days followed by 
enumeration of individual colonies within each assay.  Colonies were counted using an 
inverted microscope at low power magnification and to enable accuracy a square grid was 
printed onto transparent film and placed underneath the 35mm petri dish. 
 
 
2.11 Pharmacological Agents  
S1P and FTY720-phosphate 
Sphingosine 1-phosphate and FTY720-phosphate (Cayman Chemicals) were dissolved in 95% 
Dimethyl sulphoxide / 5% 1N Hydrochloric Acid (Sigma) to form a 20mM stock solution, 
aliquoted and stored at -20oC.   Prior to use  further dilutions were made in PBS containing 
3% fatty acid free bovine serum albumin (Sigma) to form a 1mM solution which was then 
diluted to the appropriate concentration in cell culture media for use in experiments. 
FTY720 – In vivo 
FTY720 (Cayman Chemicals) was dissolved in sterile Dimethyl sulphoxide (Sigma) to form a 
10mg/ml stock solution which was aliquoted and stored at -20oC.  Immediately prior to use 
aliquots were thawed and diluted in phosphate buffered saline to a concentration of 
0.2µg/µl ready for injection. 
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W146 
W146 hydrate (Sigma Aldrich) was dissolved in Methanol (Sigma) containing 0.05% Acetic 
Acid (Sigma) to form a 3mM stock solution and stored at -20oC.   Stock solution was diluted 
in cell culture media for use in experiments. 
 
2.12  Transwell Migration Assays  
A Transwell system (Corning Costar)was used to measure cell migration in response to 
chemoattractants.   In this assay transwell supports are placed into standard cell culture 
plates thus separating the well into two, an upper compartment and a lower compartment 
with a permeable membrane between the two compartments.  The membrane contains 
pores of the appropriate size for the cell type being studied.   Cells are placed in the upper 
compartment and media with or without the chemoattractant to be studied is place in the 
lower compartment, the wells are incubated and at the end of the designated time period 
the number of cells that have migrated to the lower chamber is enumerated. 
For migration assays using both primary KSL cells and HPC7 cells, 6.5mm 12 well plate 
Transwell inserts with a 5µm pore diameter were used (Corning Costar).   0.6ml of serum 
free media (StemPro 34 for HPC7 and DMEM + 0.1%BSA for primary KSL cells) containing the 
relevant concentration of chemoattractant was placed in individual wells of a 12 well plate, 
media alone was used as the negative control and in some experiments 100ng/ml SDF-1 was 
used as a positive control.   The transwell inserts were then carefully placed into each well 
containing media to avoid the formation of air bubbles beneath the membrane.   Cells were 
washed and resuspended at 1x106 cells/ml in the relevant serum free media and 100µl of 
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cell suspension added to each transwell insert, with 100µl of cell suspension retained in 
order to calculate numbers of input cells.   In primary KSL cell assays, lin- bone marrow cells 
were isolated from bone marrow using techniques described (Section 2.4) and used as the 
input cell population.   The lin- fraction is 10-fold more enriched for KSL cells than whole 
bone marrow.  The wells were incubated at 37oC  5%CO2 for 3 hours allowing migration to 
proceed.   The inserts were then carefully removed from the 12 well plate and the contents 
of each individual well transferred to a round bottomed tube.   In HPC7 assays 20µl of 
Trucount counting beads (Invitrogen) was added to each tube and the numbers of migrated 
cells in each well together with the number of input cells was determined and migration as a 
percentage of input cells was calculated.  The contents of each well was centrifuged and 
resuspended in 100µl PBS + 1%FCS and labelled with anti-sca1 and anti-c-kit antibodies 
(Table 2.1) using the flow cytometry protocol (Section 2.7) with the addition of 20µl 
Trucount counting beads and the numbers of c-kit+ sca1+ cells migrating was determined 
and migration as a percentage of input cells was determined. 
 
2.13  Protein Extraction and Assay  
Samples of frozen tissue (approx 80mg) were weighed,  placed in a GentleMACS M tube 
(Miltenyi Biotec) with 20µl/mg  ice cold Cell Lytic MT buffer (Sigma) containing 1% protease 
inhibitor cocktail (Sigma) and 5U/ml DNAse (Qiagen) and processed on programme Protein-
01.  The suspension was then centrifuged at 3000g for 3 minutes and the supernatant 
agitated on a Vibraplatform for 1 hour at 4oC and centrifuged at >8000g for 30 minutes.  The 
supernatant was then aliquoted and protein concentration determined using the Bradford 
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protein assay.  The Bradford reagent (Sigma) contains Brilliant Blue G dye which forms 
complexes with proteins in solution resulting in a shift in light absorbance proportional to 
the concentration of protein.   A series of protein standards were prepared by dilution of 
bovine serum albumin (Sigma) and 5µl of either standard or sample were added to individual 
wells of a 96 well plate, followed by the addition of 250µl Bradford reagent. The plate was 
agitated and allowed to incubate for 5 minutes, absorbance at 595nm was then determined 
using a spectrophotometer.  Protein concentration in individual samples was determined 
from the standard curve (Figure 2.2). 
 
 
 
Figure 2.2 Standard Curve for determination of protein concentration using the Bradford 
Assay 
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2.14 Western Blotting  
The protein samples were first separated by SDS polyacrylamide gel electrophoresis, 
stacking and resolving gels (Table 2.2) were placed between glass plates (BioRad) to 
construct a 1.5mm thick gel, inserted into the plate holder and placed in the electrophoresis 
tank.  Electrophoresis running buffer was poured into the tank to eliminate air bubbles from 
the top of the gel and to cover the electrodes.   Protein samples were diluted to 5µg/µl and 
10µl (50µg) added to 40µl SDS-PAGE loading buffer and heated for 5 minutes at 100oC.   20µl 
of the sample was added to each well of the stacking  gel and 10µl of Precision Plus Protein 
molecular weight marker (BioRad) was added to the end well, electrophoresis at 200V 
continued for 0.5 -1 hour allowing the protein to reach the bottom of the resolving gel.   The 
protein was transferred to Hybond ECL nitrocellulose membrane (Amersham) by placing the 
gel and membrane between filter paper and sponges inside a transfer cassette (BioRad).   
The cassette was placed in an electrophoresis transfer tank filled with transfer buffer and 
containing an ice pack and electrophoresis at 100V proceeded for 1 hour.   The membranes 
were then blocked to avoid non specific antibody binding by soaking in a 5% non fat milk 
solution (10g milk powder in 20mls PBS + 0.02% Tween) for 1 hour at room temperature 
followed by the addition of the primary antibodies (Table 2.3) and incubated overnight at 
4oC.   The membrane was washed three times in PBS-Tween and the secondary antibody 
diluted in PBS-Tween added, incubated for 1 hour at 4oC and washed for 30 minutes in PBS-
Tween.   Pierce ECL Western Blotting Substrate (Thermo Scientific) was added to the 
membrane for 2 minutes following which the membrane was blotted with tissue and placed 
in a film cassette.   Hyperfilm ECL (Amersham) was placed in the film cassette and after 
exposure developed in an X-Omat automated processor. 
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The membranes were stripped for reanalysis by incubating in stripping buffer for 45 minutes 
at 50oC followed by 2 hours of continuous washing under running water.   The stripped 
membrane was then probed using the same protocol commencing with blocking with 5% 
milk solution. 
Table 2.2 Reagents used for Western Blotting 
Reagent Components 
Electrophoresis Buffer Per litre - 30.3g Trizma base, 144g Glycine, 10g Sodium Dodecyl Sulphate (all Sigma Aldrich) 
Transfer Buffer Per litre – 14.4g Glycine, 3g Trizma base, 200ml Methanol (Fisher Scientific), 0.5g Sodium Dodecyl Sulphate 
(otherwise Sigma Aldrich) 
Stripping Buffer Per 100ml – 67.5ml distilled water, 20ml 10% Sodium Dodecyl Sulphate, 12.5ml 0.5M Trizma base, 0.8ml 2-
mercaptoethanol (all Sigma Aldrich) 
Loading Buffer 200mM Trizma Base pH 6.8, 20% Glycerol, 10% Sodium Dodecyl Sulphate, 0.05% bromophenol blue, 10µM B-
mercaptoethanol 
4% Stacking Gel Per gel – 6.1ml distilled water, 1.3ml 30% Degassed Acrylamide/Bis, 2.5ml 0.5M Tris-HCl pH 6.8, 0.1ml 10% 
Sodium Dodecyl Sulphate THEN ADDED 40ul 10% Ammonium Persulphate and 20µl N,N,N’,N’-
Tetramethylethylenediamine 
15% Resolving Gel Per gel – 2.4ml distilled water, 5.0ml 30% Degassed Acrylamide/Bis, 2.5ml 1.5M Tris-HCl pH 8.8, 0.1ml 10% 
Sodium Dodecyl Sulphate THEN ADDED 40ul 10% Ammonium Persulphate and 20µl N,N,N’,N’-
Tetramethylethylenediamine 
 
Table 2.3 Antibodies used for Western Blotting 
Antibody Origin Target Isotype Catalogue no. Supplier Dilution 
Anti- SphK1 Rabbit Mouse/Human IgG ab16491 Abcam 1:500 
Anti-GAPDH Rabbit Mouse/Human IgG G8795 Sigma Aldrich 1:2000 
Anti-Rabbit IgG 
HRP conjugated 
Goat Rabbit IgG A6154 Sigma Aldrich 1:10000 
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2.15 RNA Extraction 
RNA Isolation was performed using the RNeasy Mini Kit (Qiagen) for all samples other than 
primary KSL cells, when the  RNeasy Micro Kit (Qiagen) was used. 
For RNA isolation from tissue, approximately 30mg of the relevant tissue was placed in a 
GentleMACS M  tube (Miltenyi Biotec) together with 600µl of RLT buffer supplemented with 
10µl/ml 2-mercaptoethanol (Sigma).  Samples were processed on the Miltenyi GentleMACS 
processor using program RNA.01_01 producing a tissue homogenate ready for RNA 
extraction. 
For RNA isolation from cell suspensions, cells were harvested by centrifugation for 5 minutes 
at 2000rpm and complete aspiration of the cell media.  The resulting cell pellet was 
resuspended in 600µl RLT buffer supplemented with 10µl/ml 2-mercaptoethanol.  For RNA 
isolation from primary KSL cells, cells were sorted directly into 350µl RLT buffer.  This cell 
suspension was passed through a 21-gauge needle attached to a 1ml syringe multiple times 
to ensure complete cell lysis and membrane disruption. 
For all samples one volume of 70% Ethanol was added and immediately mixed by pipetting 
and this mixture transferred to an RNeasy Spin Column and centrifuged at >10,000 rpm for 
15 seconds.   The column flow through was discarded and 350µl RW1 buffer was added to 
the spin column and centrifuged at >10,000 rpm for 15 seconds.   80µl of RNase free DNase 
solution was then added directly to the spin column membrane and left to incubate for 15 
minutes at room temperature.  A further 350µl RW1 buffer was added to wash the spin 
column and centrifuged at >10,000 rpm for 15 seconds.   500µl RPE buffer was twice added 
to the spin column and centrifuged at >10,000 rpm firstly for 15 seconds then for 2 minutes.  
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The columns were transferred to a new collection tube and centrifuged for 1 minute to allow 
solvent to evaporate from the membrane, after which 40µl of RNase free water was added 
to the membrane and centrifuged at >10,000 rpm for 1 minute to elute the RNA. 
All RNA samples were assessed for quantity and purity of RNA using a Nanodrop 
spectrophotometer.  Samples were used for cDNA synthesis if the ratio of absorbance at 
260nm (A260) to absorbance at 280nm (A280) was close to 2.0, indicating low levels of 
genomic DNA contamination.   RNA samples were aliquoted and stored at -80oC pending use 
in further applications. 
 
 
2.16 cDNA Synthesis 
Each cDNA synthesis reaction was run in a thin walled PCR tube and consisted of 1µg RNA 
template added to 4µl iScript Reaction Mix and 1µl iScript Reverse Transcriptase (Bio Rad) 
and made up to a total volume of 20µl with RNase DNase free water (Qiagen).  The reaction 
mix was incubated in a thermal cycler at 25oC for 5 minutes followed by 30 minutes at 42oC 
and finally the RT was inactivated by incubation at 85oC for 5 minutes.  The reaction was 
then cooled to 10oC and either used immediately for further applications or stored at -80oC. 
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2.17 Quantitative PCR  
Polymerase chain reaction is a process by which samples of DNA undergo geometric 
amplification, yielding many copies of the original DNA sequence.  The reaction is catalysed 
by a heat stable DNA polymerase (Taq polymerase).  Taqman gene expression assays were 
used in this work.   Taqman fluorescent probes have the reporter dye FAM at the 5’ end and 
the quencher MGB at the 3’ end.  The intact probes do not fluoresce as the reporter and 
quencher are in close proximity.  As the reaction mixture cools during each cycle after the 
denaturation step the probe is able to hybridise with its target sequence.  During the 
elongation step which follows the polymerase encounters the bound probe and the 5’ 
nuclease activity of the enzyme separates the reporter from the quencher, thus rendering 
the reporter fluorescent.  The free reporter molecules are excited by the detection 
instrument which detects emission of fluorescence.  The amount of fluorescence is 
proportional to the number of copies of the target sequence. 
Individual Taqman Gene Expression Assays used in this work are listed in Table 2.4.  Each of 
these assays were inventoried and validated by the manufacturer.  Where possible exon 
spanning assays were used to avoid interference from contaminating genomic DNA. 
In order to assess gene expression of multiple chemokine receptors, a custom 96 well plate 
was designed and ordered (Chemokine AK).  This comprised gene expression assays for the 
chemokine receptors together with endogenous control genes and allowed rapid analysis of 
multiple genes in small numbers of samples. 
Each individual PCR reaction was performed in a total volume of 20µl comprising 4µl cDNA 
sample (containing 20ng cDNA), 1µl target Taqman Gene Expression Assay, 10µl Universal 
   94 
 
Master Mix (Applied Biosystems) and 5µl RNase DNase free water.  Reactions were 
performed on a 96 well PCR plate (ABI).  Each reaction on the Custom Taqman 96 Well Plate 
(Chemokine AK) consisted of 5µl cDNA sample (containing 10ng cDNA), 10µl Universal 
Master Mix and 5µl RNase DNase free water added to each well of the plate. 
PCR using Individual Assays was performed on a Stratagene MX3000p instrument and on an 
ABI Prism 7900HT instrument for the custom plate.  The programme used consisted of 
polymerase activation at 95oC for 10 minutes followed by 40 cycles of denaturing (95oC for 
15 seconds ) and annealing (60oC for 1 minute).  The fluorescence of each reaction was 
recorded at the end of each cycle.   Each reaction was performed in triplicate and control 
reactions which did not contain any cDNA template were also included.  Cycle threshold (cT) 
values were obtained and the difference between the reference and target gene calculated 
(ΔcT = cT target – cT reference).   Relative differences between samples was expressed using 
the 2-ΔΔCT, where ΔΔcT = ΔcT sample1 – ΔcT sample2.  The use of the ΔΔcT method to 
determine relative differences between samples under varying conditions is reliant upon 
there being no differences in the amplification efficiencies of the target and reference genes.  
Validation experiments were performed to examine whether ΔcT values differed across a 
range of cDNA template concentrations from the same sample. ΔcT was plotted against the 
log of cDNA amount in each reaction and the value of the gradient of the resulting semi-
logarithmic regression line was obtained.  It is generally accepted that a slope value <0.1 
signifies a valid experiment with no significant difference in amplification efficiency.  All 
validation experiments performed using the Taqman gene expression assays met this 
criterion. 
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Table 2.4 Gene Expression Assays used for PCR 
Target (Murine) Gene Expression Assay 
Sphingosine Kinase 1  Mm00448841_g1 
Sphingosine Kinase 2 Mm00445021_m1 
Sphingosine Lyase Mm00486079_m1 
Sphingosine Phosphatase Mm00473016_m1 
  
Sphingosine 1-phosphate Receptor 1 Mm02619656_s1 
Sphingosine 1-phosphate Receptor 2 Mm03039030_m1 
Sphingosine 1-phosphate Receptor 3 Mm02620181_m1 
Sphingosine 1-phosphate Receptor 4 Mm00468695_s1 
Sphingosine 1-phosphate Receptor 5 Mm02620565_s1 
  
Alpha Smooth Muscle Actin Mm00725412_s1 
Collagen 1 alpha 1 Mm00483387_m1 
  
Glyceraldehyde 3-phosphate Dehydrogenase Mm99999915_g1 
 
Target (Human) Gene Expression Assay 
  
Sphingosine Kinase 1 Hs01116530_g1 
Sphingosine Kinase 2 Hs01016543_g1 
Sphingosine Lyase Hs00187407_m1 
Sphingosine Phosphatase Hs00229266_m1 
  
Glyceraldehyde 3-phosphate Dehydrogenase Hs02758991_g1 
All gene expression assays were supplied from Applied Biosystems.  
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Table 2.4 contd. Gene Expression Assays used for PCR (continued) 
Target Gene Expression Assay 
CCR1 Mm00438260_m1 
CCR2 Mm99999051_gH 
CCR3 Mm00515543_s1 
CCR4 Mm99999052_s1 
CCR5 Mm01963251_s1 
CCR6 Mm99999114_s1 
CCR7 Mm01301785_m1 
CCR8 Mm99999115_s1 
CCR9 Mm02620030_s1 
CCR10 Mm01292449_m1 
CXCR1 Mm00731329_s1 
CXCR2 Mm99999117_s1 
CXCR3 Mm99999054_s1 
CXCR4 Mm99999055_m1 
CXCR5 Mm00432086_m1 
CXCR6 Mm02620517_s1 
CXCR7 Mm00432610_m1 
CX3CR1 Mm02620111_s1 
GAPDH Mm99999915_g1 
B-Actin Mm00607939_s1 
18S Hs99999901_s1 
All gene expression assays were supplied from Applied Biosystems. 
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Figure 2.3  Validation plot of gene assay amplification efficiency 
 RNA was isolated from liver tissue of mice with chronic carbon tetrachloride liver injury and 
cT values for SphK1 (target) and GAPDH (control) de termined across a range of RNA 
concentrations. ΔcT was calculated as cTtarget - cTcontrol and plotted against RNA 
concentration.  The gradient of the resulting regression line was calculated as -0.036 
,demonstrating no variation in amplification efficiency.  
 
 
 
2.18 Immunohistochemistry  
Frozen tissue was embedded in OCT mountant (Tissue Tek) and 5µm thick sections cut on a 
cryostat ( by Mrs.Janine Youster).  Sections were mounted on glass microscope slides coated 
with 0.01% Poly-L-Lysine (Sigma), fixed by immersing in Acetone (Sigma) for 5 minutes and 
stored at -20oC until further use. 
Formalin fixed tissue was placed in tissue cassettes and embedded in paraffin wax to 
construct tissue blocks stored at room temperature.   4µm sections were cut from paraffin 
embedded tissue blocks (by Mrs. Jean Shaw) and mounted using a heated water bath onto 
glass microscope slides and stored at room temperature for subsequent use.  Staining of 
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formalin fixed paraffin embedded sections started with dewaxing the sections through a 
series of graded alcohols and washing in deionised water.   Sections were then placed in 
Methanol (Analat) containing 0.3% hydrogen peroxide (Sigma) to quench endogenous 
peroxidise activity followed by washing three times in PBS Tween. Antigen retrieval was then 
performed with a citrate buffer, prepared by adding 1.92g anhydrous Citric Acid (Sigma) to 
1000ml distilled water and adjusted to pH 6.0 using 1M sodium hydroxide solution, this was 
then heated to 95-100oC using a microwave oven, the sections were immersed and heated 
for 20 minutes.   The sections were allowed to cool slowly to room temperature and then 
washed three times in PBS Tween.   Non specific binding of the antibodies to the sections 
was blocked by incubating the sections for 30 minutes with 10x Casein solution (Vector) 
diluted in PBS.  The casein solution was tipped off the slide and the primary antibody was 
added diluted in PBS to the appropriate concentration (Table 2.5) and incubated for 1 hour 
at room temperature in a humidified chamber on a rocker.  The sections were then washed 
three times in PBS Tween followed by addition of the relevant horse radish peroxidise 
conjugated secondary antibody (ImmPRESS Peroxidase Anti-Rabbit IgG or ImmPRESS 
Peroxidase Anti-Rat (Mouse Adsorbed) IgG, Vector Labs) for 30 minutes.   Diaminobenzidine 
(DAB) was used as the peroxidase substrate and sections were incubated with ImmPACT 
DAB reagent (VectorLabs).  Sections were then washed once in water and counterstained 
with Mayer’s haematoxylin for 1 minute, washed again in water, dehydrated through graded 
alcohols and coverslips mounted using DPX mountant. 
Frozen sections were fixed by immersion in Acetone for 20 minutes followed by blocking of 
endogenous peroxidase activity with Methanol containing 0.3% hydrogen peroxide for 20 
minutes.  The sections were washed three times in Tris buffered Saline pH 7.6.   Non specific 
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binding was blocked by incubating the sections with 10x Casein solution diluted in PBS for 30 
minutes and then the relevant primary antibody (Table 2.5) was added and incubated for 1 
hour at room temperature in a humidified chamber on a rocker.  The sections were then 
washed three times in PBS followed by addition of the relevant horse radish peroxidise 
conjugated secondary antibody (ImmPRESS Peroxidase Anti-Rabbit IgG or ImmPRESS 
Peroxidase Anti-Rat (Mouse Adsorbed) IgG, Vector Labs) for 30 minutes.   Diaminobenzidine 
(DAB) was used as the peroxidase substrate and sections were incubated with ImmPACT 
DAB reagent (VectorLabs).  Sections were washed in distilled water for 5 minutes and 
counterstained with Mayer’s Haematoxylin for 1 minute, washed with water and coverslips 
mounted 
 
 
Table 2.5 Antibodies used for Immunohistochemistry 
 
Antibody Origin Target Isotype Catalogue  Supplier Dilution Antigen Retrieval 
Anti - aSMA Rabbit Mouse IgG ab5694 Abcam 1:400 Citrate, pH6.0 
Anti- F4/80 Rat Mouse IgG2a MCA497R AbD Setrotec 1:200 Citrate, pH6.0 
Anti-Ly6G Rat Mouse IgG2a MCA2387T AbD Serotec 1:500 N/A (Frozen 
sections) 
Anti-CD45.2 Mouse Mouse IgG 14-0454-82 eBioscience 1:200 N/A (Frozen 
sections) 
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2.19  S1P Quantification 
A competitive S1P ELISA assay (Echelon Bioscience) was used for quantification of S1P 
concentrations in tissue and serum samples.  The ELISA assay performs well when compared 
with high pressure liquid chromatography giving consistently similar results (Kirby et al. 
2009) (personal communication with Prof L. Arend).   Liver and Bone Marrow samples were 
homogenised in a buffer containing 50mM Trizma-Hydrochloric Acid buffer pH 7.4, 1mM 
EDTA, 0.1mM potassium chloride, 10% Glycerol and 1% protease inhibitor.  The protein 
content of each homogenate was determined by Bradford assay and stored at -20oC.  Serum 
and lymph samples were diluted 1:10 with delipidised human serum (Echelon).  
150µl of block solution (K-1903, Echelon) was added to each well of the 96 well plate, sealed 
and incubated at room temperature for 1 hour.  The plate was then washed 4 times with 
phosphate buffered saline. 
Dilutions of S1P standards (0, 0.06, 0.13, 0.25, 0.5, 1.0, 2.0 µM) were prepared by diluting 
100µM S1P stock solution in delipidised human serum.  63µl of anti-S1P antibody (K-1901, 
Echelon) was added to each well of a mixing plate together with 188µl of either sample or 
S1P standard, the plate was mixed on a plate shaker for 1 minute. 
100µl of the mixture from each well of the mixing plate was placed in duplicate in the coated 
and washed plate, sealed and incubated at room temperature for 1 hour.   The plate was 
then washed 4 times with PBS and 100µl of streptavidin-HRP was added to each well, sealed 
and incubated for 1 hour.   After again washing 4 times with PBS, 100µl TMB substrate was 
added to each well and the plate incubated in the dark for 30 minutes, 50µl of H2SO4 stop 
solution was added to each well and light absorbance at 450nm recorded.  A standard curve 
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was constructed using the absorbance readings of the S1P standards (Fig 2.4).  S1P 
concentrations in serum and lymph were expressed as molar quantities and in liver and bone 
marrow were normalised to total protein content and expressed as pmol of S1P per mg of 
protein. 
 
 
Figure 2.4 Standard curve for S1P ELISA 
 
2.20 Sphingosine Kinase Activity Assay 
Sphingosine Kinase activity was quantified using an adenosine triphosphate (ATP) depletion 
assay.  The reaction consists of liver homogenate (prepared and protein content quantified 
as above) as the source of SphK, sphingosine added as the substrate and initiated by the 
addition of ATP.  The reaction is stopped by the addition of ATP detector which quantifies 
the remaining ATP levels in solution, the resulting luminescent signal is inversely correlated 
with SphK activity. 
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Each sample reaction was performed in a 40µl volume, consisting of 10µl of tissue sample 
homogenised in S1P assay buffer (total protein content approx 30mg), 10µl of 100µM 
sphingosine (K-4401, Echelon) and 20µl 10µM ATP (K-ATP1, Echelon).  Each ATP standard 
contained 10µl of tissue homogenisation buffer, 10µl of 100µM sphingosine and 20µl of 
each ATP dilution (0, 0.15625, 0.3125, 0.625, 1.25, 2.5, 5, 10 µM).  The reaction was started 
by the addition of the ATP to the sample wells and the plate sealed, mixed and incubated at 
room temperature for 2 hours.   40µl of luminescent ATP detector (K-LUMa, Echelon) was 
added to each well, mixed and incubated for a further 10 minutes in the dark.   The total 
luminescent signal from each well was recorded.  A standard curve using the ATP standards 
was constructed and used to determine the quantity of S1P produced from the residual 
amount of ATP in each reaction (Fig 2.5).   The results from each reaction were normalised to 
total protein content and time and expressed as pmol of S1P produced per mg of protein per 
minute. 
 
Figure 2.5 Sphingosine Kinase Activity Assay Standard Curve 
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2.21 Intravital Microscopy 
In these experiments anaesthesia and operative surgery was performed by Dr .Dean 
Kavanagh (Centre for Cardiovascular Sciences, University of Birmingham), who also provided 
guidance on cell counting techniques. 
Intravital Microscopy was performed on C57/BL6 mice which had undergone 6-8 weeks of 
carbon tetrachloride administration to induce chronic liver inury.   Mice were anaesthetised 
by intraperitoneal administration of Ketamine (Vetalar, 100mg/kg) and Xylazine 
hydrochloride (10mg/kg) in 0.9% Saline.  Further administration was delivered as required.   
Cannulation of the right common carotid artery using polyethylene portex tubing was 
performed to enable cell delivery.   Laparotomy was performed followed by removal of the 
rectus abdominis muscles and transection of the falciform ligament allowing exteriorisation 
of the liver.   The mouse was placed on a transparent dish and placed onto the stage of the 
inverted microscope.   One x10 power magnification field of view (approx 400 x 300 µm) of 
the exteriorised liver was selected for imaging, containing at least one post sinusoidal venule 
and sinusoidal capillaries.   The same field of view was used for all recordings.  
HPC-7 cells were counted and 1x106 cells were labelled with the fluorescent dye 
concentration 5µM CFSE.  1x106 cells were centrifuged at 2000rpm for 5 minutes and 
reuspended in 2ml prewarmed PBS + 0.1% BSA and 2ml 10µM CFSE solution was added 
giving a final staining concentration of 5µM.  After incubating at room temperature in the 
dark for 10 minutes, 6ml Stem Pro 34 SFM media was added and centrifuged at 2000rpm for 
5 minutes.  Cells were resuspended in Stem Pro 34 media until immediately prior to infusion 
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when they were centrifuged at 2000rpm for 5 minutes and resuspended in 100µl PBS for 
injection.  Labelled cells were injected intra arterially in a volume of 100µl. 
Video recordings lasting one minute were taken every five minutes from the time of 
injection until 60 minutes after the injection of cells.  At the conclusion of monitoring, six 
further fields of view were imaged to ensure that findings observed in the selected field of 
view were representative of other areas of the liver.  Video recordings were stored and 
analysed using Slidebook software (Intelligent Imaging Innovations). 
Quantification of the recruitment and adhesion of labelled cells to the liver was determined 
by counting the numbers of labelled cells within the monitored hepatic field of view.  Cells 
that remained static within the field of view for more than 30 seconds were considered 
adherent and those static for less than 30 seconds were considered free flowing.  
Recruitment of cells to the liver was quantified as the number of adherent labelled cells per 
field of view. 
 
2.22 Hydroxyproline Assay 
A representative tissue sample of the liver (50-100mg) was used to determine the 
hydroxyproline content of the liver.  The liver sample was accurately weighed and placed in a 
1.5ml centrifuge tube (Eppendorf), 1ml of ice cold distilled water was added and the tissue 
was homogenised with a hand held Polytron homogeniser (Sigma Aldrich).  125µl 50% 
Trichloroacetic Acid :50% Water (Sigma Aldrich) was added and the sample incubated on ice 
for 30 minutes.  The protein was then precipitated by centrifugation in a bench top 
microcentrifuge for 5 minutes at 13,000rpm.  The resultant pellet was resuspended in 500µl 
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6N Hydrochloric Acid (Sigma Aldrich) and transferred to a 12x75mm borosilicate glass tube 
tightly sealed with a screw top lid containing a rubber insert (Sigma Aldrich). The samples 
were placed in an oven at 120oC for 16 hours, the lids of the tubes were then carefully 
removed and the samples placed back in the oven at 80oC until completely dessicated 
(usually 48 hours).   The dessicated precipitate was resuspended in 500µl distilled water and 
vortexed vigorously, this was then filtered by adding to the top chamber of a centrifuge filter  
tube (Costar, 0.45µm nylon membrane, polypropylene tube). In a clean borosilicate tube 
50µl of either the filtered solution or of hydroxyproline standard (Sigma Aldrich, diluted in 
0.001N hydrochloric acid) was added to 950µl of distilled water.   Chloramine-T solution was 
made by dissolving 1.75g chloramine-T (Sodium N-chloro-p-toluenesulfonamide, Sigma 
Aldrich) in 10ml distilled water, 10ml 2-propanol and 80ml buffer (25g citric acid 
monohydrate, 6ml glacial acetic acid, 60g sodium acetate trihydrate, 17g sodium chloride 
dissolved in 500ml water, adjusted to pH 6.0 with the addition of sodium hydroxide pellets).   
500µl of Chloramine-T solution was added to each sample, vortexed and incubated at room 
temperature for 20 minutes.  Ehrlich’s solution (p-dimethylaminobenzaldehyde perchloric 
acid) was made by adding 30ml 2-propanol to 7.5g p-dimethylaminobenzaldehyde, slowly 
mixing in 13ml 60% Perchloric Acid  and bringing the total volume to 50ml with 2-propanol.   
500µl Ehrlich’s solution was added to each sample, vortexed and incubated in a 65oC heated 
water bath for 15 minutes.   The samples were then cooled to room temperature, 200µl of 
each sample and standard was placed in triplicate in a 96 well plate and a reading of light 
absorbance at 561nm taken.   A standard curve (Fig 2.6) was created using absorbance 
readings of the standards (0, 0.125, 0.25, 0.5, 1.0, 2.0, 5.0 mcg hydroxyproline).   Using the 
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previously determined weights of the samples the hydroxyproline content was corrected 
and expressed as micrograms of hydroxyproline per gram of liver tissue. 
 
 
 
Figure 2.6 Hydroxyproline Standard Curve 
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2.23 Picrosirius Red Staining of Liver Sections 
Formalin fixed paraffin embedded sections of liver tissue cut at 5µm thickness were used for 
Picrosirius Red staining.   Tissue sections were dewaxed through a series of graded alcohols 
and washed in water.  The sections were incubated with 0.5% polymobidic acid (Sigma) for 5 
minutes and then immediately incubated with Picrosirius Red solution (100mg Direct Red 80 
(Sigma) in 100ml saturated Picric Acid) for 3 hours.  The sections were washed three times in 
100% Ethanol and coverslips mounted using non aqeuos DPX mountant. 
 
 
2.24 Morphometric Quantification of Liver Tissue Sections 
For quantification of Picrosirius Red and αSMA staining a series of 10 random, non 
overlapping fields of view from each section were imaged at x20 magnification using 
Axiovision software.  Using ImageJ software (NIH) the area of positive staining was 
determined and expressed as a percentage of the total area of the field of view. 
For quantification of specific cell numbers positive for either F4/80 or Gr-1, the number of 
positively stained cells in each field of view were manually counted.  6 random, non 
overlapping fields of view from each section were counted and quantified as the numbers of 
positively stained cells per field of view. 
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2.25 Albumin assay 
Serum albumin concentrations were measured using the Quantichrom BCG Albumin assay 
kit (Bioassay Systems). Bromcresol green (BCG) forms a coloured complex with albumin with 
the intensity being proportional to the concentration of albumin.  Albumin standards were 
made by diluting BSA with distilled water and 5µl of each standard or 5µl of each sampled 
was added to the individual wells of a 96 well plate (Corning Costar).  200µl of supplied BCG 
solution was added to each well and incubated for 5 minutes at room temperature.  The 
optical density of each well of the plate was measured at 620nm absorbance.  A standard 
curve was constructed for each individual experiment and the concentration of albumin in 
each serum sample was determined. 
 
2.26 DiR labelling 
DiR (DilC18(7), 1,1’-dioctadecyltetramethyl indotricarbocyanine Iodide, MW 
1013.4)(Invitrogen) was used to fluorescently label cells prior to use in cell tracking 
experiments.  DiR is a near infra red fluorescent cyanine dye with lipophilic properties whose 
fluorescence is enhanced by incorporation into cell membranes or binding to lipophilic 
molecules but remains weakly fluorescent in water.  When applied to cells the dye diffuses 
laterally within the cell membrane allowing even staining of the entire cell.   The excitation 
wavelength of DiR is 748nm and emission wavelength 780nm which means it is particularly 
suited to tissue and in vivo imaging as near infrared light transmits well through tissues and 
less tissue autofluorescence is observed at higher light wavelengths. 
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Stock solution was prepared by dissolving 10mg DiR in 10ml Methanol and stored in the dark 
at room temperature.  Cells were resuspended in complete Stem Pro media at 1x106 cells/ml 
and 5µl/ml of DiR stock solution added to create a staining solution of 5µM DiR.  The cell 
suspension was incubated for 30 minutes in the dark at 37oC 5%CO2.  Cells were then 
washed in sterile PBS and centrifuged at 2000rpm for 5 minutes three times, and 
resuspended in sterile PBS for injection (volume 100-200µl). 
 
2.27 Near Infra Red Fluorescent Imaging 
Fluorescence is the result of a process whereby susceptible molecules (such as polyaromatic 
hydrocarbons or heterocycles) known as fluorophores or fluorescent dyes absorb excitation 
photons from light at a specific wavelength from an external source (such a lamp or a laser) 
raising their energy levels to an excited, unstable state.  As these fluorophores decay from 
the excited state they emit fluorescent light at a characteristic wavelength determined by 
the difference in energy levels between the resting and excited state. The emission 
wavelength is always longer than the excitation wavelength due to loss of energy as heat 
during the excited state prior to emission of fluorescent light. 
Fluorescent imaging of animal and tissue samples requires excitation photons to travel 
through tissue to reach the fluorescent dye.  Tissue that absorbs light may also emit 
fluorescent light in the absence of a fluorescent dye – known as autofluorescence.   
Fluorescent dyes which absorb and emit light of lower wavelengths (400-600nm) are limited 
by poor tissue penetration of excitation photons due to absorbance by pigmented 
substances such as haemoglobin and deoxyhaemoglobin and by water and lipids(Sutton et 
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al. 2008).  Tissue autofluorescence, particularly from skin, small intestine, gall bladder and 
bladder are particularly high at these wavelengths and limit the ability to use these 
fluorescent dyes in tissue imaging(Frangioni 2003). 
The use of longer wavelength (700-1000nm) in the near infra red (NIR) spectrum is 
particularly suited to tissue imaging.  NIR imaging benefits from vastly superior tissue 
penetration and almost eliminates tissue autofluorescence (Frangioni 2003; Sutton et al. 
2008).   NIR fluorescent dyes are commercially available . 
Fluorescent imaging of tissue samples was undertaken using the IVIS Spectrum Imaging 
System (Perkin Elmer).  The IVIS Spectrum comprises a 150 watt quartz tungsten halogen 
lamp with a dichroic reflector providing a light source for fluorescent excitation across 
wavelengths from 400-950nm (Fig 2.7).   Light output from the lamp is provided to the 
excitation fliter wheel assembly where it passes through a collimating lens followed by an 
excitation filter.  After passing through the excitation filter a second collimating lens focuses 
the light into a fused silica fibre optic bundle which then splits into four separate bundles 
that deliver filtered light to four reflectors in the ceiling of the imaging chamber, providing a 
relatively uniform illumination of the sample stage.   An emission filter located at the top of 
the imaging chamber collects emission from the target fluorophore and focuses it onto the 
CCD camera.  The IVIS Spectrum has a total of 10 narrow band excitation filters (ranging 
from 415 to 760nm, 30nm bandwidth) and 18 narrow band emission filters (ranging from 
490 to 850nm, 20nm bandwidth). 
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Figure 2.7 Schematic Diagram of the IVIS Spectrum Imaging System 
(A) A pictoral representation of the key components of the IVIS Sectrum. (B) Generated light 
passes through the selected excitation filter and is reflected into the imaging chamber.  
Emitted fluoresnce is filtered by the selected emission filter wheel and directed onto the 
CCD camera generating a fluorescent image. 
 
Fluorescent image data can be quantified by measuring the photon emission from the 
subject, known as radiance, it is the number of photons per second that leave a square 
centimetre of tissue and radiate into a solid angle of one steradian.  A steradian is a three 
dimensional cone of light emitted from the surface and in the same way that a radian is a 
unit of arc length for circle a steradian is a unit of solid angle for a sphere, an entire sphere 
having 4π steradians.   Measurements of radiance are unaffected by camera settings and 
image data can be quantitatively compared. 
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The fluorescent signal detected from a sample is dependent on both the amount of 
fluorescent dye present in the sample and the intensity of the incident excitation light.  The 
excitation light incident on the sample stage is not uniform over the entire field of view, the 
peak intensity is in the centre of the stage but can drop by up to 30% across the stage.   To 
eliminate the variability in the excitation light and to allow quantitative comparisions, 
fluorescent image data is converted into efficiency where Efficiency = Radiance of the 
subject / Illumnation intensity.  Illumination intensity is specific to each imaging device and is 
provided by the manufacturer.  A reference image of excitation light intensity incident on a 
highly reflective white plate is stored in the data analysis software for each excitation filter 
at every field of view and lamp power.   Radiance efficiency represents a ratio of the number 
of fluorescent photons relative to each incident excitation photon in each pixel and does not 
have units. 
Fluorescent and photographic images of individual organs were analysed using Living Image 
software.   Regions of interest (ROI) were defined around each organ and the radiance 
efficiency after subtraction of background were calculated by the software (Fig 2.8). 
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Figure 2.8 Combined photograph and fluorescence image of murine liver demonstrating 
ROI gating and quantification of radiance efficiency 
Individual organs were photographed and fluorescently imaged using the IVIS Spectrum, the 
Living Image software generated a photographic image of the organ overlaid with a 
representation of fluorescence intensity.  Region of interest (ROI) are selected around 
individual organs and total fluorescence intensity within the ROI is calculated by the 
software.  Background fluoresecne intensity is measured and subtracted meaning that only 
fluorescence generated by the imaged organ is measured.  This representative image taken 
of a liver one day following the injection of 1x106 DiR labelled HPC-7 cells demonstrates 
fluoresecne intensity within the ROI of 1.901x109. 
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2.28  Identification of Injected Cells from Tissue Samples 
Single cell suspensions of livers, spleens, kidneys and lungs from each mouse were prepared 
and enriched for mononuclear cells by centrifugation on Optiprep as previously described.  
The resulting cell suspensions were centrifuged and resuspended in PBS + 1% FCS. PE 
conjugated anti-CD45 antibody was added at a concentration of 1:100 and incubated on ice 
for 30 minutes.  The stained cells were centrifuged at 2000rpm for 5 minutes and 
resuspended in 1ml PBS + 1% FCS for analysis by flow cytometry.   Prior to analysis 20µl of 
Trucount beads were added to the sample to enable an accurate determination of total cell 
numbers.   The excitation and emission wavelengths of the DiR dye (748nm, 780nm) best 
correspond to those of the APC-Cy7 channel of the flow cytometer (650nm, 774nm).  Infused 
cells were identified by positive fluorescent staining in the APC-Cy7 channel and positive PE 
staining indicating cells which are CD45 positive and therefore haematopoietic lineages 
rather than as a result of dye contamination of other cells within the tissues. 
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3 THE ANTI-FIBROTIC EFFECT OF HAEMATOPOIETIC STEM CELLS 
 
3.1 Introduction 
There is a clear need for new therapies for liver disease, particularly with the increasing 
mismatch between supply and demand for liver transplantation.   There is considerable 
interest in the use of adult bone marrow stem cells as a new therapeutic option, intriguingly 
there have been a significant number of clinical studies performed despite a lack of 
convincing evidence from pre-clinical studies.  In particular questions remain unanswered as 
to the most effective cell population to use and the mechanisms by which theses cells exert 
a beneficial effect.    
Both animal and human studies to date have examined the beneficial effect of a variety 
different bone marrow cell populations, ranging from fresh unsorted bone marrow 
preparations to specific differentiated populations of bone marrow derived cells, for 
example macrophages (Forbes et al. 2012).   Stem and progenitor cells comprise a very small 
proportion of the total bone marrow cell population, which is an extremely heterogeneous 
population of cells containing cells at differing stages of differentiation and maturity.  This 
means that in many of the animal and human studies it is not clear whether there is a 
specific cell type within the bone marrow exerting a beneficial effect.  The heterogeneous 
nature of the studies to date make cross comparison of efficacy and pooling of data virtually 
impossible, however a common message from the human studies to date is that bone 
marrow stem cell therapy in patients with liver disease is safe and feasible (Houlihan et al. 
2008).   The initial human studies have suggested a beneficial effect but none have been 
designed, controlled or powered to robustly detect a significant improvement in liver 
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function.  Larger, randomised controlled trials of stem cell therapy for liver disease are 
currently underway which will hopefully help determine the efficacy of specific cell types but 
are unlikely to elucidate the mechanisms of benefit. 
Haematopoietic stem cells can be readily defined by their surface marker phenotype in mice 
and in humans, isolation from donor mouse bone marrow is straightforward and in humans 
routine protocols are in place for obtaining autologous stem cells (Gratwohl et al. 2010).  
The isolation of clinical grade HSC from human donors is now a routine procedure and 
means that use of HSC in clinical studies can be facilitated.  
There have only been two studies reporting the used of purified (ie KSL) HSC in animal 
models of liver injury.   Both studies reported a significant improvement in hepatic fibrosis 
following infusion of HSC.  Li and colleagues demonstrated a reduction in hepatic fibrosis and 
improved hepatocyte regeneration in a carbon tetrachloride model of liver injury, and whilst 
they showed that some infused cells adopted a hepatocyte phenotype this in itself did not 
explain the beneficial effect. Significant alterations in serum concentrations of inflammatory 
and regenerative cytokines and growth factors were seen after cell infusion(Li et al. 2013). 
Cho and co-workers also showed a reduction in hepatic fibrosis following infusion of 
HSC.(Cho et al. 2011).  In both studies 1x106 cells were infused and in one study cells were 
isolated on KSL and then cultured in vitro with no reassessment of cell phenotype or 
function following culture.  This number of cells corresponds to approximately 40-50 million 
HSC per kilogram of bodyweight which is vastly higher than the number of cells used in any 
previous animal or human study. 
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The cellular and molecular mechanisms underlying any potential beneficial effect of HSC cell 
therapy have yet to be determined.  It is now apparent that the concept of 
transdifferentiation or cell fusion of bone marrow stem cells to hepatocytes is now an 
extremely rare event and would not be of functional significance(Aurich et al. 2007).  It is 
likely when this phenomenon is observed that it is due to differentiation of pluripotent very 
small embryonic like stem cells contaminating preparations of purified stem cells, rather 
than transdifferentiation of more committed stem and progenitor cells(Kucia et al. 2006).  
Observations from more recent studies have given greater weight to the concept that 
infused cells provoke alterations in the surrounding tissue environment – the so-called 
‘paracrine effect’ – which result in fibrosis regression and hepatocyte regeneration.   
Increased expression of matrix metalloproteinases by either host derived cells(Thomas et al. 
2011) or infused cells(Sakaida et al. 2004) drive the regression of fibrosis, and recruitment of 
host derived cells crucial to the regression of fibrosis such as macrophages and neutrophils 
may be as a result of increased chemokine production from infused cells(Thomas et al. 
2011).  Infused cells expressing growth factors such as HGF and VEGF may stimulate 
hepatocyte proliferation and progenitor cell responses(Majka et al. 2001; Houlihan et al. 
2008). 
The majority of chronic liver injury is due to repeated exposure to the injurious agent and it 
is often not possible to treat or remove the injury.  No previous studies have examined the 
benefits of repeated treatment with stem cell therapy in liver disease but instead have 
focussed on a one off treatment. 
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In this first section of work I will determine the effect of repeated injections of purified 
haematopoietic stem cells on chronic liver injury.  I will attempt to elucidate further the 
mechanisms by which such benefits may be mediated with particular interest in the fate of 
the infused cells. 
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3.2 Repeated carbon tetrachloride administration induces chronic liver injury in mice 
Carbon tetrachloride was used at a dose of 1mg/kg body weight (diluted 1:4 in mineral oil 
vehicle) and administered to mice by intra peritoneal injection.  After 8 weeks of treatment a 
significant chronic liver injury had developed.   
Overall survival of all animals with chronic liver injury was greater than 95%.   
On macroscopic examination of the animals the livers of the injured mice appeared pale, 
hard with irregular edges.  There was evidence of splenomegaly and ascites was present 
within the abdominal cavity.   
Histological examination of the livers using haematoxyin and eosin staining demonstrated 
architectural distortion with a marked inflammatory cell infiltrate (Fig 3.1A,B).   Picrosirius 
red staining demonstrated deposition of collagen with bridging fibrosis between portal tracts 
(Fig 3.1C,D). 
A deterioration in hepatic synthetic function was also observed with a marked reduction in 
serum albumin (Control 4.22+/- 0.37 g/dl vs Injury 3.85+/-0.22 g/dl, p<0.05). 
 
 
 
 
 
 
 
   120 
 
 
 
Figure 3.1   
Carbon Tetrachloride Liver Injury 
 
Chronic liver injury was induced in age and sex matched C57/BL6 mice by twice weekly 
intraperitoneal administration of carbon tetrachloride (1mg/kg) in mineral oil for 8 weeks. 
Control mice received twice weekly intraperitoneal injections of mineral oil.  Tissue sections 
from both carbon tetrachloride treated mice and control mice were stained with 
haematoxylin and eosin (A,B) and with picrosirius red (C,D).  Mice treated with carbon 
tetrachloride developed significant liver injury including hepatocyte necrosis, inflammatory 
cell infiltrates, steatosis and deposition of collagenous fibrous tissue bridging between portal 
tracts. 
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3.3 Increased numbers of bone marrow derived HSC are found in the liver and blood 
during chronic liver injury 
It has been previously shown that haematopoietic stem cells can be found within the liver 
under physiological conditions and that following liver injury are mobilised from the bone 
marrow into the circulation(Wright et al. 2001; Lemoli et al. 2006; Gehling et al. 2010).  I 
used the carbon tetrachloride model of liver injury to investigate in more detail the effect of 
chronic liver inury on c-kit+ sca1+ lin- (KSL) haematopoietic stem cell mobilisation and 
recruitment to the liver.   Chronic liver injury was induced in mice by twice weekly 
administration of carbon tetrachloride for 8 weeks, mice were then sacrificed and bone 
marrow, peripheral blood and liver obtained.   KSL cells were quantified by flow cytometry as 
shown in Figure 3.2. Colony forming unit assays were used as a functional assessment of 
stem cell number. 
Significantly higher numbers of HSC determined by c-kit+ sca1+ lin- (KSL) surface phenotype 
were found in the livers (Injury 1163 +/- 173 KSL cells per liver vs Control 258.5+/-22.2 KSL 
cells per liver, p<0.01) and peripheral blood (Injury 0.397+/-0.055 KSL cells per µl blood vs 
Control 0.0674+/-0.011 KSL cells per µl blood, p<0.001) of mice with liver injury compared 
with control mice (Fig 3.3A,B).  The numbers of HSC within the bone marrow remained 
constant (Injury 2323+/-48.9 KSL cells per femur vs Control 2327+/-64.3 KSL cells per femur, 
p=ns) (Fig 3.3C).  A similar increase in the numbers of colony forming cells (CFC) within the 
liver (Injury 178.8+/-21.9 CFC per liver vs Control 38.0+/-6.15 CFC per liver, p<0.001)(Fig 
3.4B) and peripheral blood (Injury 83.42+/-13.6 CFC per ml blood vs Control 42.29 CFC per 
ml blood, p<0.05)(Fig 3.4A), and no change  
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Figure 3.2   
Identification of c-kit+ sca1+ lineage- cells within liver and peripheral blood  
 
 
Chronic liver injury was induced in age and sex matched C57/BL6 mice by twice weekly 
intraperitoneal administration of carbon tetrachloride (1mg/kg) in mineral oil for 8 weeks. 
Control mice received twice weekly intraperitoneal injections of mineral oil.  Peripheral 
blood was obtained by cardiac puncture under terminal anaesthesia and livers were 
dissected out and flushed to remove circulating blood.  Following collagenase digestion and 
enrichment for mononuclear cells using a density centrifugation gradient a single cell 
suspension was obtained from liver tissue, which was labelled with fluorescently conjugated 
antibodies to c-kit, sca-1 and lineage markers.   (A) Dead cells and cellular debris was 
excluded on  a forward scatter – side scatter plot, lineage negative cells identified and 
expression of c-kit and sca-1 determined in these cells.  (B) Representative plots from control 
and carbon tetrachloride treated mouse livers are displayed.  (C) Peripheral blood samples 
were treated with red cell lysis buffer, labelled with fluorescent antibodies in a similar 
manner to liver samples and a similar flow cytometry gating strategy used.  (D) 
Representative samples of peripheral blood from control and carbon tetrachloride treated 
mice are displayed. 
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Identification of c-kit+ sca1+ lineage- cells within liver and peripheral blood
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Figure 3.3   
Increased numbers of c-kit+ sca1+ lineage- cells are found in the liver and peripheral blood 
of mice with chronic liver injury  
 
Chronic liver injury was induced in age and sex matched C57/BL6 mice by twice weekly 
intraperitoneal administration of carbon tetrachloride (1mg/kg) in mineral oil for 8 weeks. 
Control mice received twice weekly intraperitoneal injections of mineral oil.  HSC were 
defined as c-kit+ sca1+ lineage negative (KSL) and were identified in tissue and blood 
samples as previously described.  Absolute cell numbers were quantified using counting 
beads and samples were run in duplicate.  (A,B) Significantly higher numbers of KSL cells 
were detected in the peripheral blood and livers of carbon tetrachloride treated mice than 
controls. (C) No difference was seen in the bone marrow. Data from individual mice is 
displayed (circles : control, squares : carbon tetrachloride treated) and means indicated by 
horizontal line.  **p<0.01 ***p<0.001(unpaired student’s t-test) 
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Figure 3.4   
Increased numbers of colony forming cells are found in the liver and peripheral blood of 
mice with chronic liver injury  
 
Chronic liver injury was induced in age and sex matched C57/BL6 mice by twice weekly 
intraperitoneal administration of carbon tetrachloride (1mg/kg) in mineral oil for 8 weeks. 
Control mice received twice weekly intraperitoneal injections of mineral oil.  Colony forming 
cells (CFC) within the liver, blood and bone marrow were quantified in myeloid CFU assays. 
(A,B) Significantly higher numbers of CFC were detected in the peripheral blood and livers of 
carbon tetrachloride treated mice than controls. (C) No difference was seen in the bone 
marrow. Data from individual mice is displayed (circles : control, squares : carbon 
tetrachloride treated) and means indicated by horizontal line.  * p<0.05 ***p<0.001 
(unpaired student’s t-test) 
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was observed within the bone marrow (Injury 11750+/-899 CFC per femur vs Control 
131500+/-1181 CFC per femur, p=ns) (Fig 3.4C). 
The liver is a site of fetal haematopoiesis and populations of liver resident HSC have been 
described(Taniguchi et al. 1996).  In order to test my hypothesis that the increased numbers 
of HSC within the liver and blood are bone marrow derived I devised a bone marrow 
transplantation protocol that would enable tracking of bone marrow derived cells.  BoyJ and 
C57BL6 mice differ in CD45 antigen expression, designated as CD45.1 (Ptprca BoyJ) and 
CD45.2 (Ptprcb C57BL6).  Ptprc is a protein tyrosine phosphatase, homologous to the CD45 
protein (Charbonneau et al. 1988), the a allele is carried by BoyJ (CD45.1+) mice and the b 
allele by C57BL6 (CD45.2+) mice.   This phenotypic difference has been widely used in 
competitive bone marrow repopulation experiments to track donor cells.   
BoyJ (CD45.1) mice received sub lethal doses of irradiation followed by transplantation of 
bone marrow cells from donor C57BL6 (CD45.2) mice (Fig 3.5A).  Analysis of peripheral blood 
and bone marrow from transplanted mice showed almost universal bone marrow 
reconstitution with CD45.2 (ie donor derived) cells  after 4 weeks (Fig 3.5B,C).  Subsequently 
transplanted mice underwent  8 weeks carbon tetrachloride administration, were sacrificed 
and bone marrow derived HSC quantified by flow cytometry, defined as CD45.2+ lin- sca1+ 
ckit+.   
The findings were in keeping with those seen in the initial experiments, with an 
approximately five fold increase in the numbers of bone marrow derived KSL cells in the 
peripheral blood (Injury 0.333+/-0.064 CD45.2 KSL cells per µl blood vs Control 0.077+/-
0.009 CD45.2 KSL cells per µl blood, p<0.01) (Figure 3.6A) and a three fold increase in the  
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Figure 3.5  
Generation of Bone Marrow Chimersim and Subsequent Chronic Liver Injury 
 
(A) Recipient BoyJ (CD45.1) mice received Baytril antibiotic in drinking water one week prior 
and one week following irradiation with 9Gy in two divided doses on the same day.  Bone 
marrow cells were obtained from donor C57BL6 (CD45.2) mice by flushing of the tibia and 
femurs.  Six hours following irradiation donor bone marrow cells were infused into recipient 
mice by tail vein injection.  After 4 weeks recovery, transplanted mice were divided into two 
groups at random with one group receiving twice weekly intraperitoneal administration of 
carbon tetrachloride (1mg/kg) in mineral oil and the other group receiving intraperiotneal 
injections of mineral oil alone for a further 8 weeks.   (B,C) Samples of bone marrow and 
peripheral blood were treated with red cell lysis buffer and labelled with fluorescent 
antibodies to CD45.1 and CD45.2.  Analysis of CD45 expression by flow cytometry revealed 
almost complete CD45.2 expression following transplantation compared with CD45.1 
expression prior to transplantation.  Representative flow cytometry plots of multiple 
experiments are shown. 
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Figure 3.6  
Increased numbers of bone marrow derived c-kit+ sca1+ lineage- cells in the liver and 
peripheral blood during liver injury  
 
 
Recipient BoyJ (CD45.1) mice received Baytril antibiotic in drinking water one week prior and 
one week following irradiation with 9Gy in two divided doses on the same day.  Bone 
marrow cells were obtained from donor C57BL6 (CD45.2) mice by flushing of the tibia and 
femurs.  Six hours following irradiation donor bone marrow cells were infused into recipient 
mice by tail vein injection.  After 4 weeks recovery, transplanted mice were divided into two 
groups at random with one group receiving twice weekly intraperitoneal administration of 
carbon tetrachloride (1mg/kg) in mineral oil and the other group receiving intraperitoneal 
injections of mineral oil alone for a further 8 weeks.  Bone marrow derived HSC were defined 
as CD45.2+ c-kit+ sca1+ lineage negative (CD45.2+ KSL) and were identified in liver and 
peripheral blood samples as previously described.  Absolute cell numbers were quantified 
using counting beads and samples were run in duplicate.  (A,B) Significantly higher numbers 
of bone marrow derived CD45.2+ KSL cells were detected in the peripheral blood and livers 
of carbon tetrachloride treated mice than controls. Data from individual mice is displayed 
(circles : control, squares : carbon tetrachloride treated) and means indicated by horizontal 
line.  ** p<0.01 ***p<0.001 (unpaired student’s t-test) 
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liver (Injury 788.2+/-59.79 CD45.2 KSL cells per liver vs Control 292.6+/-44.78 CD45.2 KSL 
cells per liver, p<0.001) (Fig 3.6B) of mice with liver injury when compared with control mice, 
whilst KSL cells within the bone marrow remained unchanged (Injury 3162+/-94 CD45.2 KSL 
cells per femur vs Control 2954+/-87 CD45.2 KSL cells per femur, p=ns). 
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3.4 Repeated infusions of HSC results in significant improvement in hepatic fibrosis 
Having demonstrated that there is mobilisation and recruitment of bone marrow derived 
HSC in liver injury, I sought to determine whether repeated injection of purified HSC would 
result in a reduction in hepatic fibrosis. 
BoyJ mice were randomly allocated to either treatment (n=8) or control (n=8) groups and all 
mice received 6 weeks of twice weekly carbon tetrachloride injections.  C57BL6 mice were 
used as donor mice for the KSL cells to be infused, 5x104 freshly isolated KSL cells were 
injected via the tail vein to the mice in the treatment group at the start of weeks 7,8 and 9.  
Carbon tetrachloride continued to be administered to both groups until seven days after the 
final cell injection and mice were sacrificed at 72 hours after then final carbon tetrachloride 
injection and 7 days after the final cell injection (Fig 3.7). 
Quantitative morphometric analysis of fibrosis in the liver using picrosirius red staining 
revealed significantly lower levels of collagen deposition within the liver with a 49.7% 
reduction in staining in the KSL cell treatment group compared with controls (KSL 2.207+/-
0.119 % staining area vs Control 4.388+/-0.27 %staining area, p<0.0001)(Fig 3.8A,B).   
Hepatic hydroxyproline content was also significantly lower in the KSL cell treatment group 
(KSL 328.5+/-30.4 mg Hyp per g liver vs Control 428.4+/-31.9 mg Hyp per g liver, p<0.05 ) (Fig 
3.8C).  
Serum albumin levels were measured as a marker of liver synthetic function and was 
previously shown to be lower in mice with chronic liver injury.  In the treatment group the 
serum albumin levels were significantly higher than those in the control group (KSL 4.06 +/- 
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0.37 vs Control 3.14+/-0.39, p<0.01)(Fig 3.8D), demonstrating an improvement in liver 
function. 
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Figure 3.7 
Investigation of the effects of repeated infusions of purified c-kit+ sca1+ lin- in a murine 
model of chronic liver injury - Experimental timeline   
 
Chronic liver injury was induced in age and sex matched C57/BL6 mice by twice weekly 
intraperitoneal administration of carbon tetrachloride (1mg/kg) in mineral oil for 6 weeks, 
mice were then randomly allocated to either control or cell treatment group.  (A) Mice in the 
control group continued to receive twice weekly injections of intraperitoneal carbon 
tetrachloride until week 10 and were sacrificed 72 hours following the final injection of 
carbon tetrachloride. (B) Mice in the cell treatment group received twice weekly carbon 
tetrachloride in the same way as control mice but in addition received a tail vein injection of 
5x104 purified KSL cells isolated from C57/BL6 donor mice on the first day of weeks 7,8 and 
9, mice were sacrificed 72 hours after the final injection of carbon tetrachloride which was 7 
days following the final cell injection. 
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Figure 3.8 
 Significant improvement in hepatic fibrosis following repeated injection of purified KSL 
cells  
 
(A) Formalin fixed paraffin embedded liver tissue sections from mice treated with KSL cell 
infusions (white bars) and control mice (black bars) were stained for picrosirius red.  6 
random, non-overlapping images were obtained from each section and staining was 
quantified as a percentage of the image positive for picrosirius red using ImageJ software.  
Significantly lower levels of picrosirius red staining was detected in mice treated with KSL cell 
infusions than in control mice. n=8 each group, mean +/-SD % area stained shown, *p<0.05 
(two tailed, unpaired students t-test).   (B) Representative photomicrograph images (x20 
magnification) of picrosirius red staining (red, no counterstain) from control and KSL treated 
mice.   (C) Hydroxyproline content in samples of liver tissue from KSL cell treated mice (white 
bars) and control mice (black bars) was determined and expressed as mg of Hydroxyproline 
per gram of liver tissue. Significantly lower amounts of hydroxyproline were found in livers 
from mice receiving repeated KSL cell injections compared with livers from control mice. n=8 
each group, mean+/-SD hydroxyproline content shown, *p<0.05 (two tailed, unpaired 
students t-test). (D) Serum samples were obtained by centrifugation of whole blood from 
control mice (black bars) and mice treated with KSL cell injections (white bars) and serum 
albumin concentration was measured by bromocresol green colorimetric assay.  Serum 
albumin concentration was higher in mice treated with KSL cell injections than control mice. 
n=8 each group, mean+/-SD serum albumin concentration shown, *p<0.05 **p<0.01 
***p<0.001(two tailed, unpaired students t-test). 
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A key process in the development of chronic liver injury is activation of hepatic stellate cells 
to αSMA expressing activated myofibroblasts.  Morphometric analysis of liver sections 
stained for αSMA by immunohistochemistry showed a marked three fold reduction in αSMA 
positive staining area in the KSL cell treatment group (KSL 2.422+/-0.20 % staining area vs 
Control 7.055+/-0.334 % staining area, p<0.0001 )(Fig 3.9A,B).  Quantitative analysis of genes 
expressed by activated myofibroblasts  demonstrated a 0.19+/-0.07 fold reduction in hepatic 
αSMA expression (p<0.0001) and a 0.29+/-0.14 fold reduction in hepatic col1α1 expression 
(p<0.0001) in mice treated with KSL cells (Fig 3.9 C,D).   
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Figure 3.9 
Significant reduction in hepatic activated myofibroblasts following repeated injections of 
purified KSL cells  
 
(A) Formalin fixed paraffin embedded liver tissue sections from mice treated with KSL cell 
infusions (white bars) and control mice (black bars) were stained for aSMA.  6 random, non-
overlapping images were obtained from each section and staining was quantified as a 
percentage of the image positive for aSMA using ImageJ software.  Significantly lower levels 
of aSMA staining was detected in mice treated with KSL cell infusions than in control mice. 
n=8 each group, mean +/-SD % area stained shown, ***p<0.001 (two tailed, unpaired 
students t-test).   (B) Representative photomicrograph images (x20 magnification) of aSMA 
staining (brown, DAB substrate, haematoxylin counterstain) from control and KSL treated 
mice.   (C,D) RNA was extracted from liver tissue from mice treated with KSL cell infusions 
(white bars) and control mice (black bars) and using quantitative RT-PCR gene expression of 
(C)col1a1 and (D) aSMA were determined, normalised to GAPDH expression and relative to 
control mice using the 2-ddCT method. Hepatic gene expression of both col1a1 and aSMA was 
significantly lower in KSL cell treated mice than control mice. n=8 each group, mean +/-SD 
fold change shown, ***p<0.001 (wilcoxon signed rank test). 
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3.5 Increased numbers of recipient derived rather than donor derived cells 
HSC infused in this series of experiments were derived from C57BL6 mice and were CD45.2+ 
and the recipient mice with chronic liver injury were BoyJ CD45.1+ mice.  Sections from livers 
of the treated mice were analysed for the presence of infused cells by immunohistochemical 
staining for CD45.2.  Despite analysing multiple serial and non-serial tissue sections, CD45.2+ 
cells were largely not detected and were found in isolation only rarely (Fig 3.10).  Due to the 
scarcity of these cells within the liver sections at seven days after infusion it was not possible 
to analyse further for any lineage differentiation or transdifferentiation that may have 
occurred to be responsible for the beneficial effect  observed.  It was clear, however, that 
there are not significant numbers of infused cells localised to areas of fibrosis or 
inflammation at this timepoint. 
The effect of HSC infusions on endogenous repair mechanisms via a ‘paracrine effect’ has 
been postulated as the most likely mechanism by which infused mononuclear cells exert 
their effect (Houlihan et al. 2008; Forbes et al. 2012).  The effect of repeated HSC infusions 
on endogenous cell populations postulated to be involved in the resolution of fibrosis was 
analysed by immunohistochemical analysis of liver sections for F4/80 as a marker of 
macrophages(Austyn et al. 1981) and Ly6G as a marker of neutrophils(Fleming et al. 1993).  
Liver sections from mice treated with KSL cells contained higher numbers of both F4/80+ 
(KSL 44.2+/-11.8 cells per fov vs Control 24.99+/-7.5 cells per fov, p<0.0001)(Fig 3.11C,D) and 
Ly6G+ (KSL 12.42+/-2.74 cells per fov vs Control 5.646+/-2.514 cells per fov, p<0.0001) (Fig 
3.11A,B) cells compared with controls. 
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Figure 3.10  
Absence of significant numbers of injected cells in the liver seven days after injection  
 
Formalin fixed paraffin embedded liver tissue sections were taken from mice seven days 
after the final injection of KSL cells and from control mice and stained for CD45.2 expression, 
indicating the presence of injected cells or progeny of infused cells. The detection of CD45.2 
positive cells was an extremely rare event. (A,B) Representative photomicrograph images 
(x20 magnification) of CD45.2 staining of liver sections from (A) control and (B) KSL cell 
treated mice, one image demonstrated the presence of a CD45.2 positive cell with higher 
magnification (x100) image shown (inset box).  
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Absence of significant numbers of injected cells in the liver seven days 
after injection
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Figure 3.11   
Increased numbers of endogenous cell populations within the liver following repeated 
injection of purified KSL cells   
 
Formalin fixed paraffin embedded liver tissue sections from mice treated with KSL cell 
infusions (white bars) and control mice (black bars) were stained for F4/80 and Ly6G.  (A,C) 
Representative photomicrograph images of liver sections from control and KSL treated mice 
stained for (A) Ly6G (brown, DAB substrate, haematoxylin counterstain, x20 magnification) 
and (C) F4/80 (brown, DAB substrate, haematoxylin counterstain, x100 magnification). (B,D) 
The number of individual stained cells were manually counted in 6 random, non-overlapping 
fields of view (x100 for F4/80, x20 for Ly6G). Significantly higher numbers of Ly6G+ and 
F4/80+ cells were seen within the livers of mice treated with KSL cells compared with 
controls. n=8 each group, mean+/-SD number of cells per field of view shown, ***p<0.001 
(two tailed, unpaired students t-test).   
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Increased numbers of endogenous cell populations within the liver 
following repeated injection of purified KSL cells
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I concluded that these cells represented endogenous, recipient derived cells as they were 
present in significant numbers with a complete lack of cells staining positive for CD45.2 (Fig 
3.10), the phenotype of the donor cells.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   150 
 
3.6 Myeloid and lymphoid progenitor cells exert a similar anti fibrotic effect as HSC 
There has been particular interest in the beneficial effect of cells of the monocyte-
macrophage lineage in liver injury(Thomas et al. 2011; Bird et al. 2013). One of the earliest 
stages in HSC differentiation is that of commitment to a common myeloid progenitor (CMP) 
or a common lymphoid progenitor (CLP).  I investigated whether differentiation into cells of 
a myeloid lineage is a potential mechanism by which HSC exert their beneficial effect by 
examining the effect of myeloid and lymphoid progenitors on hepatic fibrosis. 
CMP were defined as c-kit+ sca1- lineage- IL7Rα- and CLP as ckit lo sca1 lo lineage- IL7Rα+ 
(Kondo et al. 1997) and were freshly isolated from C57BL6 donor mice (Fig 3.12A).  Colony 
forming unit assays were performed to determine myeloid colony forming ability.  Large 
numbers of myeloid colonies were grown from freshly isolated HSC (73.5+/-6.4 CFC per 500 
cells), whilst colonies from CMP were less plentiful (17.5+/-8.3 CFC per 500 cells).  Only 
rarely could myeloid colonies be identified from freshly isolated CLP (1.1 +/- 0.202 CFC per 
500 cells), demonstrating their inability to differentiate into cells of myeloid lineage (Fig 
3.12B). 
Further experiments were performed according to the previous protocol, however repeated 
infusions of either CMP or CLP were administered in place of KSL cells.  
Assessment of hepatic fibrosis demonstrated a significant reduction in picrosirius red 
staining in mice receiving either CMP or CLP  to levels comparable with HSC treatment (KSL 
2.207+/-0.119 % staining area, CMP 1.937+/-0.129 %staining area, CLP 2.269+/-0.133 
%staining area vs Control 4.38+/-0.27 %staining area, all p<0.01, one way anova with 
Bonferroni post test correction) (Fig 3.13A).  Hepatic hydroxyproline content was also 
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significantly lower in both the CMP and CLP groups compared with control mice (KSL 
328.5+/-30.3 mg Hyp per g liver, CMP 331.5+/-22.5 mg Hyp per g liver, CLP 360.8+/-27.1 mg 
Hyp per g liver vs Control 428.4+/-31.9 mg Hyp per g liver, all groups: p<0.05, one way anova 
with Bonferroni post test correction)(Fig 3.13B)  Analysis of αSMA staining showed a 
significant reduction after both CMP and CLP infusions (KSL2.42+/-0.200 %staining area, 
CMP 2.792+/-0.255 % staining area, CLP 3.694+/-0.325 %staining area vs Control 7.055+/-
0.334 % staining area, p<0.001 all groups, one way anova with Bonferroni post test 
correction)(Fig 3.13D) and αSMA and col1α1 gene expression was significantly lower in both 
groups at levels similar to those seen after HSC infusions (Fig 3.13E,F).  Serum albumin levels 
were significantly higher than control in both the CMP and CLP treated mice, although the 
improvement was not as marked as seen in KSL treated mice (KSL 4.06+/-0.37 g/dl, CMP 
3.513+/-0.28 g/dl, CLP 3.517+/-0.35 g/dl vs Control 3.146+/-0.39, p<0.05 all groups, one way 
anova with Bonferroni post test correction)(Fig 3.13C).   
Overall the observed pattern of results demonstrated a similar beneficial effect of both 
myeloid and lymphoid progenitors suggesting that myeloid differentiation is not a key 
mechanism involved in the beneficial action of HSC and that early progenitor cells appear 
equally as efficacious as more primitive stem cells. 
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Figure 3.12 
Isolation of common myeloid and common lymphoid progenitor cells 
 
Bone marrow cells were obtained from donor mice following dissection of the tibia and 
femurs by flushing the marrow cavity with DMEM + 10%FCS.  Cells were treated with red cell 
lysis buffer and filtered prior to labelling with fluorescently conjugated antibodies to lineage 
specific markers (CD11b, CD8a, CD5, Ter119, Gr-1, B220), c-kit, sca-1 and IL-7Ra.  (A) After 
exclusion of cell debris, dead cells and cell doublets, a further division of the lineage negative 
fraction was made on Il7Ra expression, followed by c-kit and sca-1 expression.  Common 
myeloid progenitors (CMP) were defined as lineage negative, IL7Rα-, c-kit+, sca1- and 
common lymphoid progenitors (CLP) as lineage negative, IL7Rα +, c-kit lo , sca-1 lo.  (B) The 
ability of each stem and progenitor cell population to form myeloid colonies was determined 
by myeloid CFU assay.  KSL (white bars) and CMP (grey bars) cells formed colonies of myeloid 
cells but CLP (black bars) did not.  Mean +/- SD number of colonies formed per 500 plated 
cells displayed. Assays performed in duplicate from 3 separate isolations. 
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Figure 3.13   
Repeated injection of either purified CMP or CLP results in a similar anti fibrotic effect to 
purified KSL cells   
 
(A) Formalin fixed paraffin embedded liver tissue sections from mice treated with KSL (white 
bars), CMP (light grey bars) and CLP (dark grey bars) cell infusions and control mice (black 
bars) were stained for picrosirius red.  6 random, non-overlapping images were obtained 
from each section and staining was quantified as a percentage of the image positive for 
picorsirius red using ImageJ software.  A similar reduction in picorsirius red staining was seen 
in all three treatment groups (KSL,CMP and CLP) compared with control mice. n=8, mean +/-
SD % area stained shown, *p<0.05 vs control (one way anova with bonferroni multiple 
comparison test).   (B) Hydroxyproline content in samples of liver tissue from KSL (white 
bars), CMP (light grey bars) and CLP (dark grey bars) cell treated mice and control mice 
(black bars) was determined. Significantly lower amounts of hydroxyproline were found in 
livers from mice receiving repeated KSL, CMP or CLP cell injections compared with livers 
from control mice. n=8, mean+/-SD hydroxyproline content shown, *p<0.05 (one way anova 
with bonferroni multiple comparison test). (C) Serum samples were obtained by 
centrifugation of whole blood from control mice (black bars) and mice treated with KSL 
(white bars), CMP (light grey bars) and CLP (dark grey bars) cell injections (white bars) and 
serum albumin concentration was measured by bromocresol green colorimetric assay.  
Serum albumin concentration was higher in mice treated with KSL , CMP and CLP cell 
injections than control mice. n=8, mean+/-SD serum albumin concentration shown, *p<0.05 
(one way anova with bonferroni multiple comparison test). (D) Formalin fixed paraffin 
embedded liver tissue sections from mice treated with KSL (white bars), CMP (light grey 
bars) and CLP (dark grey bars) cell infusions and control mice (black bars) were stained for 
aSMA.  6 random, non-overlapping images were obtained from each section and staining 
was quantified as a percentage of the image positive for aSMA using ImageJ software.  A 
similar reduction in aSMA staining was seen in all three treatment groups (KSL,CMP and CLP) 
compared with control mice. n=8, mean +/-SD % area stained shown, *p<0.05 vs control 
(one way anova with bonferroni multiple comparison test).  (E,F) RNA was extracted from 
liver tissue from mice treated with KSL (white bars), CMP (light grey bars) and CLP (dark grey 
bars) cell infusions and control mice (black bars) and using quantitative RT-PCR gene 
expression of (E)col1a1 and (F) aSMA were determined, normalised to GAPDH expression 
and relative to control mice using the 2-ddCT method. Hepatic gene expression of both col1a1 
and aSMA was significantly lower in KSL, CMP and CLP cell treated mice than control mice. 
n=8 each group, mean +/-SD fold change shown, *p<0.05 (wilcoxon signed rank test). 
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3.7 Conclusions 
There has been considerable interest in the therapeutic benefits of bone marrow derived 
stem cells for patients with liver disease.  There have however been mixed reports of the 
effects of injecting unselected bone marrow cells which comprise a heterogeneous 
population of cells, and the specific cell type or types responsible for either an anti- or pro- 
fibrotic effect is not clear(Sakaida et al. 2004; Cho et al. 2011; Thomas et al. 2011).  In this 
first part of work I sought to clarify the effect of a specific, purified population of bone 
marrow cells – the c-kit+ sca1+ lineage – fraction – which represents primitive 
haematopoietic stem cells and early mulitpotent progenitor cells. 
I have shown that increased numbers of haematopoietic stem cells are mobilised into the 
bloodstream and recruited into the liver during chronic liver injury and importantly, have 
confirmed through the generation of bone marrow chimerism that these HSC are derived 
from the bone marrow rather than an expansion of liver resident HSC, a site of fetal 
haematopoiesis (Taniguchi et al. 1996).  This is in keeping with previous observations that 
HSC are present at higher numbers in the blood of patients following liver resection or 
transplantation (Lemoli et al. 2006; Gehling et al. 2010).  This may represent a mechanism of 
repair and regeneration when hepatocyte replication and hepatic progenitor cell responses 
are overwhelmed, and it has been shown that liver regeneration is significantly improved in 
patients receiving CD133+ cells prior to liver resection(am Esch et al. 2012). 
This work examined the effects on hepatic fibrosis of repeated injections of a purified 
population of haematopoietic stem and progenitor cells defined by the expression of c-kit 
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and sca-1 and lack of lineage markers.   Freshly isolated cells were administered through the 
tail vein into the systemic circulation at weekly intervals on 3 separate occasions.  
The findings of these studies demonstrate a marked reduction in hepatic fibrosis in mice 
treated with HSC compared with control mice receiving no treatment.  The beneficial effect 
of repeated injections of a relatively small number of highly purified HSC has not previously 
been shown. 
Significant reductions in extracellular matrix (ECM) deposition as measured by picrosirius red 
staining and hepatic hydroxyproline content were noted.  This was accompanied by a 66% 
reduction in αSMA+ activated hepatic myofibroblasts.  These observations are consistent 
with a reversal of the positive feedback that occurs during fibrogenesis whereby quiescent 
hepatic stellate cells undego activation to pro fibrogenic activated hepatic myofibroblasts 
with associated deposition of ECM, which in turn acts as a pro-survival signal for 
myofibroblasts.  These data suggest that injection of KSL cells interrupts this process and 
promotes breakdown of ECM and inactivation or apoptosis of myofibroblasts.  These studies 
were not designed to determine the precise mechanisms of action of KSL cell injection but 
rather to confirm their therapeutic effect in promoting resolution of fibrosis and to provide 
potential insights into the mechanisms involved which I will discuss further. 
 There was associated with this an improvement in serum albumin concentration which 
confirms that there was an improvement in liver function alongside the reduction in hepatic 
fibrosis.   
The experimental design of these studies was deliberately chosen with translation to human 
applications in mind, particularly as clinical trials of HSC in liver disease are 
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underway(www.clinicaltrials.gov). The number of cells to be infused and the route of 
delivery of the cells were two key variables considered.   
Two previous studies have shown the beneficial effect of a single injection of KSL cells on 
liver fibrosis, however in both cases 1x106 cells were injected – twenty fold the number of 
cells per injection in this work.  In one study KSL cells were cultured in vitro and injected 
prior to further phenotyping or assessment of colony forming ability.  KSL cells represent a 
rare population of cells, comprising 0.05% of bone marrow cells and the yield of KSL cells 
from one donor mouse was in the order of 5-10,000 KSL cells per mouse.  An injection of 
1x106 represents the administration of approximately 40x106 cells /kg to a C57BL6 mouse, 
the equivalent number of cells in a 70kg human would be 2.8x109 cells.  Lorenzini et al 
studied GCSF induced stem cell mobilisation and harvesting in patients with liver cirrhosis 
and showed that the mean number of HSC isolated was 1.2x106/kg(Lorenzini et al. 2008).  
The choice of number of cells to inject was made based in practical terms on the numbers of 
donor mice required but also for applicability of results to represent more closely the 
numbers of cells that could be isolated and used in patients with cirrhosis. 
Previous studies in both humans and animal models have used a variety of approaches to 
cell injection, including peripheral vein injection, portal vein injection and hepatic artery 
injection (Houlihan et al. 2008).   Access to the hepatic vessels requires specialised 
procedures involving significant risk, particularly if repeated injections are to be considered, 
and data from human studies have shown rare but catastrophic complications of hepatic 
vessel injection (Mohamadnejad et al. 2013).  These studies used a peripheral vein injection 
to administer the cells and no complications related to cell injection in these studies were 
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noted, although in the bone marrow transplantation studies one mouse died immediately 
after injection presumably due to massive embolus of either air or cells as not other signs of 
overwhelming injury or infection could be found.  It would be expected that a greater 
number of cells would engraft the liver if injected via the portal vein than if injected via a 
peripheral vein, however these findings suggest that the therapeutic effect is not completely 
lost.  The trafficking of injected cells and subsequent tissue distribution has not been well 
studied and will be addressed in subsequent parts of this work. 
I had hoped that the fate of the injected KSL cells may provide some insights into the 
potential mechanisms of effect and in these experiments injected donor cells could be 
identified by expression of CD45.2, given that recipient mice expressed CD45.1.  However, 
the identification of injected cells within recipient liver at seven days after injection was an 
extremely rare event and no meaningful conclusions could be obtained with regard to the 
fate of injected cells, either in location within the liver or subsequent phenotypic fate.  It 
raises the question whether repeated injection of cells is necessary to maintain the 
therapeutic effect or whether cell injection acts as a stimulus for endogenous repair which 
continues in the absence of the injected cells. 
I examined the effect of KSL cell injection on endogenous cell populations through 
immunostaining for the macrophage marker F4/80 and the neutrophil marker Ly6G.  Higher 
quantities of both cell populations were noted in the livers of mice which had received KSL 
cell injections.  In previous studies there have been mixed reports, where some authors have 
suggested that the anti fibrotic effect is mediated through recruitment of endogenous cells 
producing matrix metalloproteinases (Thomas et al. 2011) , others have suggested that 
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differentiation into cells of macrophage/monocyte lineages is the mechanism 
involved(Sakaida et al. 2004).   The lack of staining for the donor cell marker CD45.2 
confirmed that these were recipient derived cells, implying stimulation of endogenous repair 
mechanisms rather than differentiation of injected pluripotent KSL cells.  Further work to 
confirm upregulation of MMPs following KSL cell injection and to clarify the cellular source of 
MMPs (ie donor vs recipient) is required. 
The final studies in this part of work were designed to confirm whether differentiation of 
injected KSL cells into cells of a myeloid lineage, particularly those of macrophage-monocyte, 
given the reports of the anti fibrotic effect of bone marrow derived macrophages (Thomas et 
al. 2011).  I was able to isolate both common myeloid progenitors (CMP) and common 
lymphoid progenitors (CLP) through surface phenotyping(Kondo et al. 1997).  An assessment 
of colony forming cells confirmed that CMP possessed myeloid colony forming ability 
whereas CLP did not.  
The experimental design replicated that of the KSL studies and demonstrated that injection 
of either CMP or CLP resulted in an anti fibrotic effect remarkably similar to that seen with 
KSL cells. Injection of both cell types compared favourably with KSL cells, with significant 
reduction in hepatic collagen and numbers of αMSA+ hepatic myofibroblasts.  Theses studies 
conclude that differentiation to myeloid lineages is not required for stem or progenitor cells 
to generate an anti fibrotic effect and is not the key mechanism of action for these cells.  
These findings suggest that stimulation of endogenous repair mechanisms, mediated 
through production and secretion of molecular signalling mediators– the so-called ‘paracrine 
effect’- is the mechanism involved.  Primitive, undifferentiated stem and progenitor cells 
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may function as effector cells in the immune system and may regulate immune cell 
trafficking through their ability to produce and secrete cytokines and chemokines at higher 
concentrations than more mature, differentiated cells(Granick et al. 2012). 
In summary, I have shown for the first time the anti fibrotic effect of repeated infusions of 
purified HSC.  This has been achieved with smaller numbers of cells than used in previous 
studies which is encouraging as this represents cell numbers relevant to human studies. The 
injected cells could not be identified in the recipient livers although significant increases in 
endogenous cell populations were observed. 
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4 SPHINGOSINE 1-PHOSPHATE METABOLISM IN LIVER INJURY 
 
4.1  Introduction 
S1P is produced by the phosphorylation of sphingosine by sphingosine kinase 1 and 2 
(SPhK1,2) and degraded irreversibly for sphingosine lyase (SPhL)and reversibly by 
sphingosine phosphatise(SphP) (Olivera et al. 2013). S1P has a short half life (Venkataraman 
et al. 2008)() and therefore S1P levels are controlled by the balance of activity between 
synthesising and degrading enzymes(Venkataraman et al. 2008).   Sphingosine lyase is a 
predominantly tissue resident enzyme vital for maintaining low tissue concentrations of S1P, 
and is absent from platelets and erythrocytes which contain large intracellular stores of 
S1P(Ito et al. 2007).  Vascular endothelial cells, including hepatic sinusoidal endothelial cells 
contribute to the synthesis of S1P in the blood through expression of sphingosine kinase 
1(Venkataraman et al. 2008).  A role for the liver in S1P production is further suggested by 
the observation by Kurano et al that plasma S1P levels are lower in mice following 
hepatectomy (Kurano et al. 2013).  Furthermore, activation of SPhK has been demonstrated 
following stimulation by various growth factors and cytokines induced during liver injury (Xia 
et al. 1999; Rivera et al. 2008).  Venkataraman  and colleagues demonstrated that lymphatic 
endothelial cells are responsible for the synthesis of lymphatic S1P(Venkataraman et al. 
2008).  Intracellular signalling of S1P regulates many cellular processes(Rosen et al. 2009) 
and the balance between intracellular S1P and its metabolic precursor ceramide determines 
cell fate(Takabe et al. 2008).  S1P favours cell survival(Zhang et al. 1991; Olivera et al. 1993) 
whilst ceramide is pro-apoptotic(Cuvillier et al. 1996), controlled by the balance between 
synthesizing (sphingosine kinase) and degrading (sphingosine phosphatase and lyase) 
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enzymes.   Studies on the role of S1P in the constituent cells of the liver are limited.  In 
hepatocytes, Ikeda and colleagues  demonstrated that S1P exerted an antiproliferative effect 
in vitro which was mediated through increased Rho activation(Ikeda et al. 2003).   Bile acid 
induced hepatocyte apoptosis was accompanied by an increase in S1P levels and inhibition 
of sphingosine kinase 1 reduced apoptosis through suppression of intracellular calcium 
signalling (Karimian et al. 2013), whilst inhibition of sphingosine kinase 2 in hepatocytes 
subjected to anoxia-reoxygenation reduced both S1P production and hepatocyte death(Shi 
et al. 2012).  In contrast to the effects seen in hepatocytes, Zheng et al showed that 
exposure to S1P reduced ethanol induced apoptosis of sinusoidal endothelial cells by 
increasing intracellular calcium and endothelial nitric oxide synthetase activity(Zheng et al. 
2006).  The pathological hallmark of hepatic fibrosis is the activation of hepatic stellate cells 
to form fibrogenic myofibroblasts(Friedman 2008), stimulated by cytokines such as 
TGFβ(Henderson et al. 2008).  Yang et al observed a correlation between the hepatic 
expression of SphK1 and that of TGFβ (Yang et al. 2013), whilst TGFβ is also a potent 
stimulator of SphK activity(Rivera et al. 2008).  S1P has been shown to stimulate hepatic 
stellate cell proliferation and migration (Ikeda et al. 2000), mediated through the S1P2 
receptor as in S1P2 knock out mice accumulation of hepatic myofibroblasts was reduced 
following liver injury resulting in lower levels of hepatic fibrosis (Ikeda et al. 2009). Liu and 
colleagues demonstrated migration of human hepatic stellate cell line to S1P and stimulation 
of fibrogenesis by stellate cells upon exposure to s1P(Liu et al. 2011).  The contractility of 
hepatic stellate cells can be increased by S1P in vitro (Yang et al. 2013) and S1P also 
increased portal pressure in rats with chronic liver injury (Ikeda et al. 2004). It has been 
suggested that there is ‘crosstalk’ between S1P and TGFβ during liver injury promoting the 
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development of hepatic fibrosis, although the exact cellular and molecular mechanisms 
involved are yet to be discovered (Takuwa et al. 2012).   There is current interest in the 
contribution of bone marrow derived mesenchymal stem cells (MSC) to the hepatic 
myofibroblast population and it has been reported that homing of MSC to the injured liver is 
mediated by S1P signalling via the S1P3 receptor.  In murine models of liver injury 
administration of an S1P3 antagonist resulted in reduced MSC migration to the liver and a 
reduction in hepatic fibrosis(Li et al. 2009; Li et al. 2009). 
Alterations to S1P metabolism have been shown to occur under a variety of inflammatory 
and injurious conditions (Takuwa et al. 2012). Li and colleagues have shown significant 
increases in liver and serum S1P levels in both carbon tetrachloride and bile duct ligation 
murine models of liver injury(Li et al. 2009; Li et al. 2009).  The increase in hepatic S1P was 
associated with upregulation of hepatic SphK1 expression during liver injury with no 
alternations in SphL or SphP.  Hepatic SphK activity was correlated with serum S1P 
concentration, and as no corresponding increase in SphK in blood cells was observed lead 
the authors to surmise that the rise in serum S1P was derived from the liver (Li et al. 2009). 
Li also reported that in samples of human fibrotic liver, S1P levels were higher than normal 
liver accompanied by increased sphingosine kinase expression (Li et al. 2011). However, 
contrary to these findings, Ikeda measured plasma S1P levels in patients with chronic 
hepatitis C virus infection and found levels were significantly lower than in matched controls 
and that plasma S1P levels were inversely correlated with the degree of hepatic fibrosis 
(Ikeda et al. 2010). 
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S1P regulates migration of a variety of different cell types, including lymphocytes and other 
immune cell populations, mediated through maintenance of concentration gradients 
between different body fluids and tissues.  In particular, Massberg and colleagues have 
shown that S1P regulates the egress of HSC from peripheral tissues (low S1P concentration) 
into draining lymphatics (high S1P concentration)(Massberg et al. 2007).  There is also 
emerging evidence of the role of S1P in mobilisation of HSC from the bone marrow into the 
circulation (Ratajczak et al. 2010; Juarez et al. 2012)   
It is clear that alterations to S1P metabolism occur during liver injury which may directly 
(through autocrine or paracrine mechanisms) or indirectly through altered cellular migration 
affect the progression of liver injury.  The key to altered cell migration is changes in S1P 
gradients between body compartments. A greater understanding of the changes that occur 
to S1P metabolism during liver injury will provide further insights into the mechanisms of  
HSC trafficking. In this section of work my aim is to determine the changes that occur to S1P 
concentrations in liver injury and the mechanisms responsible for these changes. 
 
 
 
 
 
 
   166 
 
4.2 S1P levels in liver and serum are increased during chronic liver injury 
I used the carbon tetrachloride model of liver injury to investigate the differences in 
concentrations of S1P in different body compartments during chronic liver injury.  The areas 
of interest were the key tissues or fluids involved in the trafficking and recirculation of HSC 
as previously described (Massberg et al. 2007), namely the bone marrow, peripheral blood, 
liver and lymph fluid.    
Carbon tetrachloride was administered twice weekly for 8 weeks, which as previously shown 
induces a significant chronic liver injury.  Control mice received twice weekly injections of 
mineral oil, the diluting vehicle for carbon tetrachloride.   S1P levels were measured using a 
proprietary ELISA which has been shown to correlate with results obtained from high 
performance liquid chromatography(Kirby et al. 2009) (Prof L. Arend, personal 
communication). 
Higher concentrations of S1P were found in both the livers (Injury 68.79+/-7.42 pmol per mg 
protein vs Control 39.45+/-7.06 pmol per mg protein, p<0.05)(Fig 4.1B)and serum (Injury 
1.71+/-0.13 µM vs Control 1.15+/-0.18 µM, p=0.0025) (Fig 4.1A)of mice with chronic injury 
compared with control mice.  Although no significant difference was seen in S1P 
concentration in the bone marrow or lymph, there was a suggestion that levels in the bone 
marrow were lower (Injury 312.7+/-74.5 pmol per mg protein vs Control 378.5+/-86.1 pmol 
per mg protein, p=ns) (Fig 4.1C) and in the lymph were higher (Injury 0.104+/-0.015 µM vs 
Control 0.084+/-0.012 µM, p=ns) during liver injury (Fig 4.1D).  
Previous studies have demonstrated the importance of a gradient in S1P levels between 
different body compartments as being crucial for cellular migration.  The differences in the  
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Figure 4.1  
S1P Levels in Liver Tissue and Serum are elevated in Chronic Liver Injury induced by Carbon 
Tetrachloride  
 
Chronic liver injury was induced in age and sex matched C57/BL6 mice by twice weekly 
intraperitoneal administration of carbon tetrachloride (1mg/kg) in mineral oil for 8 weeks. 
Control mice received twice weekly intraperitoneal injections of mineral oil. Mice were 
sacrificed and levels of S1P in serum and lymph were measured directly  by ELISA and 
concentration quantified.  Samples of bone marrow and liver were homogenised in buffer as 
described (Section 2.18) and protein concentration determined by Bradford assay.  
Concentration of S1P within the homogenate was determined by ELISA and quantified 
relative to protein concentration in each sample. Bars represent mean +/- SEM. N=5 mice 
per group, *p<0.05,** p<0.01 (two tailed, unpaired students t-test). 
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Figure 4.1
S1P Levels in Liver Tissue and Serum are elevated in Chronic Liver Injury 
induced by Carbon Tetrachloride 
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units of measurement used and the methods of normalisation do not necessarily permit a 
direct comparison between the values for different body compartments and direct 
measurement of concentrations in the tissue interstitial fluid have not been possible.  
However when the relative changes in levels between control and injury are examined this 
suggests that the gradient between the bone marrow and peripheral blood increases to 
favour the peripheral blood due to the 1.5 fold increase in serum S1P concentration, and the 
gradient between the liver and draining lymph changes to favour the liver due to the 1.7 fold 
increase in the liver concentration. 
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4.3 Sphingosine Kinase 1 expression and activity is increased in the liver during chronic 
liver injury 
S1P has a short half life and concentrations are determined according to the balance 
between its synthesizing enzymes (Sphingosine Kinase 1 and 2) and degrading enzymes 
(Sphingosine Lyase and Phosphatase).  Changes in these enzymes during liver injury were 
investigated further by firstly examining relative changes in liver gene expression of the four 
enzymes by qPCR. 
The striking finding was that of a 5.5 fold upregulation of SphK1 hepatic gene expression 
during liver injury (CCl4 Injury 5.57+/-0.65 fold increase vs control, p<0.001), whilst 
expression of the other enzymes remained unchanged (SphK2 1.027+/-0.709, SphL 1.131+/-
1.013, SphP 0.817+/-0.683 fold increase vs control, p=ns)(Fig 4.2).   
To determine whether this upregulation of SphK1 during chronic liver injury was specific to 
the liver or represented a systemic response to toxic injury, gene expression in three other 
major organs – spleen, lung and kidney - was also determined.  No significant changes in 
gene expression were seen in other organs examined (Fig 4.3). 
An alternative model of liver injury was also used to confirm the findings in the carbon 
tetrachloride model and ensure that the observations were not restricted a one particular 
aetiology of liver injury.  The Methionine Choline Deficient Diet was fed to C57BL6 mice for 6 
weeks, resulting in a 40% loss of body weight (the maximum permitted by Home Office 
Project Licence for humane reasons).  This resulted in an established injury with steatosis, 
hepatocyte ballooning, inflammatory infiltrates and fibrosis.  
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Figure 4.2  
Hepatic Sphingosine Kinase 1 gene expression is upregulated in Chronic Liver Injury  
 
Chronic liver injury was induced in age and sex matched C57/BL6 mice by twice weekly 
intraperitoneal administration of carbon tetrachloride (1mg/kg) in mineral oil for 8 weeks. 
Control mice received twice weekly intraperitoneal injections of mineral oil. Mice were 
sacrificed and hepatic gene expression of sphingosine kinase 1, sphingosine kinase 2, 
sphingosine lyase and sphingosine phosphatase relative to GAPDH was determined.   Bars 
represent mean +/- SEM  fold change relative to control mice. N=5 mice per group, *** 
p<0.0001 
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Hepatic Sphingosine Kinase 1 gene expression is upregulated in 
Chronic Liver Injury
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Figure 4.3  
Upregulation of Sphingosine Kinase 1 gene expression in Chronic Liver Injury  
is restricted to the liver 
 
Chronic liver injury was induced in age and sex matched C57/BL6 mice by twice weekly 
intraperitoneal administration of  carbon tetrachloride (1mg/kg) in mineral oil for 8 weeks. 
Control mice received twice weekly intraperitoneal injections of mineral oil. Mice were 
sacrificed and gene expression of sphingosine kinase 1, sphingosine kinase 2, sphingosine 
lyase and sphingosine phosphatase relative to GAPDH was determined in (A)spleen, (B) 
kidney and (C) lung.   Bars represent mean +/- SEM  fold change relative to control mice. N=5 
mice per group,. 
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Upregulation of Sphingosine Kinase 1 gene expression in Chronic Liver Injury 
is restricted to the liver
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A similar pattern of changes in relative gene expression was seen with 4.4 fold upregulation  
of hepatic SphK1 gene expression in the liver of injured mice (MCD Injury SphK1 4.408+/-
1.464 fold increase vs control, p<0.001) (Fig 4.4).  Gene expression of the other enzymes was 
unaltered (SphK2 0.805+/-0.221, SphL 0.774+/-0.474, SphP 0.935+/-0.065 fold increase vs 
control, p=ns)(Fig 4.4). 
These findings suggested an important role for SphK1 in the liver during chronic liver injury, 
therefore further studies of this enzyme were performed by examining hepatic protein 
expression and tissue enzymatic activity. 
Semi quantitative determination of changes in hepatic SphK1 protein levels was performed 
using western blotting.  Clear differences in the intensities of the protein bands at the 
expected molecular weight (37kDa) for SphK1 were observed (Fig 4.5A). 
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Figure 4.4  
Hepatic Sphingosine Kinase 1 gene expression is upregulated in an alternative model of Chronic 
Liver Injury   
 
Age and sex matched C57/BL6 mice were fed a Methionine Choline Deficient Diet for 6 
weeks to induce chronic liver injury, control mice were fed normal chow. Mice were 
sacrificed and hepatic gene expression of sphingosine kinase 1, sphingosine kinase 2, 
sphingosine lyase and sphingosine phosphatase relative to GAPDH was determined.   Bars 
represent mean +/- SEM  fold change relative to control mice. N=5 mice per group, *** 
p<0.0001 
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Figure 4.4
Hepatic Sphingosine Kinase 1 gene expression is upregulated in an 
alternative model of Chronic Liver Injury
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Analysis of the  enzymatic activity of SphK1 within the liver was performed as previously 
described using a commercially available assay. Significantly higher levels of SphK activity 
were demonstrated in injured livers compared with controls (CCl4 Injury 5.76+/- 0.95 nmol 
S1P/min/mg protein vs 2.03+/-0.25 nmol S1P/min/mg protein, p<0.01)(Fig 4.5B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   179 
 
Figure 4.5  
 Sphingosine Kinase Activity in Murine Liver Injury  
 
Chronic liver injury was induced in age and sex matched C57/BL6 mice by twice weekly 
intraperitoneal administration of  carbon tetrachloride (1mg/kg) in mineral oil for 8 weeks. 
Control mice received twice weekly intraperitoneal injections of mineral oil.  (A)Samples of 
liver tissue from mice in each group were lysed for protein extraction and expression of 
sphingosine kinase 1 (SphK1) and GAPDH in each sample determined by western blotting.  A 
blot demonstrating SphK1 and GAPDH expression in livers from carbon tetrachloride treated 
mice and mineral oil treated mice is shown and is representative of 3 separate experiments. 
(B) Samples of liver tissue were homogenised in buffer solution and used in an ATP depletion 
assay to measure the enzymatic activity of SphK within the livers of carbon tetrachloride 
treated (black bars) and mineral oil treated (white bars) mice.  The rate of phosphorylation 
of sphingosine to S1P was determined from the rate of depletion of ATP and expressed as 
nmol of S1P produced per minute per mg of liver protein. n=5, mean+/-SD rate of S1P 
formation shown, **<0.01 (two tailed unpaired students t-test). 
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Sphingosine Kinase Activity in Murine Liver Injury 
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4.4 Similar changes in Sphingosine Kinase 1 expression are seen in humans with chronic 
liver disease 
Changes in relative gene expression of the enzymes responsible for S1P metabolism were 
determined in samples of human liver from normal donors and explanted livers of patients 
undergoing liver transplantation for alcohol related liver disease (ALD).  A similar pattern to 
that seen in murine livers was observed in the human liver samples. A significant 12.5 fold 
upregulation of hepatic SphK1 gene expression was noted (ALD Injury 12.55+/-6.1 fold 
increase vs normal liver, p<0.001) with no significant changes in the other enzymes (Fig 4.6).  
Samples were also obtained from diseased livers with a variety of differing aetiologies of 
chronic liver disease (alcoholic liver disease, primary biliary cirrhosis, autoimmune hepatitis, 
non alcoholic fatty liver disease, chronic hepatitis C) and acute liver failure (paracetamol 
overdose).   The same pattern of changes in enzyme gene expression was seen regardless of 
the underlying aetiology, however the sample sizes for each individual condition prevent a 
thorough statistical analysis given the amount of individual variation (Fig 4.7). 
Further investigation of SphK1 protein expression by western blotting in human liver 
samples demonstrated increased SphK 1 expression in a variety of liver diseases (Fig 4.8A).  
Samples of human liver from patients with alcohol related liver disease were used to 
determine SPhk enzymatic activity which was 4-fold higher than in normal human liver 
samples (ALD Injury 4.38+/-1.11 nmol S1P/min/mg protein vs Normal 1.04+/-0.21 nmol 
S1P/min/mg protein, p<0.05)(Fig 4.8B).  
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Figure 4.6  
Upregulation of SphK1 in Human Alcohol Related Chronic Liver Disease  
 
Samples of frozen liver tissue were obtained from either normal donor liver or explanted 
livers from patients with alcohol related chronic liver disease. Gene expression of 
sphingosine kinase 1, sphingosine kinase 2, sphingosine lyase and sphingosine phosphatase 
relative to GAPDH was determined.   Bars represent mean +/- SEM  fold change relative to 
normal liver. N=6 per group, *** p<0.0001 
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Figure 4.7  
Upregulation of SphK1 in Human Liver Disease of Differing Aetiologies  
 
Samples of frozen liver tissue were obtained from either normal donor liver or explanted 
livers from patients with liver disease (ALD Alcoholic liver disease, PBC primary biliary 
cirrhosis, AIH Autoimmune hepatitis, NAFLD Non alcoholic fatty liver disease, HCV Hepatitis 
C virus, POD Paracetamol ovedose).  Gene expression of sphingosine kinase 1, sphingosine 
kinase 2, sphingosine lyase and sphingosine phosphatase relative to GAPDH was determined.   
Bars represent mean +/- SEM fold change relative to normal liver. N=3 per group. 
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Upregulation of SphK1 in Human Liver Disease of Differing Aetiologies 
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Figure 4.8  
Sphingosine Kinase Activity in Human Liver Disease 
 
Samples of frozen liver tissue were obtained from either normal donor liver or explanted 
livers from patients with liver disease (ALD Alcoholic liver disease, PBC primary biliary 
cirrhosis, AIH Autoimmune hepatitis, NAFLD Non alcoholic fatty liver disease, HCV Hepatitis 
C virus). (A)Samples of human liver tissue were lysed for protein extraction and expression of 
sphingosine kinase 1 (SphK1) and GAPDH in each sample determined by western blotting.  A 
blot demonstrating SphK1 and GAPDH expression in normal and diseased livers is shown and 
is representative of 3 separate experiments. (B) Samples of liver tissue were homogenised in 
buffer solution and used in an ATP depletion assay to measure the enzymatic activity of SphK 
in diseased (black bars) and normal (white bars) liver tissue.  The rate of phosphorylation of 
sphingosine to S1P was determined from the rate of depletion of ATP and expressed as nmol 
of S1P produced per minute per mg of liver protein. n=5, mean+/-SD rate of S1P formation 
shown, *p<0.05, (two tailed unpaired students t-test). 
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4.5 Upregulation of Sphingosine Kinase predominantly occurs in liver sinusoidal 
endothelial cells 
In order to investigate the cellular source of the increased hepatic expression and activity of 
Sphk1 in liver injury I isolated two main cell types from the liver.  The isolation of liver 
sinusoidal endothelial cells from murine liver by immunomagnetic selection using CD146 as a 
marker of LSEC had recently been optimised in our laboratories and I was able to use this 
technique to isolate LSEC.  I used slow centrifugation as a method of isolating hepatocytes 
from a single cell suspension and density gradient separation to isolate peripheral blood 
mononuclear cells. 
Analysis of gene expression revealed differences in the relative expression of enzymes 
between the cell types within normal liver.  Sphk1 was the most abundantly expressed 
enzyme in LSEC with much lower levels of SphL and SphP. In contrast hepatocytes expressed 
predominantly degrading enzymes SphP and SphL with less SphK1 expression (Fig 4.9).  
Having previously shown significant upregulation of SphK1 during liver injury, I investigated 
changes that occurred to SpqK1 expression in individual cell types during liver injury.  Freshly 
isolated LSEC, hepatocytes and peripheral blood mononuclear cells from both control mice 
and mice with carbon tetrachloride induced chronic liver injury were analysed for expression 
of SphK.   During liver injury expression of SphK 1 on LSEC was markedly higher than in 
control mice (Injury 5.26+/-1.26 fold increase vs control, p<0.001.)(Fig 4.10A), although 
expression was unchanged in other cell types (Hepatocytes 1.70+/-0.86 fold increase vs 
control, p=ns, PBMC 1.24+/-0.51 fold increase vs control, p=ns) (Fig 4.10B,C).  
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Figure 4.9   
Expression of Sphingosine Kinase, Lyase and Phosphatase in individual cell populations  
Liver tissue and blood was obtained from C57BL6 mice. Liver sinusoidal endothelial cells 
(LSEC) were isolated by density gradient centrifugation of non parencyhmal cells and 
immunomagentic isolation of CD146+ cells.  Hepatocytes were isolated by slow speed 
centrifugation of liver cell suspension.  Peripheral blood mononuclear cells (PBMC) were 
isolated by red cell lysis and density gradient centrifugation. Gene expression of sphingosine 
kinase 1, sphingosine kinase 2, sphingosine lyase and sphingosine phosphatase relative to 
GPADH was determined in each cell type by the 2-dCT method. Bars represent mean +/- SEM 
expression relative to GAPDH. N=3 per group. 
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Figure 4.10  
Alterations in SphK1 expression during liver injury in individual cell populations 
Chronic liver injury was induced in age and sex matched C57/BL6 mice by twice weekly 
intraperitoneal administration of carbon tetrachloride (1mg/kg) in mineral oil for 8 weeks. 
Control mice received twice weekly intraperitoneal injections of mineral oil. Liver sinusoidal 
endothelial cells (LSEC) were isolated by density gradient centrifugation of non parencyhmal 
cells and immunomagentic isolation of CD146+ cells.  Hepatocytes were isolated by slow 
speed centrifugation of liver cell suspension.  Peripheral blood mononuclear cells (PBMC) 
were isolated by red cell lysis and density gradient centrifugation. Gene expression of 
sphingosine kinase 1 normalised to GAPDH and fold change in cells from injured mice 
relative to control mice was determined. Bars represent mean +/- SEM fold change relative 
to control mice. N=3 per group, ***p<0.001, two tailed unpaired students t-test). 
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Figure 4.10
Alterations in SphK1 expression during  liver injury in individual cell populations
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4.6 Conclusions 
Sphingosine 1-phosphate is a key regulator of many cellular processes, acting as both an 
intracellular and extracellular signalling molecule(Takabe et al. 2008; Olivera et al. 2013).   
The role of S1P during liver injury has not yet been fully elucidated but important functions 
are likely to include control of the balance between cell survival and apoptosis through 
intracellular signalling and crosstalk between S1P and TGFβ cell signalling in the 
development of hepatic fibrosis (Yang et al. 2013).  S1P functions as a regulator of 
haematopoietic stem cell trafficking, with specific roles demonstrated in controlling the 
egress of HSC from peripheral tissues into draining lymphatics (Massberg et al. 2007)and in 
promoting the mobilisation of HSC from the bone marrow into the peripheral blood 
(Ratajczak et al. 2010).  In both cases it is the generation of a concentration gradient of S1P 
between different body compartments that stimulates cell migration (Schwab et al. 2005).  
In the previous section of work I had demonstrated increased mobilisation of bone marrow 
derived HSC into the blood during liver injury, and increased numbers of bone marrow 
derived HSC within the liver during liver injury.  It was therefore of great interest to 
determine whether changes in S1P concentrations, and in particular changes in the S1P 
gradients, occurred during liver injury. 
I have shown that during chronic liver injury significant increases in S1P within the serum 
and liver are generated, whilst the bone marrow and lymph concentrations remain 
unchanged.  It is very difficult to make direct comparisons between tissue concentrations, 
predominantly because it is not possible to directly measure S1P within the interistial fluid 
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but within the tissue as a whole.  However, this limitation aside, it is clear from examining 
the relative changes that occur during liver injury that : 
(i)an increase in serum S1P whilst bone marrow S1P remains unchanged would provide a 
greater stimulus to mobilisation of HSC and, 
(ii) an increase in hepatic S1P without a change in lymph S1P would result in a reduction in 
the S1P gradient between liver and lymph. 
There was a significant upregulation of sphingosine kinase 1 during liver injury in both the 
carbon tetrachloride and MCD models of liver injury, this is in keeping with previous 
observations from Li and colleagues who have also demonstrated this change in the bile duct 
ligation model of cholestatic liver injury(Li et al. 2009; Li et al. 2009).  S1P has a short half life 
and concentrations of S1P are tightly regulated by the balance between the synthesizing and 
degrading enzymes, therefore the observed increase in hepatic sphingosine kinase 1 would 
explain the increased S1P concentration.  The changes seen in sphingosine kinase were 
restricted to the liver and were not as a result of a multi system inflammatory or toxic 
response.  Many cytokines and growth factors have been shown to stimulate sphingosine 
kinase 1 activity, and in particular those that are upregulated during liver injury such as 
TNFα(Xia et al. 1999).  
I was also able to study the changes that occur to enzymes regulating S1P concentrations in 
human liver as this has not been well described previously.  I have shown that in keeping 
with the changes seen in the animal models there is significant upregulation of sphingosine 
kinase 1 which is replicated across a variety of human liver diseases including those of viral, 
immune, cholestatic and acute aetiologies.  These data provide reassurance that the animal 
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model is an acceptable method for further study.  It was not possible for me to examine 
changes in serum levels of S1P from human subjects particularly as one report suggests that 
serum S1P levels were lower in patients with hepatitis C related cirrhosis(Ikeda et al. 2010), 
as opposed to the higher levels seen in the animal model.   The significance of this is not 
clear and requires further investigation but it is possible that serum S1P levels may alter 
across the spectrum of fibrosis, with levels initially rising and then falling as cirrhosis and 
liver failure become established. 
Having shown that there is upregulation of sphingosine kinase 1 within the liver during liver 
injury I investigated the cellular source of this increase.   Endothelial cells of both the 
vascular and lymphatic vessels have been shown to be sources of S1P within the blood and 
lymph(Venkataraman et al. 2008; Fukuhara et al. 2012), whilst sphingosine kinase expression 
within the liver sinusoidal endothelial cells contributes to the serum S1P 
concentration(Venkataraman et al. 2008).  Using cell isolation techniques previously 
optimised in our laboratories I was able to isolate populations of hepatocytes, liver 
sinusoidal endothelial cells and peripheral blood mononuclear cells for further analysis.  
Hepatocytes predominantly expressed SphP and SphL, whilst endothelial cells and 
mononuclear cells expressed sphk.  This would suggest that hepatocytes are net ‘degraders’ 
of S1P and endothelial and mononuclear cells net ‘producers’ of S1P.  It has been recognised 
that tissues are abundant in SphL, required for low S1P levels to maintain the S1P tissue 
gradient, whilst endothelial cells have a secretory function and contribute to serum S1P 
concentrations(Connolly et al. 2010; Fukuhara et al. 2012).     Cells freshly isolated from mice 
with liver injury and control mice were also analysed for sphingosine kinase expression and I 
noted that there was significant upregulation of sphingosine kinase within the liver 
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sinusoidal endothelial cells during liver injury whilst expression in hepatocytes and 
mononuclear cells remained unaltered.  I propose that during liver injury stimulation of liver 
sinusoidal endothelial cells results in upregulation of SphK1 which contributes to the 
increases in both hepatic and serum S1P concentrations. 
Platelets and mononuclear cells have previously been shown to be important sources of S1P, 
with platelets in particular containing high levels of intracellular S1P, which can be secreted 
upon activation (Yatomi et al. 1997; Yang et al. 1999).   During liver injury platelets and 
mononuclear cells are important in the development of liver injury and fibrosis and are 
recruited to the liver in significant numbers (Iannacone et al. 2005)and this may represent an 
important alternative source for the increased levels of S1P seen within the liver.   Future 
experiments to investigate this further could include the adoptive transfer of bone marrow 
from SphK1 KO mice into WT mice followed by the induction of liver injury and subsequent 
analysis of S1P enzymes to determine the contribution SphK deficient haematopoietic cells. 
In this section of work my interest has predominantly been in the effect of liver inury upon 
S1P concentration gradients given the emerging importance of S1P as a regulator of HSC 
trafficking.  I have not, however, made attempts to further elucidate the role of increased 
S1P levels in the progression of liver injury and the development of fibrosis. 
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5 SPHINGOSINE 1-POSPHATE AND HAEMATOPOIEITC STEM CELL TRAFFICKING IN 
LIVER INJURY 
 
5.1 Introduction 
It has been previously shown that both human and murine haematopoietic stem cells 
express S1P receptors(Kimura et al. 2004; Seitz et al. 2005)  and migrate in vitro to S1P(Seitz 
et al. 2005) , however it is only recently that the role of S1P in HSC homing and trafficking is 
becoming clearer(Massberg et al. 2007).  This is an area of considerable interest, not only for 
the potential role of HSC in tissue regeneration, but also because a greater understanding of 
the mechanisms regulating mobilisation of HSC from the bone marrow into the circulation 
and homing from the circulation to the bone marrow will help optimise and refine bone 
marrow transplantation techniques for haematological disease. 
Ratacjzak and colleagues have investigated the role of S1P in the mobilisation of HSC from 
the bone marrow following administration of the stimulatory cytokine GCSF.  This resulted in 
activation of the complement cascade resulting in lysis of red blood cells by the membrane 
attack complex (Ratajczak et al. 2010), and as red blood cells contain large reserves of S1P 
(Bode et al. 2010)this results in increased plasma S1P levels.  The increased plasma S1P 
promotes chemotaxis of HSC from the bone marrow into the circulation (Ratajczak et al. 
2010).   In  a separate study by Golan and colleagues, administration of GCSF increased 
serum S1P concentration but also appeared to make bone marrow cells more responsive to 
S1P by upregualting the surface expression of the S1P1 receptor on bone marrow cells(Golan 
et al. 2012).   The CXCR4 antagonist can also induce mobilisation of HSC by interfering with 
the SDF-1 retention signal within the bone marrow, a recent study by Juarez et al has shown 
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that this process is also dependent upon an adequate S!P gradient and S1P receptor 
signalling(Juarez et al. 2012).   SphK1 knock out mice have lower plasma S1P concentrations 
than control mice, this results in a lower S1P gradient between the blood and bone marrow, 
and consequently lower CXCR4 antagonist induced mobilisation was seen in these mice than 
in control mice(Juarez et al. 2012).  Similarly administration of the S1P receptor antagonist 
FTY720 downregulated S1P1 receptor expression on HSC and resulted in reduced 
mobilisation of HSC (Juarez et al. 2012). 
The homing of HSC to the bone marrow and extramedullary tissues has been shown to be 
mediated by chemokine receptor signalling, and in particular CXCR4 (Kollet et al. 2003), 
CCR2 (Si et al. 2010)) regulate homing of HSC to the liver. Cell surface chemokine receptors 
recognise membrane bound ligand resulting in cell activation and transendothelial migration 
along chemokine gradients.  To date there has yet to be demonstrated a role for S1P 
receptor signalling in HSC recruitment to bone marrow or other tissues.  There is however, 
evidence of considerable crossover between S1P receptor and chemokine receptor 
signalling.   Both S1P and chemokine receptors are G protein coupled receptors sharing 
signalling pathways, including the coupling of both S1P1 and CXCR4 to the Gai subunit with 
subsequent PI3K activation (Cyster 2005), and cross talk between CCR7 and S1P1 regulates 
the egress of T lymphocytes from lymph nodes (Pham et al. 2008).  In human CD34+ HSC, S1P 
receptor signalling has been shown to increase their CXCR4 mediated migration towards 
SDF-1(Whetton et al. 2003).  However overexpression of S1P1 on human CD34+ HSC resulted 
in reduced cell surface CXCR4 expression and  a significant reduction in migration to SDF-1 
but increased S1P induced migration(Ryser et al. 2008). Treatment of human CD34+ HSC with 
FTY720 which downregulates S1P1 expression(Oo et al. 2007) resulted in the opposite effect, 
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with increased SDF-1 induced migration but with no alteration in surface CXCR4 expression 
(Kimura et al. 2004). 
HSC circulate in peripheral blood at low frequency (Wright et al. 2001) and following 
administration of FTY720 in mice the numbers of circulating HSC are reduced, however this 
effect is variable with some reports suggesting a much greater reduction (Massberg et al. 
2007) than others(Juarez et al. 2012).   The effect of FTY720 on HSC numbers within the 
bone marrow is either constant (Juarez et al. 2012) or increased(Golan et al. 2012) in similar 
experimental models.  The administration of FTY720 following injection of human CD34+ HSC 
into NOD/SCID mice resulted in significantly higher rates of homing to the bone marrow than 
in control mice(Kimura et al. 2004).  Significantly higher numbers of colony forming cells 
could be obtained from the livers of mice receiving FTY720 over a period of seven days than 
untreated mice(Massberg et al. 2007), this was explained to be due to reduced egress of HSC 
from the liver rather than increased recruitment. 
Liver injury results in the mobilisation of HSC and accumulation within the liver, it is now 
apparent that S1P receptor signalling has a crucial role in both the mobilisation of bone 
marrow cells and in their trafficking to organs.  It is not clear whether the recruitment of HSC 
to extra medullary tissues involves a direct role for S1P receptor signalling or an indirect role 
through modulation of chemokine receptor signalling.   In this section of work I will 
characterise in detail the repertoire of chemokine receptors expressed by HSC and the effect 
of S1P signalling on chemokine receptor expression.  I will determine whether FTY720 
increases the number HSC within the liver during liver injury and whether HSC recruitment 
to the injured liver is dependent upon S1P receptor signalling. 
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5.2 Characterisation of HPC-7 cells 
The relative scarcity of KSL cells within the bone marrow (approx 0.05% of bone marrow 
cells) means that studies requiring large numbers of cells are virtually impossible given the 
huge numbers of donor mice required for cell isolation. 
The HPC-7 cell line has been widely used both within our instution and more widely as a 
model to study HSC at both molecular and cellular levels, particularly in studies of HSC 
trafficking and tissue recruitment(Kavanagh et al. 2010; Volpe et al. 2013; White et al. 2013). 
HPC-7 cells were readily cultured in serum free media supplemented with Stem Cell Factor 
and antibiotics.  Cell proliferation was sensitive to cell density in culture with optimum cell 
concentrations of  0.8-2.0 x106 cell per ml. 
I confirmed the surface phenotype of HPC-7 cells by flow cytometry and demonstrated 
expression of c-kit and sca-1 and the absence of markers of lineage differentiation (Fig 5.1B-
E).  I also confirmed colony forming ability in vitro (Fig 5.1A). 
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Figure 5.1   
Expression of Haematopoietc Stem Cell Markers on HPC-7 Cells 
(A)HPC-7 cells were cultured in Methocult GF media for 7 days and significant numbers of 
myeloid colony forming cell clusters were identified. Representative image of CFU-GM 
colony shown. Cultured HPC-7 cells were labelled with fluorescently conjugated antibodies 
to lineage markers (CD11b, CD5, CD8a, Ter119, Gr-1, B220), c-kit and sca-1 and analysed by 
flow cytometry. (B) Dead cells and debris were excluded by gating on a plot of forward 
scatter – side scatter and surface expression of (C) lineage markers, (D) c-kit and (E) sca-1 
measured.  Representative histograms displayed (isotype control: grey, antibody: red line). 
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5.3 HSC express S1P receptors and migrate to S1P 
The relative gene expression of the S1P receptors were determined in both freshly isolated 
KSL cells and cultured HPC7 cells.  Quantitative PCR was used and expression relative to 
GAPDH was determined.   In both cell types S1P1 receptor was the most abundantly 
expressed and whilst S1P2 and S1P4 receptors were expressed in both cell types to a lesser 
degree, neither cell type expressed S1P5 receptor.  The striking difference between the cell 
types was that of S1P3 receptor expression, as although strong expression was detected in 
KSL cells this was absent in HPC7 cells (Fig 5.2A,B). 
Given the high levels of S1P1 gene expression and knowledge of its role in cellular migration, 
further analysis of the cellular expression of S1P1 was performed.  Flow cytometry was used 
to determine cell surface expression of S1P1 on both freshly isolated KSL cells and cultured 
HPC7 cells, and in separate experiments both cell types were also permeabilised to detect 
both intracellular and extracellular S1P1 receptor expression.  Both KSL and HPC7 cells 
displayed marginal cell surface expression of S1P1 receptor.  However, analysis of 
permeabilised cells demonstrated abundant intracellular stores of S1P1 (Fig 5.2C,D). 
The functional role of the S1P receptors expressed by HSCs was assessed by their migration 
in vitro to S1P.  Using a transwell assay the migration of both KSL and HPC7 cells to varying 
concentration of S1P was determined.   Dose dependent migration was observed in both KSL 
and HPC7 cells with maximal levels of migration at 1µM S1P for both cell types (KSL 12.69+/-
0.99 % input cells migrated, HPC-7 14.55+/-1/776 % input cells migrated)(Fig 5.3A,B). 
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Figure 5.2  
Primary murine haematopoietic stem cells and HPC-7 cells express Sphingosine 1-
phosphate receptors  
(A,B) Gene expression of S1P receptors 1-5 in freshly isolated KSL cells and cultured HPC-7 
cells relative to GAPDH by the 2 -ΔCT method was determined.  Bars represent mean +/- SEM 
expression in three independent experiments. 
(C,D)Surface S1P1 receptor expression on freshly isolated KSL cells and cultured HPC-7 cells 
was analysed by flow cytometry. After fixation and permeabilisation of the cells, total 
intracellular S1P1 receptor expression was also assessed. Representative histograms of 3 
independent experiments are displayed (grey area: isotype control, red line: S1P1 antibody). 
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Figure 5.3  
Primary murine haematopoietic stem cells and HPC-7 cells migrate n vitro  to Sphingosine 
1-phosphate  
(A)Bone marrow cells negative for lineage marker expression were isolated by FACS sorting 
and used in a transwell migration assay. 1x105 lineage negative cells were added to the top 
well of the transwell and migration to varying concentrations of S1P proceeded for 4 hours. 
Cells migrating into the bottom well were analysed for expression of c-kit and sca-1 and 
quantified by flow cytometry. KSL cells migrating to the lower well were expressed as a 
percentage of the total number of KSL cells added to the top well.   Bars represent the mean 
+/- SEM of 3 separate experiments. (B) In similar experiments using HPC-7 cells, cells were 
counted using flow cytometry and expressed as a percentage of the total number of HPC-7 
cells added to the top well. Bars represent the mean +/- SEM of 3 separate experiments  
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5.4 FTY720 inhibits migration of HSC to S1P 
The partial S1P receptor agonist/ competitive antagonist FTY720 was used to study the 
effects of S1P receptor modulation on HSC migration using the transwell assay system.   
FTY720 was used at a concentration of 1µM and when incubated with both KSL and HPC7 
cells did not have any adverse effect on cell viability (Fig 5.4A). Flow cytometry 
demonstrated that incubation with FTY720 resulted in a marked reduction in cell surface 
S1P1 receptor expression (Fig 5.4B).  
In both KSL and HPC-7 cells, FTY720 did not affect baseline levels of migration to control 
media (KSL: FTY720 4.34+/-0.95 % migration vs Control 3.84+/-0.88 % migration, p=ns; HPC-
7: FTY720 3.12+/-1.01 vs Control 3.11+/-1.41% migration, p=ns) (Fig5.5A,B), however 
significantly less migration to S1P was observed in cells treated with FTY720 than in cells 
treated with control media alone (KSL: FTY720 7.19+/-1.77 % migration vs Control 11.61+/-
2.08 % migration, p<0.01; HPC-7 FTY720 5.62+/-0.89 % migration vs Control 13.03+/-1.06 % 
migration, p<0.01)(Fig 5.5A,B). 
FTY720 acts at multiple S1P receptor subtypes (Brinkmann et al. 2002)and to examine in 
more detail the contribution of S1P1 receptor to HSC migration, a direct S1P1 receptor 
antagonist, W146, was used in repeat experiments to determine the effects of S1P1 receptor 
blockade alone on HSC migration.  W146 had no effect on cellular viability and incubation of 
the cells with W146 did not alter cell surface S1P1 receptor expression using flow cytometry 
(Fig 5.4). 
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Figure 5.4  
Effect of S1P receptor modulators on cell viability and cell surface S1P1 expression 
(A)Whole bone marrow was incubated in media containing either dilutant control, FTY720-
phosphate (FTY720-P) or W146 for 3 hours.  Cells were then labelled with fluorescently 
conjugated antibodies to lineage markers, c-kit and sca-1.  Prior to analysis by flow 
cytometry, a viability dye was added and the number of dead KSL cells were determined, 
expressed as a percentage of the total cell number of KSL cells.  No significant difference was 
seen in cell viability following treatment with FTY720-P or W146. Bars represent the mean+/-
SD of 3 separate experiments.   (B)Following treatment with FTY720-P or W146, cells were 
also labelled with S1P1 antibody and cell surface expression of S1P1 measured by flow 
cytometry.  FTY720-P redcued the surface of expression of S1P1 whereas W146 had no 
effect when compared with control media alone.   Representative histogram of three 
separate experiments shown (grey area: isotype control, red line: control media alone, light 
blue line :W146, dark blue line : FTY720-P). 
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W146 treatment did not alter migration of KSL or HPC-7 cells to control media (KSL: W146 
4.65+/-0.70 %migration vs Control 3.84+/-0.88 % migration, p=ns; HPC-7: W146 3.25+/-1.19 
vs Control 3.10+/-1.41 % migration, p=ns)(Fig 5.5A,B). Treatment with W146 resulted in 
significantly impaired migration to S1P in both KSL and HPC7 cells, similar to the effect of 
FTY720 (KSL: W146 5.96+/-1.31 % migration vs Control 11.61+/-2.08 % migration, p<0.01; 
HPC-7 W146 6.89+/-1.65 % migration vs Control 13.03+/-1.06, p<0.01)(Fig 5.5A,B).  These 
observations suggest that the effect of FTY720 on HSC migration to S1P is mediated through 
the S1P1 receptor. 
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Figure 5.5  
FTY720 and W146 inhibit migration of primary murine haematopoietic stem cells and HPC-
7  cells to Sphingosine 1-phosphate in vitro 
Bone marrow cells negative for lineage marker expression were isolated by FACS sorting and 
used in a transwell migration assay. 1x105 lineage negative cells were added to the top well 
of the transwell and migration proceeded for 4 hours. Top and bottom wells of the transwell 
assay contained either 1µM S1P, 1µM FTY720-P, 1µM W146 or dilutant control media as 
shown. Transwells were incubated for 4 hours at 37oC, 5%CO2 and cells migrating into the 
bottom wells were analysed by flow cytometry for expression of c-kit and sca-1 and 
quantified using counting beads.  Migration was quantified by calculating the numbers of c-
kit+ sca1+ cells in the bottom well as a percentage of the total number added to the top 
well. Exposure of freshly isolated KSL cells to FTY720-P and W146 significantly inhibited in 
vitro migration to S1P. Results of three separate experiments performed in duplicate.  Mean 
+/- SD % input cells shown, * p<0.05 (one way anova with bonferroni multiple comparison 
test) (B) Similar experiments using cultured HPC-7 cells were performed and cells migrating 
into the bottom well quantified by flow cytometry using counting beads.  Migration was 
quantified by calculating the numbers of cells in the bottom well as percentage of the total 
number added to the top well.  Exposure of cultured HPC-7 cells to FTY720 and W146 
significantly inhibited in vitro migration to S1P. Results of three separate experiments 
performed in duplicate.  Mean +/- SD % input cells shown, * p<0.05 (one way anova with 
bonferroni multiple comparison test) 
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5.5 Chemokine receptor expression on HSC is unaltered by S1P  
The chemokine system is vital for cell migration and trafficking and the full repertoire of 
chemokine receptors expressed by murine HSC has not previously been described(Wright et 
al. 2002).  An analysis of gene expression of the chemokine receptors by both freshly 
isolated KSL and cultured HPC7 cells was performed using quantitative PCR with 
normalisation to GAPDH expression using the ΔΔCT method.  Genes were considered not 
expressed if a signal was not detected or detected after more than 35 cycles of annealing.  
CCR9 was the most abundantly expressed receptor in the KSL cells, with high levels of CCR2, 
CXCR2 and CXCR4 also present.  CCR1,CCR4,CCR7, CXCR1 and CXCR3 were also expressed at 
lower levels. A similar pattern of expression was seen in HPC-7 cells with the same receptors 
also being expressed, however there was a striking difference in CCR9 expression with levels 
in HPC7 being almost undetectable compared with the abundant expression in KSL cells (Fig 
5.6A).  CXCR4 was most abundantly expressed in HPC7 cells at levels markedly higher than 
CCR2 and CXCR3 which were the next most highly expressed (Fig 5.6B). 
Flow cytometry was used to analyse further the cell surface expression of the chemokine 
receptors for which gene expression had been detected in HSC.  The cell surface expression 
of chemokine receptors was determined on both freshly isolated KSL (Fig 5.7A)and cultured 
HPC7 cells (Fig 5.8A), chemokine receptors identified by gene expression were chosen for 
further study.   On KSL cells, CCR2, CCR9 and CXCR4 were present (6.37+/-3.14, 22.2+/-4.19, 
14.84+/-2.95 % expression respectively), but there was no appreciable (less than 2%) 
expression of the remaining receptors (Fig 5.7B).  In contrast on cultured HPC7 cells CXCR4 
was almost  
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Figure 5.6  
Chemokine Receptor Expression on primary KSL cells and HPC-7 cells 
Gene expression of chemokine receptors in (A) freshly isolated KSL cells and (B) cultured 
HPC-7 cells was determined by quantitative PCR. Expression relative to GAPDH by the 2 -ΔCT 
method was determined.  Bars represent mean +/- SEM expression in three independent 
experiments.  
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Figure 5.7  
Cell Surface Expression of Chemoknie Receptors on KSL cells 
(A)Cell surface chemokine receptor expression on freshly isolated KSL cells was determined 
by sequential gating of bone marrow cells to identify KSL cells and analysis of isotype (grey) 
and receptor (red line) expression of chemokine receptors.  Plots demonstrate CXCR4 
expression and are representative of multiple experiments. (B) Cell surface expression of 
chemokine receptors expressed as a percentage of total KSL cells staining positive for each 
receptor.  Bars represent mean+/- SEM expression of 3 separate experiments. 
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Figure 5.8 
Cell Surface Expression of Chemoknie Receptors on HPC-7 cells 
(A)Cell surface chemokine receptor expression on cultured HPC-7 cells was determined by 
gating  on cell population to exclude debris and dead cells and analysis of isotype (grey) and 
receptor (red line) expression of chemokine receptors.  Plots demonstrate CXCR4 expression 
and are representative of multiple experiments. (B) Cell surface expression of chemokine 
receptors expressed as a percentage of total KSL cells staining positive for each receptor.  
Bars represent mean+/- SEM expression of 3 separate experiments. 
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ubiquitously expressed (81.97+/-4.39 % expression) and significant levels of CCR2 were also 
noted (36.96+/-7.93 % expression), CCR9 in contrast to KSL cells was present at much lower 
levels (10.49+/-0.66 % expression) on HPC7 cells (Fig 5.8B). 
S1P and FTY720 have previously been shown to influence cellular migration through 
modulation of chemokine receptor signalling (Ryser et al. 2008),I studied the effect of S1P 
exposure on chemokine receptor expression.  Freshly isolated KSL and cultured HPC7 cells 
were incubated with S1P and subsequent chemokine receptor expression compared with 
cells incubated in control media was determined.   In KSL cells there was a two-fold increase 
in CXCR4 surface expression following incubation, however this was observed both in cells 
treated with S1P and in control treated cells (Baseline 14.84+/-2.96, Control media 28.35+/-
3.7, S1P media 28.92+/-2.21 % expression)(Fig 5.9A).  No other changes in chemokine 
receptor expression were observed in either KSL or HPC7 cells following exposure to S1P(Fig 
5.9A,B). 
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Figure 5.9 
Alterations in Chemokine Receptor Expression on KSL and HPC-7 cells 
after incubation with S1P 
 
(A) Bone marrow cells were incubated in serum free  media  containing either 1µM S1P or 
dilutant control for 4 hours at 37oC 5%CO2. Cell surface chemokine receptor expression on 
incubated KSL cells was determined by sequential gating of bone marrow cells to identify KSL 
cells and analysis of chemokine receptor expression as previously shown.  Chemokine 
receptor expression of KSL cells incubated in control media (grey) or 1µM S1P (black), 
compared with freshly isolated cells (white). Bars represent mean+/- SEM of 3 separate 
experiments, * p<0.05 (one way anova with bonferroni multiple comparison test). (B) HPC-7 
cells were incubated in serum free media containing either 1µM S1P or dilutant control for 4 
hours at 37oC 5%CO2. Cell surface chemokine receptor expression on incubated HPC-7 cells 
was determined by gating on cell population to exclude debris and dead cells and analysis of  
chemokine receptor expression as previously shown.  Chemokine receptor expression of 
cells incubated in control media (white) and 1µM S1P (black). Bars represent mean+/- SEM 
of 3 separate experiments. 
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5.6 FTY720 administration increases the number of HSC found in the liver during 
chronic liver injury 
A significant increase in the number of bone marrow derived HSC in the liver during chronic 
liver injury was previously shown.   There is published data from Massberg and colleagues 
demonstrating that FTY720 administration in vivo results in HSC accumulation in peripheral 
tissues.  These findings lead me to investigate the effect of FTY720 on HSC accumulation 
within the liver during liver injury (Fig 5.10A). 
FTY720 was administered to mice with chronic liver injury for 7 daysa this resulted in a 
significantly higher number of c-kit+ sca1+ lineage- (KSL) cells within the liver of mice 
receiving FTY720 compared with control animals (FTY720 1697+/-247 KSL cells per liver vs 
Control 982+/-110 KSL cells per liver, p<0.05)(Fig 5.10B).  The number of HSC present in the 
peripheral blood was lower in mice receiving FTY720, although this was not statistically 
significant (FTY720 0.36+/-0.1 KSL cells per µl vs Control 0.43+/-0.14 KSL cells per µl, 
p=ns).(Fig 5.10C) 
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Figure 5.10  
Accumulation of KSL cells within the liver following administration of FTY720 in vivo 
(A)Chronic liver injury was induced in age and sex matched C57/BL6 mice by twice weekly 
intraperitoneal administration of carbon tetrachloride (1mg/kg) in mineral oil for 8 weeks, 
mice were then randomly allocated to receive either FTY720 (1mg/kg) or dilutant control by 
daily intraperitoneal injection for 7 days. HSC were defined as c-kit+ sca1+ lineage negative 
(KSL) and were identified in liver and peripheral blood  by flow cytometry as previously 
described.  Absolute cell numbers were quantified using counting beads and samples were 
run in duplicate.  (B,C) Significantly higher numbers of KSL cells were detected in the livers  
of mice treated with FTY720 than controls, whilst in peripheral blood the numbers were 
unchanged. Data from individual mice is displayed (circles : control, squares : carbon 
tetrachloride treated) and means indicated by horizontal line.  * p<0.05 (unpaired student’s 
t-test) 
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5.7 FTY720 does not affect recruitment of HSC to the liver 
Intra vital microscopy was used to determine the effect of FTY720 on HSC recruitment to the 
injured liver, W146 was also used to confirm the role of S1P1 in HSC recruitment.   HPC7 cells 
were used given the difficulty obtaining sufficient numbers of freshly isolated KSL cells to 
perform the experiments.  Cells were incubated with control media, FTY720 or W146 prior to 
injection and injected into the carotid artery as previously described. 
In mice receiving control media cells, the number of adherent cells was highest in the first 
minute after injection with a gradual increase in the number of cells recruited over the 
subsequent 60 minutes (Fig 5.11A). Recruitment of cells treated with either FTY720 or W146 
followed a similar pattern. Although there was some variation in individual experiments, the 
average number of adherent cells per field of view was not significantly different at any 
timepoint over the 60 minutes between control cells and cells treated with FTY720 or W146 
(Adherent cells at 60 minutes: Control 10.3+/-0.66, FTY720 9.66+/-2.4, W146 9.0+/-1.15, 
p=ns)(Fig 5.11B). 
Tissue distribution of the infused cells at 60 minutes following injection was determined by 
immunofluorescent microscopic analysis of serial sections of central and peripheral regions 
of the liver.   There were no differences observed in the numbers of fluorescently labelled 
cells per field of view between control cells and FTY720 or W146 treated cells (Fig 5.12A,B). 
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Figure 5.11 
FTY720 and W146 do not affect recruitment of HPC-7 cells to injured liver 
Chronic liver injury was induced in age and sex matched C57/BL6 mice by twice weekly 
intraperitoneal administration of carbon tetrachloride (1mg/kg) in mineral oil for 8 weeks.  
Under anaesthesia, individual mice underwent cannulation of the carotid artery followed by 
laparotomy and mobilisation of the liver.  Mice were placed onto the stage of an inverted 
fluorescent microscope whereby a representative area of the liver could be monitored by 
intra vital microscopy.  1x106 cultured HPC-7 cells were labelled with CFSE and treated for 
one hour with either FTY720-P (1µM), W146 (1µM) or control media and then washed and 
resuspended in PBS for injection.  Cells were injected slowly into the carotid artery and a one 
minute recording of fluorescent cell recruitment to the imaged liver was recorded 
immediately and at 5 minute intervals for 60 minutes. (A) A representative image of intra 
vital microscopy of the liver demonstrating adherent fluorescent cells. (B) Mice were 
randomly allocated to receive cells treated with FTY720-P (blue line), W146 (green line ) or 
control media (red line) and the number of adherent cells in the selected field of view at 
each time point counted.  n=3 each group, mean+/-SD number of cells per field of view 
shown, p=ns (two way anova). 
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Figure 5.12  
Distribution of cells treated with FTY720 and W146 following injection 
After completion of intra vital microscopy experiments mice were sacrificed, individual 
organs removed and snap frozen in liquid nitrogen.  Sections were cut from both the central 
and peripheral regions of the liver using a cryotome and directly analysed by fluorescent 
microscopy (FITC filter).  The number of individual fluorescent cells were manually counted 
in 6 random, non-overlapping fields of view (x20 magnification) per section of (A) central 
liver tissue and (B) peripheral liver tissue. No difference in numbers of injected cells within 
the liver was seen between cells treated with FTY720-P, W146 or control media. n=3 each 
group, mean+/-SD number of fluorescent cells per field of view shown, p=ns (one way anova 
with bonferroni multiple comparison test) 
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5.8 Conclusions 
S1P has been previously shown by the work of Massberg and colleagues to be a regulator of 
HSC trafficking(Massberg et al. 2007), and having shown the beneficial effects of HSC in liver 
injury and alterations in S1P levels during liver injury, I studied the effects of S1P receptor 
modulation on HSC trafficking during liver injury. In line with previous studies, I confirmed 
the expression of S1P receptors and demonstrated migration in vitro to S1P.   FTY720 is an 
S1P receptor agonist at all subtypes except S1P2, resulting in receptor internalisation and 
degradation without G protein signalling rendering cells unresponsive to S1P(Oo et al. 2007).   
Loss of cell surface S1P1 following exposure to both S1P and FTY720 has also been shown in 
other cell types(Maeda et al. 2007). As expected FTY720 treatment of HSC resulted in loss of 
surface expression of S1P1 and impaired migration to S1P.  Treatment with the competitive 
antagonist at the S1P1 receptor, W146, did not alter S1P1 expression but also resulted in a 
loss of S1P induced migration.  These findings suggest that, in line with previous work, 
migration of HSC to S1P is mediated by the S1P1 receptor.  
HSC are a rare population of cell within the bone marrow, limiting the repeated study of 
large numbers of cells in assays such as intravital microscopy.   The HPC-7 cell line has 
previously been used in studies of HSC trafficking and recruitment.   Similarities in the 
findings of initial studies of S1P receptor expression and migration confirmed that HPC-7 
cells represent a suitable model for studying the effect of S1P receptor modulation on HSC 
trafficking. 
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Given that a role has been has shown for chemokine receptors in the trafficking of HSC to 
injured organs I investigated in more detail the expression profile of chemokine receptors on 
KSL cells.   I confirmed previous observations regarding the expression of CXCR4 (Sasaki et al. 
2009) and demonstrated increased cell surface expression on KSL cells following a period of 
culture(Sasaki et al. 2009).  This increased expression was not altered by incubation with S1P 
and is likely to relate to the effect of culture.  Exposure to constitutively high levels of SDF-1 
within the bone marrow environment acts a retention signal for HSC within the bone 
marrow through CXCR4.  In contrast, HPC-7 cells cultured in an environment free of SDF-1 
exhibit almost universal CXCR4 expression, which is further increased by the presence of 
Stem Cell Factor in the culture media which has been shown to upregulate CXCR4 
expression. 
Given that a role has been has shown for chemokine receptors in the trafficking of HSC to 
injured organs I investigated in more detail the expression profile of chemokine receptors on 
KSL cells.   I confirmed previous observations regarding the expression of CXCR4 and 
demonstrated increased cell surface expression on KSL cells following a period of culture. 
This increased expression was not altered by incubation with S1P and is likely to relate to the 
effect of culture.  Exposure to constitutively high levels of SDF-1 within the bone marrow 
environment acts a retention signal for HSC within the bone marrow through CXCR4.  In 
contrast, HPC-7 cells cultured in an environment free of SDF-1 exhibit almost universal 
CXCR4 expression, which is further increased by the presence of Stem Cell Factor in cthe 
culture media which has been shown to upregulate CXCR4 expression(Peled et al. 1999).  I 
noted low levels of CCR2 expression in keeping with a previous report from Si and colleagues 
who demonstrated that CCR2 receptor expression increases as myeloid differentiation 
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progresses(Si et al. 2010)  and the role of CCR2 in monocyte/macrophage migration is well 
established(Li et al. 2008). Expression of CCR9 on KSL cells was unexpected as previous 
reports have suggested that this is not expressed by HSC (Schwarz et al. 2007) but is 
expressed on less primitive haematopoietic progenitors and is required for thymic migration 
of lymphoid progenitor cells (Zlotoff et al. 2010). In my studies I have used KSL to define my 
cell population which includes both haematopoietic stem cells and multipotent progenitor 
cells(Adolfsson et al. 2001), and CCR9 expression has previously been demonstrated upon 
MPPs(Schwarz et al. 2007) and in particular lymphoid primed MPPs (Zlotoff et al. 2010) 
destined for the thymus. 
Other than the increase in CXCR4 expression on KSL cells following culture there were no 
alterations in chemokine receptor expression after culture with S1P.  Crosstalk between S1P 
receptors and chemokine receptors has previously been described and enhanced CXCR4 
signalling has also been shown to occur without alteration in CXCR4 surface expression 
(Ryser et al. 2008), so my findings do not discount the possibility of enhanced signalling of 
other chemokine receptors following exposure to S1P.  A major drawback of these findings 
are the absence of functional studies of chemokine receptors, namely migration assays to 
individual receptor ligands.  These would be crucial to further understanding links between 
S1P receptor signalling and chemokine receptor signalling. 
The findings of the chemokine receptor expression studies also further validate the use of 
the HPC-7 cell line in functional studies.  Analysis of chemokine receptor expression revealed 
a similar repertoire of receptor expression albeit with some relative differences related to 
the more heterogeneous nature of the KSL cell population.  Differences in cell surface 
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receptor expression were seen but as previously described are likely to be due to the effects 
of cell culture. 
FTY720 has been shown to impair HSC migration in vitro and in vivo administration results in 
an increase in HSC within extramedullary tissues, having confirmed the effect of FTY720 on 
KSL cells in vitro I investigated the effect of FTY20 in vivo during liver injury.  Having 
previously shown a significant increase in bone marrow derived KSL cells within the liver 
during injury, treatment of seven days with FTY720 further increased the number of KSL cells 
within the liver.  Treatment with FTY720 during liver injury did not significantly alter the 
numbers of KSL cells in the peripheral blood and this is in contrast to studies administering 
FTY720 to normal mice where a reduction in circulating HSC has been described.  In one 
study a profound reduction in peripheral blood HSC was seen(Massberg et al. 2007), 
although in a study by Juarez et al a significant decrease was only observed after increasing 
the sample sizes of the groups analysed (Juarez et al. 2012).   
The proposed mechanism for the action of FTY720 on HSC in vivo is reduced egress into 
draining lymphatics rather than an effect on recruitment of HSC.   Studies of HSC recruitment 
using intravital microscopy failed to show any effect of either FTY720, or the competitive 
S1P1 receptor antagonist W146, on recruitment to the injured liver.  Based upon these 
findings I propose that the increase number of KSL cells within the liver following 
administration of FTY720 is as a result of accumulation due to reduced egress rather than an 
effect of FTY720 on cell recruitment. 
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6 MODULATION AND OPTIMISATION OF HSC TRAFFICKING WITH FTY720 
 
6.1  Introduction  
 
Although clinical studies of bone marrow derived stem cells for liver disease are at an 
advanced stage in testing of their safety and efficacy(Houlihan et al. 2008), a particular area 
of uncertainty remains whether the number of cells administered and indeed the number of 
cells reaching the injured liver dictates their therapeutic effect.  Stem cells are rare 
populations of cells and strategies to improve trafficking to the liver may be of therapeutic 
benefit.  The molecular mechanisms mediating the recruitment and retention of HSC to the 
liver are areas of particular interest however the tissue distribution of infused cells over time 
is not well described. 
Injected bone marrow cells have been detected within the liver, predominantly localised to 
peiportal regions (Sakaida et al. 2004; Li et al. 2013). Sakaida and colleagues showed that 
injected GFP+ bone marrow cells were present in the periportal regions of the liver 7 days 
after infusion (Sakaida et al. 2004).   Significantly higher numbers of injected cells were 
found in the livers of animals with either acute or chronic liver injury, compared with normal 
mice (Cho et al. 2011; Li et al. 2013).  Li and colleagues have recently shown that following 
systemic injection of GFP+ HSC, the cell signal first appears in the lungs and then rapidly 
decreases by which time signal is apparent in the liver (predominantly) and spleen.   Signal 
within the liver then continued to accumulate over the following days (Li et al. 2013).  A 
similar effect was seen with the injection of fluorescently labelled cells into mice with acute 
liver injury, cell signal accumulated within the liver over 24 hours and then dropped over the 
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next 48 hours at which point the signal declined dramatically.  Lower levels of signal were 
found in the spleen and kidney(Ezzat et al. 2012).  Mesenchymal stem cells injected into 
mice with acute ischaemia reperfusion liver injury were detected only in the first 24 hours in 
the lungs, whilst the number of cells in the liver increased over 24 hours and then began to 
decline(Kanazawa et al. 2011).    
Recent developments in optical imaging technologies have enabled real time in vivo imaging 
of mice treated with labelled cells.  In vivo fluorescence imaging to track tissue distribution 
of injected cells can be performed by using fluorescent cell dyes to directly label cells 
(Kalchenko et al. 2006; Ezzat et al. 2012) or by using donor cells from mice expressing 
fluorescent proteins.   Near infra red fluorescence is particularly attractive as at longer 
wavelengths there is increased contrast between the fluorescent dye and background tissue 
fluorescence which is predominantly due to water and haemoglobin  and lower abruption of 
near infra red light results in greater tissue penetration and improved fluorescent signal 
resolution(Kalchenko et al. 2006; Zhang et al. 2012). Ushiki et al recently described the tissue 
distribution of NIR fluorescently labelled HSC immediately after injection in bone marrow 
transplantation experiments.  They found that this technique was sensitive and accurate for 
the detection of very small numbers of labelled cells across a wide variety of organs(Ushiki et 
al. 2010).  Both they and other authors found that ex vivo optical imaging of individual 
organs improved sensitivity and enabled greater discrimination of tissue distribution of 
injected cells(Ushiki et al. 2010; Ezzat et al. 2012; Li et al. 2013). 
I have previously shown that repeated injections of HSC significantly improve liver injury and 
fibrosis and subsequently that administration of FTY720 in mice with liver injury increases 
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the accumulation of HSC within the liver.  In this final section of work I will examine in more 
detail the tissue distribution of HSC following systemic injection over time and determine 
whether administration of FTY720 alters these dynamics.  Ultimately I will determine 
whether the beneficial effect of repeated HSC injection can be enhanced by administration 
of FTY720 during liver injury. 
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6.2 Near Infra Red fluorescent labelling of haematopoietic stem cells 
Near infra red (NIR) fluorescent imaging has been used to study the trafficking of various cell 
types in vivo, low tissue background signal and greater tissue penetration makes it 
particularly suited to in vivo imaging.  I used a commercially available cell dye (DiR, 
Invitrogen) and designed a series of initial experiments to optimise and validate my cell 
labelling strategy. 
Cell labelling with increasing concentrations of DiR resulted in a concentration dependent 
increase in the fluorescent signal detected in vitro with IVIS imaging (Fig 6.1A,C), whilst 
median fluorescence intensity measured by flow cytometry did not greatly increase at 
concentrations above 5µM (Fig 6.1B).   Toxicity of DiR labelling appeared to increase with 
concentrations of 10µM and above, but when labelled with 5µM there was no increase in 
the number of dead cells following labelling compared with unlabelled cells (Unlabelled 
1.46+/-0.22, 5µM 1.32+/-0.16, 10µM 2.39+/-0.46, 20µM 3.7+/-0.47 % dead cells)(Fig 6.1D).  
Cells labelled with 5µM DiR maintained their proliferative ability with rates cell growth 
comparable with unlabelled cells (range 95.45-100% compared with unlabelled cells)(Fig 
6.1E).    
Accurate tracking of cells relies on the ability to determine cell number based upon 
fluorescence intensity and I was able to demonstrate a strong linear relationship (r2=0.989) 
between total numbers of labelled cells and fluorescent signal when imaged in vitro by the 
IVIS system (Fig 6.2A,B). 
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Figure 6.1  
Optimisation of DiR labelling of murine HSC  
1x106 cultured HPC-7 cells were incubated with varying concentrations of DiR fluorescent 
dye for 10 minutes at room temperature, washed and resuspended in media. (A) 
Fluorescence of cells at different DiR concentrations was measured using the IVIS spectrum. 
(B) Representative IVIS image (fluorescence overlaid on photograph) of cells labelled with 
varying concentrations of DiR. (C) Median fluorescence intensity (MFI) of cells labelled with 
varying concentrations of DIR measured by flow cytometry.  (D) Viability of labelled cells at 
different concentrations of DiR measured by viability dye exclusion determined by flow 
cytometry. n=3, Mean+/-SD % dead cells in each sample. (E)Proliferation of cells labelled 
with 5µM DiR, determined by comparison with proliferation of unlabelled cells at different 
timepoints. n=3, mean +/- SD % proliferation compared with unlabelled cells at each 
timepoint. 
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Optimisation of DiR labelling of HSC 
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Figure 6.2   
Correlation between cell number and fluorescence intensity  
HPC-7 cells were labelled with 5µM DiR for 10 minutes at room temperature, washed and 
resuspended in complete media.  Cells were counted manually with a haemocytometer 
using trypan blue exclusion and varying numbers of cells added to individual wells of a 96 
well plate as indicated.  (A) Fluorescence intensity of varying numbers of cells labelled with 
5µM DiR was measured using the IVIS imaging system. n=3, mean+/-SD fluorescence shown. 
(B) Representative IVIS image (fluorescence intensity overlaid on photograph) of indicated 
numbers of cells labelled with 5µM DiR 
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Having used HPC-7 cells to optimise and refine the strategy for cell labelling, I confirmed 
these findings using primary KSL cells.  After labelling bone marrow preparations with 5µM 
DiR there was no appreciable cell toxicity as determined by the number of dead labelled KSL 
cells compared with unlabelled KSL cells (DiR labelled 0.81+/-0.09 vs Unlabelled 0.79+/-
0.14)(Fig 6.3A).  Proliferation also remained unaffected, with DiR labelled KSL cells retaining 
their colony forming ability (Fig 6.3B).   Finally the median fluorescence intensity of labelled 
KSL cells was equivalent to the median fluorescence intensity of labelled HPC-7 cells (Fig 
6.3C). 
Over a period of seven days there was a 59% loss of fluorescent signal in vitro from labelled 
HPC-7 cells, however the fluorescent signal at day 7 remained 48-fold higher than unlabelled 
cells (Fig 6.4A). 
It has been reported that NIR fluorescent dye transfer can occur from labelled cells and 
contaminate unlabelled cells(Lassailly et al. 2010). To investigate for this possibility HPC-7 
cells were labelled with 5µM DiR and incubated mixed with unlabelled HPC-7 cells in a 1:1 
ratio, at various timepoints cell samples were analysed by flow cytometry for the proportion 
of DiR positive cells.  The proportion of DiR positive labelled cells remained constant at 
around 50% across all timepoints demonstrating minimal transfer of fluorescent dye 
between cells (Fig 6.4B). 
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Figure 6.3  
Comparison of KSL and HPC-7 DiR staining  
Freshly isolated KSL cells were incubated with 5µM DiR for 10 minutes at room temperature, 
washed and resuspended in media. (A) Cell viability of labelled cells (black bars) was 
measured by viability dye exclusion determined by flow cytometry and compared with 
unlabelled cells (white bars). n=3, mean+/-SD % dead cells shown. (B) Colony forming ability 
in labelled (black bars) and unlabelled (white bars) cells was measured by in vitro 
methylcellulose assay. n=3, mean +/- number of colonies formed shown.  (C) Median 
fluorescent intensity of HPC-7 cells and KSL cells labelled with 5µM DiR was determined by 
flow cytometry.  n=3, mean+/-SD MFI shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   246 
 
DiR / M
C
F
U
0 5
0
20
40
60
M
F
I
HPC-7 KSL
100
101
102
103
DiR / M
%
 d
e
a
d
 c
e
ll
s
0 5
0.0
0.2
0.4
0.6
0.8
1.0
A B
C
Figure 6.3 
Comparison of KSL and HPC-7 DiR staining 
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Figure 6.4  
Loss of  fluorescent signal and fluorescent dye cell transfer  
(A)1x106 cultured HPC-7 cells were labelled with 5µM DiR for 10 minutes at room 
temperature, washed and resuspended in complete media. A cell sample was taken at each 
timepoint and MFI determined by flow cytometry.  (B) 1x106 cultured HPC-7 cells were 
labelled with 5µM DiR for 10 minutes at room temperature, washed and resuspended in 
complete media together with 1x106 unlabelled HPC-7 cells.  A cell sample was taken at each 
timepoint and the percentage of fluorescent DiR labelled cells in the sample determined by 
flow cytometry. n=3, mean+/- SD % fluorescently labelled cells shown. 
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6.3 Tracking of injected HSC by fluorescence imaging 
My initial aim was to track the fate of injected HSC in real time through the use of the IVIS in 
vivo imaging system.  Initial experiments involved whole animal in vivo fluorescent imaging 
following administration of 1x106 DiR labelled HPC-7 via the tail vein.  A fluorescent signal 
could be detected in the anatomical region of the liver, and a higher signal was detected in 
mice with liver injury compared with control mice in keeping with the hypothesis that liver 
injury results in increased recruitment of HSC to the liver. However only a weak fluorescent 
signal could be detected, possibly due to reduced tissue penetration and the presence of 
black fur despite extensive shaving, and it was difficult to accurately discriminate the organs 
from which the fluorescent signal was emitted (Fig 6.5A).   
Ex vivo fluorescent imaging of the individual organs using the IVIS system provided much 
greater clarity on the fluorescent signal from each organ and enabled detection of 
fluorescent signal at lower intensities such as from the lungs and kidneys which had 
previously been undetectable with whole animal imaging (Fig 6.5B).    
Ex vivo imaging of the liver demonstrated minimal fluorescence in mice which had received 
unlabelled cells, and again confirmed greater recruitment of labelled cells to injured liver 
compared with controls (Fig 6.5C).    
Region of Interest (ROI) gating analysis with Living Image software permitted accurate 
quantification of fluorescence in individual organs and I performed further experiments to 
investigate levels of tissue autofluorescence and background fluorescence.  In mice with liver 
injury tissue autofluorescence was significantly higher in the liver than in other organs , 
however this was negligible compared with tissue fluorescence following injection of DiR 
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labelled cells.  Injection of unlabelled HPC-7 cells resulted in no appreciable change in 
fluorescence compared with untreated mice.  There was a minor increase in fluorescence of 
the liver following administration of free DiR alone but levels remained lower than after 
injection of DiR labelled cells (Fig 6.6). 
After injection of 1x106 DiR labelled HPC-7 cells the fluorescence signal from the livers of 
mice with carbon tetrachloride induced liver injury was significantly higher than control 
mice, whilst the fluorescent signal from other organs remained unchanged (Fig 6.6). This 
confirms that recruitment of injected HSC to the liver is higher in liver injury than in normal 
liver. 
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Figure 6.5  
Increased fluorescent signal and tissue discrimination with ex vivo imaging over in vivo 
imaging  
(A)1x106 HPC-7 cells labelled with 5µM DiR were administered via tail vein injection to 
C57BL6 mice treated with twice weekly injections of either carbon tetrachloride( CCl4, 
1mg/kg) or mineral oil (MO) for eight weeks.  Mice were euthansed after 1 hour and whole 
animal imaging was performed using the IVIS imaging system (B) Ex vivo imaging of 
individual organs. (C) Ex vivo imaging of livers alongside liver from an untreated age and sex 
matched C57BL6 mouse.  All images are combined image of fluorescence intensity overlaid 
on photograph shown and are representative of multiple experiments 
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Figure 6.6   
Lack of significant background or tissue autofluorescence 
C57BL6 mice were treated with either carbon tetrachloride (CCl4, 1mg/kg) or mineral oil 
(MO) for eight weeks and then received either 1x106 unlabelled HPC-7 cells, 5µM free DiR or 
1x106 DiR labelled cells via tail vein injection.  Mice were euthanased and ex vivo imaging  
performed using the IVIS imaging system. No significant tissue auto fluorescence or 
background fluorescence was seen compared with injection of DiR labelled cells.  Tissue auto 
fluorescence was higher in the liver than other organs. All images are combined image of 
fluorescence intensity overlaid on photograph shown and are representative of multiple 
experiments. 
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6.4 Increased hepatic accumulation of HSC with FTY720 administration 
I had previously demonstrated that administration of FTY720 to mice with liver injury 
resulted in increased accumulation of bone marrow derived HSC within the liver, this lead 
me to hypothesize that the administration of FTY720 would increase the accumulation of 
injected HSC within the injured liver.  Given the number of cells required for such 
experiments and the relative scarcity of primary KSL cells I elected to use HPC-7 cells for 
initial experiments to determine the tissue distribution of injected cells at various timepoints 
and study the effect of FTY720 administration. 
High levels of fluorescent signal were detected in the liver and lungs shortly after cell 
injection, and whilst the signal in the lungs rapidly declined over the following 48 hours, the 
signal in the liver accumulated over the first 48 hours and then gradually declined (Fig 
6.7A,B).   Fluorescent signal was detected in the spleen after 24 hours and remained 
constant but fluorescent signal was virtually undetectable in the kidney (Fig 6.7B).   
A similar pattern was observed in mice treated with FTY720, significantly however the 
fluorescent signal within the liver of FTY720 treated mice was 27% higher than untreated 
mice after 48 hours (p=ns) and the difference increased to 50% and 86% higher than control 
at day 4 and day 7 respectively (p<0.01 at both timepoints)(Fig 6.7A,B). 
In order to reinforce the data on tissue distribution of injected cells I also quantified the 
numbers of fluorescent DiR labelled cells within selected organs by preparing single cell 
suspensions for analysis and quantification by flow cytometry (Fig 6.8A).  Given the scarcity 
of injected cells in the populations analysed, accuracy of analysis was improved by co-
staining for CD45 to exclude non-haematopoietic cells with subsequent gating of the 
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resultant cell population according to the expected size and granularity of HPC-7 cells (Fig 
6.8A).   
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Figure 6.7  
Administration of FTY720 increased the number of injected HSC within the liver – 
Fluorescence Intensity 
C57BL6 mice received twice weekly administration of carbon tetrachloride via 
intraperitoneal injection for 8 weeks.  5x105 DiR labelled HPC-7 cells were then injected via 
the tail vein followed by daily administration of either FTY720 (1mg/kg) or vehicle control by 
intraperitoenal injection for 7 days.  Mice were then euthanased either 1 hour following 
injection (time 0) or 1,2,4,7 days after injection and ex vivo imaging of organs performed 
using  the IVIS imaging system . (A) Representative combined photographic and fluorescence 
intensity images of livers from mice treated with either FTY720 (FTY720) or vehicle (Control) 
at timepoints following cell injection.  (B) Fluorescence was measured by ROI analysis in 
organs from mice treated with either FTY720 (blue line) or vehicle (red line) and quantified 
as radiance efficiency following background subtraction.  Graphs represent fluorescence in 
individual organs at timepoints studied. Points represent mean +/-SD, n=3 per group at each 
timepoint, * p<0.05 **p<0.01 (student’s unaired t-test at each timepoint). 
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Figure 6.8  
Administration of FTY720 increased the number of injected HSC within the liver – Cell 
quantification  
C57BL6 mice received twice weekly administration of carbon tetrachloride via 
intraperitoneal injection for 8 weeks.  5x105 DiR labelled HPC-7 cells were then injected via 
the tail vein followed by daily administration of either FTY720 (1mg/kg) or vehicle control by 
intraperitoenal injection for 7 days.  Mice were then euthanased either 1 hour following 
injection (time 0) or 1,2,4,7 days after injection and DiR labelled cells within individual 
organs quantified by flow cytometry as previously described. (A) Sequential gating strategy 
used to identify injected DiR labelled cells.  (Initial forward scatter – side scatter gate to 
eliminate cell debris and dead cells followed by identification of CD45 positive DiR positive 
cells to eliminate cellular contamination of non haematopoietic cells and back gating of this 
population on forward scatter – side scatter to confirm expected size and granularity)  (B) 
Absolute numbers of injected cells within individual organs analysis from mice treated with 
either FTY720 (blue line) or vehicle (red line) was quantified by flow cytometry at each 
timepoint.  Points represent mean +/-SD number of cells within each organ at timepoint 
studied, n=3 per group at each timepoint. *p<0.05 **p<0.01 (students unpaired t-test at 
each timepoint). 
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This analysis confirmed the distribution of injected cells over time within the liver and lungs.  
In mice treated with FTY720 there significantly higher numbers of injected cells within the 
liver at day 2 (FTY720 46671 cells per liver vs Control 29155 cells per liver, p<0.05) and day 4 
(FTY720 41294 cells per liver vs Control 23349, p<0.05), with a trend to higher numbers of 
cells at day 7 (Fig 6.8B). 
To confirm that the findings observed following injection of HPC-7 cells were also true of 
primary KSL cells I undertook a repeat experiment but given the scarcity of primary KSL cells 
chose to examine only one timepoint.  I chose day 4 following injection as the timepoint to 
test given the marked difference between FTY720 treated and untreated mice with HPC-7 
cells.    
Mice treated with FTY720 had 1.4-fold increase in  fluorescent signal in the liver at day 4 
following cell injection (FTY720 2.057x109 vs Control 1.45x109, p<0.05)(Fig 6.9A,B). This was 
confirmed with quantification of DiR labelled cells by flow cytometry demonstrating a 75% 
increase in DiR positive cells in the livers of FTY720 treated mice(FTY720 13514+/-1506 vs 
Control 7687+/-1556, p<0.05)(Fig 6.9B). 
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Figure 6.9  
Administration of FTY720 increased the number of injected KSL cells  
within the liver 
 
C57BL6 mice received twice weekly administration of carbon tetrachloride via 
intraperitoneal injection for 8 weeks.  1x105 DiR labelled KSL cells were then injected via the 
tail vein followed by daily administration of either FTY720 (1mg/kg) or vehicle control by 
intraperitoenal injection for 7 days.  Mice were euthanased on day 4 after cell injection and 
ex vivo imaging of organs performed using  the IVIS imaging system. (A) Representative 
combined photographic and fluorescence intensity images of organs from mice treated with 
either FTY720 (FTY720) or vehicle (Control) at timepoints following cell injection.  (B) 
Fluorescence was measured by ROI analysis and quantified as radiance efficiency following 
background subtraction.  Graphs represent fluorescence intensity of the liver. Data from 
individual mice is displayed (circles : control, squares : FTY720 treated) and means indicated 
by horizontal line.  * p<0.05 (unpaired student’s t-test). (C) Absolute numbers of injected 
cells, identified as CD45 positive DiR positive were quantified as previously described (Fig 
6.8) ,within the liver were quantified by flow cytometry. Data from individual mice is 
displayed (circles : control, squares : FTY720 treated) and means indicated by horizontal line.  
* p<0.05 (unpaired student’s t-test). 
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6.5 Enhanced anti fibrotic effect of HSC with FY720 administration 
Having previously demonstrated the anti fibrotic effect of repeated injection of purified HSC 
and subsequently an increase in the number of injected cells within the liver with 
administration of FTY720, the ultimate aim of this work was to determine whether 
administration of FTY720 enhanced or improved the anti fibrotic effect of HSC in liver injury. 
I utilised a similar experimental design to my previous experiments examining the anti 
fibrotic effect of HSC (Fig 6.10) . Four experimental groups were included: i) control mice 
with liver injury alone, ii) mice with liver injury receiving FTY720 alone to control for the 
effect of FTY720 on liver fibrosis and function, iii) mice with liver injury receiving repeated 
injections of purified KSL cells and iv) mice with liver injury receiving repeated injections of 
KSL cells together with FTY720 administration for duration of cell injections. 
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Figure 6.10 
Investigation of the effects of FY720 in conjunction with repeated infusions of purified HSC 
in a murine model of chronic liver injury - Experimental timeline  
Chronic liver injury was induced in age and sex matched C57/BL6 mice by twice weekly 
intraperitoneal administration of carbon tetrachloride (1mg/kg) in mineral oil for 6 weeks, 
mice were then randomly allocated to a treatment group.  (A) Mice in the control group 
continued to receive twice weekly injections of intraperitoneal carbon tetrachloride until 
week 10 and were sacrificed 72 hours following the final injection of carbon tetrachloride.  
(B) Mice in the FTY720 treatment group received twice weekly carbon tetrachloride in the 
same way as control mice but in addition received thrice weekly FTY720 (1mg/kg) via 
intraperitoneal injection from the start of week 7, mice were sacrificed at the start of week 
10, 72 hours after the final injection of carbon tetrachloride.  (C)  Mice in the cell treatment 
group received twice weekly carbon tetrachloride in the same way as control mice but in 
addition received a tail vein injection of 5x104 purified KSL cells isolated from C57/BL6 donor 
mice on the first day of weeks 7,8 and 9, mice were sacrificed at the start of week 10, 72 
hours after the final injection of carbon tetrachloride, 7 days following the final cell injection.  
(D) Mice in the cell treatment plus FTY720 group received twice weekly carbon tetrachloride 
in the same way as control mice but in addition received a tail vein injection of 5x104 purified 
KSL cells isolated from C57/BL6 donor mice on the first day of weeks 7,8 and 9 and thrice 
weekly FTY720 (1mg/kg) via intraperitoneal injection from the start of week 7, mice were 
sacrificed at the start of week 10, 72 hours after the final injection of carbon tetrachloride, 7 
days following the final cell injection.   
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There was no effect on hepatic fibrosis with administration of FTY720 alone. No differences 
in picrosirius red staining (Control 4.19+/-0.63 % staining vs FTY720 4.38+/-0.74 % staining, 
p=ns) or hepatic hydroxyproline content (Control 436.5+/-26.6 mg per g protein vs FTY720 
462.0+/-35.5 mg per g protein, p=ns) were seen. αSMA staining and gene expression of 
myofibroblast activation was similar in both groups. Serum albumin levels showed no 
significant change. 
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Fgure 6.11  
Further reduction in hepatic fibrosis in mice treated with FTY720 in conjunction  
with repeated KSL cell injections 
(A) Formalin fixed paraffin embedded liver tissue sections from mice treated with KSL cell 
infusions (white bars) and with KSL cells plus FTY720 (grey bars) were stained for picrosirius 
red.  6 random, non-overlapping images were obtained from each section and staining was 
quantified as a percentage of the image positive for picorsirius red using ImageJ software.  
Lower levels of picrosirius red staining was detected in mice treated with FTY720 and KSL 
cels compared with KSL cell infusions alone. n=12-13 each group, mean +/-SD % area stained 
shown, *p<0.05 (two tailed, unpaired students t-test).   (B) Representative photomicrograph 
images (x20 magnification) of picrosirius red staining (red, no counterstain) from control 
mice and mice treated with FTY720 alone, KSL cells alone and KSL cells plus FTY720.   (C) 
Hydroxyproline content in samples of liver tissue from KSL cell treated mice (white bars) and 
from KSL cells plus FTY720 treated mice(grey bars) was determined and expressed as mg of 
Hydroxyproline per gram of liver tissue. Lower amounts of hydroxyproline were found in 
livers from mice receiving KSL cell injections plus FTY720 compared with livers from mice 
receiving KSL cells alone. n=12-13 each group, mean+/-SD hydroxyproline content shown. 
(D) Serum samples were obtained by centrifugation of whole blood from mice treated with 
KSL cell injections (white bars) and from mice treated with KSL cells plus FTY720 (grey bars) 
and serum albumin concentration was measured by bromocresol green colorimetric assay. 
n=12-13 each group, mean+/-SD serum albumin concentration shown. 
 
 
 
 
 
 
 
 
   269 
 
%
 s
ir
iu
s
 r
e
d
 s
ta
in
in
g
 a
re
a
KSL KSL + FTY720
0.0
0.5
1.0
1.5
2.0
2.5
m
g
 H
y
d
ro
x
y
p
ro
li
n
e
 /
 g
 L
iv
e
r
KSL KSL + FTY720
0
100
200
300
400
A
lb
u
m
in
 g
/d
l
KSL KSL + FTY720
0
1
2
3
4
5
Control FTY720
KSL KSL + FTY720
A
C
B
D
Fgure 6.11
Further reduction in hepatic fibrosis in mice treated with FTY720 in conjunction 
with repeated KSL cell injections
*
 
   270 
 
Figure 6.12  
Further reduction in activated hepatic myofibroblasts in mice treated with FTY720 in 
conjunction with repeated KSL cell injections   
 
(A) Formalin fixed paraffin embedded liver tissue sections from mice treated with KSL cell 
infusions (white bars) and with KSL cells plus FTY720 (grey bars) were stained for aSMA.  6 
random, non-overlapping images were obtained from each section and staining was 
quantified as a percentage of the image positive for aSMA using ImageJ software.  
Significantly lower levels of aSMA staining was detected in mice treated with FTY720 and KSL 
cell infusions than those treated with KSL cells alone. n=12-13 each group, mean +/-SD % 
area stained shown, *p<0.05 (two tailed, unpaired students t-test).   (B) Representative 
photomicrograph images (x20 magnification) of aSMA staining (brown, DAB substrate, 
haematoxylin counterstain) from control mice and mice treated with FTY720 alone, KSL cells 
alone and KSL cells plus FTY720.   (C,D) RNA was extracted from liver tissue from mice 
treated with KSL cell infusions (white bars), KSL cells plus FTY720 (grey bars) and control 
mice (black bars) and using quantitative RT-PCR gene expression of (C)col1a1 and (D) aSMA 
were determined, normalised to GAPDH expression and relative to control mice using the 2-
ddCT method. Hepatic gene expression of both col1a1 and aSMA was significantly lower in 
both KSL cell treated and KSL cells plus FTY720 mice than control mice, but no difference was 
seen between the two treatments was seen. n=12-13each group, mean +/-SD fold change 
shown, *p<0.05 (wilcoxon signed rank test). 
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The administration of FTY720 in conjunction with KSL cell injections did result in further 
improvements in some of the hepatic fibrosis markers, above the improvement seen with 
KSL cell injection alone.  There was a further reduction in picosirus red staining (KSL 2.21+/-
0.11 %staining vs KSL+FTY720 1.86+/-0.10 %staining, p<0.05)(Fig 6.11A,B) and although a 
12% reduction in hepatic hydroxyproline content (KSL 328.9+/-83.63 vs KSL+FTY720 289.2+/-
90.94, p=ns)(Fig 6.11C) was observed this did not reach significance.  αSMA staining for 
activated myofibroblasts was reduced in FTY720 treated mice (KSL 2.31+/-0.22 %staining vs 
KSL+FTY720 1.82+/-0.19 %staining, p<0.05)(Fig 6.12 A,B) but as gene expression of αSMA 
and col1α1 had been profoundly suppressed in mice treated with KSL cell injection, no 
further improvements were observed with the addition of FTY720 (Fig 6.12C,D).   Serum 
albumin levels were not significantly higher in mice treated with FTY720 compared with 
those treated with KSL cell injections alone (Fig 6.11D). 
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6.6 Conclusions 
In earlier sections of this work I demonstrated the anti fibrotic effect of repeated injection of 
haematopoietic stem and progenitor cells, these cells were injected into a peripheral vein 
rather than directly into the portal circulation.  It has been shown previously that cells 
injected through a peripheral vein are recruited to the liver(Sakaida et al. 2004; Cho et al. 
2011), which is confirmed by the therapeutic effect observed with peripheral vein injection.   
The dynamics of cell trafficking and tissue distribution after injection is not well understood. 
In the initial studies of this section of work I optimised a method of labelling HSC with a near 
infra red fluorescence lipophilic membrane dye – DiR.  A near infra red dye was used to 
reduce the effects of tissue autofluorescence and improve tissue penetration when tracking 
injected cells through tissues.   At the concentration used, 5µM, the dye did not affect cell 
viability or impair proliferation in either primary KSL cells or cultured HPC-7 cells.  The 
fluorescence intensity of DiR labelled cells showed a slight decline over time but maintained 
significantly higher signal than unlabelled cells and over tissue background fluorescence.  
When comparing the effect of different treatments on cell trafficking, the decline in 
fluorescence would be consistent between groups and allow relative comparisons to be 
made. 
The fluorescent signal from DiR labelled cells was directly proportional to the concentration 
of labelled cells within samples in vitro.  This was confirmed during the in vivo experiments 
where tissue fluorescent intensity following injection of DiR labelled cells was approximately 
proportional to the number of cells injected.  This confirmed that use of tissue fluorescence 
intensity was an appropriate method of quantifying DiR labelled cells within different organs.   
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Concerns have previously been raised regarding the possibility of dye transfer between 
labelled and unlabelled cells(Lassailly et al. 2010), however I did not observe any significant 
transfer of dye between labelled and labelled HPC-7 cells in  culture.  When quantifying DiR 
labelled cells within tissues using flow cytometry I used additional antibody staining and 
sequential gating as a precautionary measure to attempt to eliminate any contamination 
effect. 
Attempts at whole animal in vivo imaging were thwarted by low fluorescent signal, which 
may have been due to impaired tissue penetration and increased light absorbance in mice 
with black fur.  The fluorescent signal observed could not be well discriminated and did not 
allow adequate assessment of cell trafficking to different organs, in particular signal from the 
lungs was not detected.  Ex vivo fluorescent imaging of individual organs, as used in other 
studies of HSC trafficking (Ushiki et al. 2010; Li et al. 2013), allowed detection of much lower 
fluorescent intensities and clear discrimination of the signal from individual organs.  The liver 
exhibited higher background tissue autofluorescence than other organs but this was 
insignificant compared with fluorescent signal after labelled cell injection. 
Studies of the fate of HSC after injection have shown rapid clearance from the circulation 
with uptake in a variety of different organs and only minimal homing to the bone marrow 
initially.   Use of the HPC-7 cell line enabled study of larger cells numbers and repeated 
experiments.  My studies have shown that immediately after injection, uptake of labelled 
cells into the liver is greater in mice with liver injury compared with control mice, a finding 
consistent with established data showing increased recruitment of HSC to injured liver 
(Kavanagh et al. 2010; Cho et al. 2011; Li et al. 2013). 
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I studied the subsequent tissue distribution of injected cells over the course of seven days.   
There was an even distribution to HSC accumulation between the lungs and liver 
immediately after injection allaying concerns over the trapping of injected cells within the 
pulmonary vasculature.  Over the subsequent 24-48 hours cells cleared from the lungs but 
continued to accumulate in the liver and subsequently the spleen.   Maximal cell 
accumulation in the liver was at 48 hours with subsequent slow decline following this.      I 
did not examine homing of injected cells to the bone marrow in these studies due to low 
levels of uptake. This findings indicate that administration of HSC by tail vein injection does 
result in recruitment of cells to the liver, but the significant numbers of cells in the lungs may 
mean greater cell recruitment to the liver would occur after portal vein injection although I 
did not study this.  Work by Dr.Dean Kavanagh (PhD 2010) suggests that portal vein injection 
results in greater recruitment of cells to the liver compared with peripheral injection, 
however the difference in cell recruitment between normal and injured mice is lost with 
portal vein injection.   The implications of this include the possibility of a maximal threshold 
of cell recruitment which cannot be exceeded, or a mechanical component to cell 
recruitment after portal vein injection rather than being adhesion molecule mediated. 
The techniques used in these studies have shown to be more sensitive and consistent for 
tracking the trafficking of injected cells given that the whole organ is assessed rather than 
methods such as tissue section analysis where only a fraction of the total organ can be 
analysed.  This explains why in previous studies KSL cells are difficult to identify in tissue 
sections at 7 days after injection, as approximately 20,000 or more sections could be 
generated per liver and from my whole organ studies only 10,000 cells were found in the 
liver at day 7.  
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I previously observed that administration of FTY720 affects HSC migration and results in an 
accumulation of bone marrow derived HSC within the injured liver. The studies in this 
section of work have shown that administration of FTY720 following cell injection also 
results in an increased accumulation of injected cells in the liver compared to untreated 
mice.   The number of cells within the liver was no different over the first 24 hours but a 
difference became apparent at 48 hours which was maintained until day 7.  There was 
increased numbers of cells within the spleen after 48 hours with the most pronounced 
difference seen at day7 but this did not reach significance.  These findings are consistent 
with the observations from Massberg that tissue dwell time is approximately 36-48 hours 
and that FTY720 results in tissue accumulation due to impaired tissue egress(Massberg et al. 
2007).  These studies had been conducted using cultured HPC-7 cells given the scarcity of 
primary KSL cells, in order to confirm these findings with KSL cells I chose a single timepoint 
to assess accumulation of injected cells within the liver, this was day 4 when the difference 
between cells in the liver of FTY720 treated and untreated mice was most pronounced.   
Both fluorescent intensity of the liver and quantified cell numbers in the liver were greater in 
the FTY720 treated mice than the controls, confirming the observations made using the cell 
line. 
From the published data on the effect of bone marrow derived stem cells on liver injury it is 
not clear whether the numbers of cells injected correlates with the beneficial effect seen.  
There have been no studies examining the effect of different ‘doses’ of cells and direct 
comparison of independent studies is complicated by the variety of experimental designs in 
terms of cell type, cell number, route of delivery and outcome measures(Houlihan et al. 
2008).  Two previous studies using KSL cells have used significantly higher numbers of 
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(cultured) cells than in my studies and shown a beneficial effect, and although I studied 
repeated injections, the effect was not proportional to the higher numbers of cels used(Cho 
et al. 2011; Li et al. 2013). In general human studies have attempted to standardise 
protocols by using fixed numbers of cell per kg body weight .  I hypothesized that increasing 
the number of injected cells within the liver would enhance their therapeutic effect, this 
would be of particular benefit in optimising the effect of the scarce population of KSL cells 
and studied the effect of FTY720 administration combined with KSL cell injections on liver 
fibrosis. 
FTY720 administration in conjunction with repeated KSL cell injections lead to a further 
reduction in hepatic fibrosis compared with KSL cell injections alone.  Significant reductions 
in ECM collagen deposition measured by picosirius red staining and in numbers of αSMA+ 
myofibroblasts were noted, a reduction in hepatic hydroxyproline content did not achieve 
statistical significance which may have been related to variability in assessing the low levels 
of hydroxyproline in the assay.   
Treatment with FTY720 alone without KSL cell injections did not significantly alter any 
marker of hepatic fibrosis.  In some animal models of organ injury, for example renal 
ischemia reperfusion injury and experimental autoimmune encephalitis, FTY720 treatment 
has resulted in either reduced severity or improved recovery from injury.  These have 
predominantly been immune mediated injury rather than chronic fibrosis models and it is 
possible that treatment with FTY720 may be beneficial in an immune mediated liver injury or 
even if given prior to the onset of fibrosis rather than to reduce fibrosis. It would appear that 
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treatment with FTY720 alone lacks the postulated regenerative stimulus provided by KSL 
cells and it is this effect that is required to initiate the resolution of fibrosis. 
Taken in conjunction with the observations that FTY720 treatment results in an increase in 
the numbers of injected cells in the liver, these findings suggest that increasing the numbers 
of injected KSL cells in the liver results in an enhanced anti fibrotic effect.  The observation 
that FTY720 treatment alone does not impact upon fibrosis implies that the increased 
numbers of KSL cells are the reason for improved fibrosis rather than increased numbers of 
KSL cells in the liver as result of improved fibrosis due to FTY720 treatment. 
It remains unclear however whether there is indeed an optimum ‘dose’ for KSL cell injection 
and whether a plateau of cell recruitment to the liver is reached as the Kavanagh data 
(Kavanagh et al. 2010)suggests or whether a maximal stimulus to endogenous repair is 
reached which cannot be improved upon.  However, autologous HSC are not a limitless 
resource partly due to impaired bone marrow function in cirrhosis (Lorenzini et al. 2008)and 
partly due to the risks of the side effects of mobilising agents such as GCSF, and therefore 
approaches to optimise their therapeutic effect are prudent. 
Modulation of S1P signalling represents a potential mechanism for optimising the effect of 
HSC as it results in increased HS within the liver.  
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7 DISCUSSION 
 
7.1 Background 
There is a growing need for new therapies for chronic liver disease.   The incidence of liver 
disease is rapidly rising, driven by increases in obesity and alcohol related liver disease (Leon 
et al. 2006).   Current treatments for liver disease consist of treatment of the underlying 
disease where possible, for example anti viral therapy for Hepatitis C, and treatment of the 
complications of liver disease, such as diuretics for ascites and beta-blockers for varices.   
Liver transplantation is the only curative treatment for end stage liver disease, however this 
is limited by the availability of donor organs, post operative complications and recurrence of 
underlying liver disease.  There are no alternative treatments for underlying hepatic fibrosis 
and cirrhosis that are common to all forms of chronic liver disease. 
Since the first reports of the contribution of the bone marrow to hepatic regeneration by 
Petersen et al, there has been growing interest in the potential role of bone marrow derived 
cells as a treatment for liver disease (Petersen et al. 1999).  There has been rapid progress to 
clinical studies of bone marrow cells in patients with liver disease despite a relative lack of 
convincing evidence for either the effect or mechanism of effect from pre-clinical models.  
Sakaida and colleagues described a reduction in hepatic fibrosis following infusion of bone 
marrow cells, however subsequent studies have reported mixed findings(Sakaida et al. 2004; 
Thomas et al. 2011) (Cho et al. 2011). A difficulty in interpreting these studies is the 
heterogeneous nature of bone marrow cells and the uncertainty over the cell population 
responsible for the anti fibrotic effect.   Although a therapeutic effect has been 
demonstrated the mechanism of action remains to be determined.   Initially bone marrow 
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cell transdifferentiation or cell fusion resulting in hepatocyte repopulation had been 
proposed but it is now generally accepted not to be a frequent occurrence and would not 
account for an improvement in liver function or a reduction in fibrosis. 
Haematopoietic stem cells represent a rare population of cells within the bone marrow and 
engraftment of injured organs occurs at low frequency.  The mechanisms by which HSC 
engraft the bone marrow have been well studied(Mazo et al. 2011), although understanding 
of the mechanisms of tissue homing is more limited and tissue specific mechanisms may be 
important. Attempts to optimise the therapeutic potential of HSC through modulation of 
surface adhesion molecules in murine models of colitis and kidney injury have been reported 
(Kavanagh et al. 2013; White et al. 2013).   Sphingosine 1-phosphate has been shown to be 
an important regulator of HSC egress from tissues in draining lymphatics, and modulation of 
S1P receptor signalling by FTY720 resulted in reduced egress and an accumulation of HSC 
within peripheral tissues(Massberg et al. 2007). 
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7.2 Summary of Main Findings 
The work presented in this thesis has generated new insights into the benefits of 
haematopoietic stem cell therapy for liver disease, the role of S1P in liver injury and in HSC 
trafficking, and the potential for enhancing the therapeutic effects of HSC through 
modulation of S1P signalling.   
The main findings arising from this work include: 
 The numbers of bone marrow derived haematopoietic stem cells found within the 
liver and peripheral blood are higher during liver injury 
 Chronic liver injury increases the level of S1P within the liver and serum 
 The rise in S1P within the liver and serum is accompanied by an increased hepatic 
expression of sphingosine kinase 1, predominantly in liver sinusoidal endothelial cells 
 Increased sphingosine kinase 1 expression is also seen human liver disease 
 Administration of FTY720 further increases the number of HSC within the liver during 
chronic liver injury which does not appear to be mediated by increased recruitment 
to the liver 
 Repeated injection of purified haematopoietic stem and progenitor cells  improves 
hepatic fibrosis 
 Increased numbers of endogenous macrophages and neutrophils are found in the 
injected liver after HSC injection 
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 The anti fibrotic effect is not dependent upon myeloid differentiation of injected HSC 
 Administration of FTY720 increases the accumulation of injected HSC within the liver, 
and augments the anti fibrotic effect of injected HSC 
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7.3 Role of S1P in HSC Mobilisation during Liver Injury 
The novel use of a bone marrow chimera demonstrated increased mobilisation of HSC into 
the circulation and increased HSC within the liver during liver injury. These findings, together 
with evidence of the alterations that occur in S1P concentrations within the liver and blood 
during liver injury, support the emerging evidence that S1P is an important regulator of HSC 
mobilisation and trafficking (Fig 7.1).    
It has been shown that administration of the sphingosine lyase inhibitor THI results in higher 
serum S1P concentration and increased mobilisation of HSC(Schwab et al. 2005; Golan et al. 
2012), and that DOP, which inhibits sphingosine lyase within the bone marrow resulting in 
higher bone marrow S1P levels, reduces mobilisation (Juarez et al. 2012).  It is not clear 
whether S1P levels in the blood correlate with the severity of liver injury or with the 
numbers of HSC mobilised into the circulation and this would be worthy of further study in 
both animal models and in patients.   It is interesting that a solitary study of patients with 
HCV cirrhosis demonstrated reduced serum S1P concentrations(Ikeda et al. 2010) and more 
work in humans is required to understand better changes in S1P across the spectrum of 
fibrosis and cirrhosis given the consistent findings from this work and other studies in animal 
models.  
My work confirms the observations from other studies of S1P induced HSC migration in vitro 
(Seitz et al. 2005), and Rataczajk and colleagues have shown that GCSF induced HSC 
mobilisation from the bone marrow is mediated by chemotaxis to S1P and is independent of 
SDF-1 levels (Rataczjak et al. 2010).  They have shown that GCSF induced activation of the 
complement system results in the release of lytic enzymes by granulocytes which disrupt the  
   284 
 
Figure 7.1 Proposed Effect of Liver Injury and FTY720 on HSC Trafficking 
Under normal conditions there is continual low level mobilisation and circulation of HSC 
which is mediated in part by response to an S1P gradient between bone marrow and blood 
(Rataczjak et al 2010).  During liver injury the gradient increases due to increased S1P levels 
in the blood which occurs in conjunction with increased hepatic SphK1 expression and 
increased hepatic S1P concentration.  Increased HSC mobilisation from the bone marrow 
and recruitment into the liver occurs during liver injury.  The mechanisms by which injected 
HSC are recruited to the liver are not fully understood but have been shown to include 
chemokine receptor CXCR4 and CCR2(Kollet el al 2003, Si et al 2010) and integrin α4β1 
(Kavanagh et al 2010) signalling. Administration of FTY720 does not affect recruitment of 
HSC to the liver but results in an accumulation of bone marrow derived HSC within the 
injured liver.  The effect of FTY720 on HSC is to reduce surface expression of S1P1 receptor 
making cells unresponsive to the S1P gradient and reducing egress of HSC from the liver. 
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Figure 7.1  
Proposed Effect of Liver Injury and FTY720 on HSC Trafficking 
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SDF-1 – CXCR4 interaction on HSC within the bone marrow, and that levels of S1P are 
increased within the blood through complement mediated lysis of erythrocytes containing 
large stores of S1P and subsequently HSC migration occurs across the exaggerated S1P 
gradient between the bone marrow and circulation(Ratajczak et al. 2010). My work has 
shown an increase in the S1P gradient between bone marrow and blood during liver injury 
which I propose as a potential mechanism for the increased HSC mobilisation that occurs 
during liver injury.   
Drug induced mobilisation of HSC from the bone marrow in patients with cirrhosis is not as 
effective as in healthy controls and may occur for a variety of reasons including impaired 
bone marrow function and splenic sequestration of cells, but this data raises the possibility 
that impaired responsiveness to the S1P gradient, or reduced serum S1P levels in patients 
with cirrhosis are potential mechanisms. 
In contrast to the role of S1P in bone marrow mobilisation, this data does not show a role for 
S1P receptor signalling in the recruitment of HSC to the injured liver.  Neither FTY720 or the 
competitive antagonist to S1P1 W146 affected recruitment of HSC (albeit a cell line) in an in 
vivo assay over 60 minutes.  Furthermore, an increase in S1P in both the liver and serum was 
observed during liver injury which provides no evidence to suggest that there is a reversal of 
the expected ‘high to low’ S1P gradient from blood to liver.  The mechanisms responsible for 
HSC recruitment to the injured liver are not completely understood and include SDF-1:CXCR4 
and VLA4:α4β1  interactions and chemokine receptors CXCR4 and CCR2 (Kollet et al. 2003; Si 
et al. 2010; Mazo et al. 2011).  My studies do not provide any evidence that S1P receptor 
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signalling is involved either directly or indirectly, through modulation of chemokine receptor 
signalling, in the recruitment of HSC to the injured liver. 
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7.4 Proposed Mechanisms Mediating the Anti Fibrotic Effect of HSC 
A significant improvement in hepatic fibrosis following repeated injection of a purified 
population of KSL cells (including both haematopoietic stem and progenitor cells) is a novel 
finding and represents the first time this has been tested in a robust and clinically relevant 
model.   
Previous studies of KSL cells have used either cultured cells with no clear phenotype or less 
robust models of liver fibrosis(Cho et al. 2011; Li et al. 2013). This work has used a smaller 
number of cells than previous studies but taken the approach of repeated injection rather 
than a one off treatment.  The numbers of cells used in these studies are likely to be more 
physiologically relevant, particularly given the data on impaired stem cell mobilisation in 
patients with cirrhosis, and are higher than the number of KSL cells found in an injection of 
108 bone marrow cells.   
Although a significant reduction in fibrosis was observed, this must be interpreted with the 
observation that the murine carbon tetrachloride model of liver injury is probably more 
analogous to an advanced fibrotic stage of liver disease seen in humans rather than overt 
cirrhosis with marked architectural disruption and regenerative nodule formation. 
A further concern with the extrapolation of these results to humans relates to the source of 
the injected cells, in these studies transgenic donor mice were used to isolate the cells 
whereas autologous cells would be most appropriate in human studies.  A report from 
Mannheimer et al found that injections of bone marrow cells isolated from rats with liver 
injury did not exert the same anti fibrotic effect as those from healthy donors(Mannheimer 
et al. 2011). 
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This work was designed to address the question of therapeutic efficacy rather than to 
specifically to examine the mechanisms responsible for the anti fibrotic effect.  Several 
findings have, however, provided some insight into the mechanisms involved – the low 
number of injected cells present within the liver at seven days after injection, the increase in 
endogenous cell populations and the consistent effect of both myeloid and lymphoid 
progenitors are suggestive of a regenerative paracrine effect mediated by stem and 
progenitor cells rather than an effect mediated directly by differentiation of injected cells.  
The paracrine effect has previously been defined as ‘a form of communication between two 
different cells, where one cell releases chemical mediators to its immediate environment, 
which results in a change in the behaviour of a cell in its adjacent environment’ (Anthony et 
al. 2013). 
The resolution of fibrosis involves a reduction in ECM production, increased MMP activity 
and a reduction in activated myofibroblasts, through senescence, apoptosis or reversion to 
inactive stellate cells (Iredale et al. 1998; Bataller et al. 2005; Kisseleva et al. 2012). These 
processes are interlinked as collagen 1 within ECM promotes myofibroblast survival and  
increases matrix secretion and TIMP production(Ramachandran et al. 2012). A reduction in 
scar tissue is required to reduce myofibroblast activation as mice with non degradable 
collagen 1 fail to resolve fibrosis (Issa et al. 2003). As expected with resolution of fibrosis 
these studies demonstrate a marked reduction in both activated myofibroblasts and hepatic 
collagen deposition. 
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The vital role of macrophages in both the progression and resolution of hepatic fibrosis is 
increasingly recognised(Fallowfield et al. 2007; Ramachandran et al. 2012). This was 
demonstrated in work from Duffield and colleagues showing that depletion of macrophages 
during the resolution of fibrosis resulted in impaired breakdown of scar tissue but also that 
depletion during the development of fibrosis reduced the formation of scar tissue (Duffield 
et al. 2005).  Potential mechanisms involved include myofibroblast apoptois induced by 
macrophage secretion of TWEAK and MMP(Bird et al. 2013) , phagocytosis of pro 
inflammatory signalling molecules from damaged hepatocytes, increased MMP 9 and 13 
production (Fallowfield et al. 2007) and the recruitment of additional anti fibrotic cells such 
as neutrophils expressing MMP9 and MMP8 (Mantovani et al. 2004; Harty et al. 2008). 
The mechanisms by which HSC influence the resolution of fibrosis remain unclear but based 
upon these observations and the currently limited evidence I would propose that further 
investigation of the effect of cytokines and growth factors secreted by HSC within the 
environment of the fibrotic liver warrant further investigation.  HSC are capable of secreting 
cytokines and chemokines at concentrations far in excess of other cells of the immune 
system(Granick et al. 2012) and display effector properties within immune regulation 
through cytokine stimulation of other cells – a further example of a paracrine effect.   
The response of HSC to pro inflammatory and pro fibrotic stimuli within the injured liver 
have not been studied and there are particular molecules that merit further consideration.   
This work has demonstrated the recruitment of endogenous cells expressing macrophage 
and neutrophil markers and a study of bone marrow derived macrophages demonstrated 
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increased hepatic expression of both macrophage (MCP-1, MIP1α) (Fallowfield et al. 2007) 
and neutrophil (MIP2, KC) chemokines after cell injection (Thomas et al. 2011).   
TWEAK, secreted by macrophages (Bird et al. 2013) induces myofibroblast apoptosis and 
stimulates hepatic progenitor cell activation(Kallis et al. 2011).  This occurs following bone 
marrow cell injection even in normal liver and represents a potential mechanism for effect 
either directly through HSC secretion of TWEAK or indirectly through the recruitment of 
increased numbers of macrophages.   
IL-10, an anti inflammatory cytokine which also promotes ECM breakdown (Cheong et al. 
2006), was elevated in patients with liver disease who had received bone marrow cell 
infusion and was associated with a reduction in TGFβ and IL-6(Suh et al. 2012). Subsequently 
the same study demonstrated that bone marrow cells from IL-10 knockout mice had no 
effect on hepatic fibrosis, despite upregulation of MMP9 and MMP 13, whereas wild type 
bone marrow improved fibrosis (Suh et al. 2012). Treatment with bone marrow derived stem 
cells with adenoviral induced expression of IL-10 in rats with liver injury suppressed 
inflammation, reduced myofibroblast activation and resulted in an improvement in liver 
function(Lan et al. 2008). 
The mechanisms by which HSC induce resolution of fibrosis, are therefore, likely to be 
multifactorial and involve complex interactions between signalling molecules rather than an 
individual signal.  Future studies should examine the repertoire of signalling molecules, such 
as chemokines and cytokines, secreted by HSC in response to liver injury and studies using 
cells from appropriate knock out mice may help clarify the role of individual molecules. 
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7.5 Role of S1P in Liver Injury 
The increased S1P concentration and upregulation of hepatic sphingosine kinase observed in 
this work has previously been described in various models of murine liver injury.  I confirmed 
that similar changes in enzyme expression can be seen in human liver injury, however 
further evaluation in serum S1P levels should be considered as it has been reported that 
serum S1P levels in patients with hepatitis C cirrhosis were lower than healthy controls 
(Ikeda et al. 2010).  
The significance of the alterations in S1P related to cellular trafficking and stem cell 
mobilisation have been discussed, although the significance of S1P in the development of 
fibrosis requires further study. 
A possible role for S1P in the development of fibrosis has been suggested by Li and 
colleagues following observations that the S1P3 receptor mediates both myofibroblast and 
mesenchymal stem cell migration and treatment with a selective S1P3 antagonist reduced 
myofibroblast activation and hepatic fibrosis(Li et al. 2009; Li et al. 2009). A direct effect of 
S1P in stimulating hepatic stellate cell motility and proliferation has been shown and 
myofibroblast activation was reduced and hepatocyte proliferation increased in S1P2 
receptor knock out rats with liver injury, whilst no S1P induced proliferation was seen in 
S1P2 knockout myofibroblasts in vitro.(Ikeda et al. 2000; Ikeda et al. 2009). The importance 
of S1P2 receptor signalling in the development of hepatic fibrosis was also proposed by 
studies showing reduced αSMA gene expression together with a reduction in TIMP-1 and 
TGFβ in S1P2 knock out mice with liver injury. (Serriere-Lanneau et al. 2007). In a rat study 
S1P2 was shown to mediate an increase in portal pressure through contractility of 
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myofibroblasts(Ikeda et al. 2004).  Furthermore the existence of  a feedback loop whereby 
S1P2 signalling by exogenous S1P upregulates sphingosine kinase 1 expression and results in 
increased exogenous S1P, was proposed by the observation that sphingosine kinase 1 was  
downregulated in S1P2 knockout mice (Serriere-Lanneau et al. 2007).    
The observations from this work show that FTY720 treatment alone did not affect hepatic 
fibrosis. However, FTY720 has been shown to be beneficial in injury to other organs, and 
may be explained by factors such as those relating to choice of dose and timing of 
administration in relation to onset of injury. However, the previously described importance 
of S1P2 and S1P3 signalling in the development of hepatic fibrosis may also explain these 
findings. FTY720 is an S1P receptor functional antagonist with no activity on the S1P2 
receptor and with markedly less activity on the S1P3 receptor than the S1P1 receptor 
(Brinkmann et al. 2002), and it is possible that an increasing the dosage of FTY720 would 
activate S1P2 and S1P3 as well as S1P1. 
Endothelial cells are a significant source of extracellular S1P, particularly within the vascular 
and lymphatic circulation (Venkataraman et al. 2008).  I have demonstrated for the first time 
a significant expression of sphingosine kinase 1 in liver sinusoidal endothelial cells(LSEC) and 
in particular the preferential upregulation of sphingosine kinase 1 in LSEC during liver injury 
compared with hepatocytes and mononuclear cells.  Sinusoidal endothelial cells are 
activated by cytokines produced during liver injury such as TNFα, inducing changes in 
adhesion molecule expression and modulating cell recruitment (Lalor et al. 2002).  Increased 
S1P production through stimulation of sphingosine kinase activity is also mediated through 
TNFa(Xia et al. 1998) and other stimulants of sphingosine kinase include PDGF, NGF, EGF, 
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FGF, VEGF, IL1b and LPS – all of which may be upregulated within the liver during liver 
injury(Takabe et al. 2008). Further examination of the specific role of these cytokines in the 
upregulation of Sphingosine kinase in sinusoidal endothelium may help better understand 
the role of S1P in the pathogenesis of hepatic fibrosis. 
Cells other than those of the liver that may contribute to the increase in S1P seen in both 
serum and liver during liver injury include platelets and peripheral blood mononuclear 
cells(Iannacone et al. 2005; Oo et al. 2010). Platelets in particular possess large intracellular 
stores of S1P which can be released upon activation(Yatomi et al. 1997; Yang et al. 1999), as 
has been demonstrated in models of cardiac injury.  Platelets are recruited to the liver, 
particularly during the development of immune mediated liver damage(Iannacone et al. 
2005), and this may represent a source of increased S1P during liver injury.  Peripheral blood 
mononuclear cells express high levels of sphingosine kinase, although this data suggests a 
lack of upregulation during liver injury. This is supported the observation that peripheral 
blood mononuclear cells do not secrete S1P in response to stimulation in vitro (Yatomi et al. 
1997), however increased numbers of mononuclear cells are found within the liver during 
injury and may contribute to increased S1P.  Further investigation could involve generation 
of bone marrow chimerism using bone marrow from sphingosine kinase knock out mice to 
study the contribution of sphingosine kinase and S1P derived from haematopoietic cells to 
liver and serum S1P during liver injury.  Ultimately this may also help determine whether S1P 
derived from extra hepatic cells, particularly in the case of platelets, contributes to the 
progression of fibrosis. 
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7.6 The Effect of FTY720 on HSC Trafficking and  Enhancing the Anti Fibrotic Effect 
Observations from these studies suggested a role for S1P in the mobilisation of HSC from the 
bone marrow during liver injury, and whilst administration of FTY720 resulted in 
accumulation of HSC within the injured liver this was not mediated by altered HSC 
recruitment.  These findings, together with those of Massberg, lead me to study the effect of 
FTY720 on the fate of injected HSC. 
The findings from the therapeutic studies of repeated HSC injection demonstrating an anti 
fibrotic effect suggested that injection of cells into a peripheral vein did not prevent efficacy.  
Previous studies had suggested that injected cells may become trapped in the pulmonary 
vascular bed, thus hindering their homing to injured organs (Kavanagh et al. 2010).  In this 
comprehensive study I have shown that accumulation of injected cells does occur initially in 
the lungs, cells quickly dissipated and ongoing recruitment was seen in the liver and spleen 
at subsequent timepoints.  This pattern of tissue distribution is similar to that seen with 
injections of other cell populations, such as dendritic cells (personal communication, Dr 
Stuart Curbishley). 
Increased accumulation of endogenous HSC during liver injury following FTY720 treatment 
within the liver was demonstrated in this study and confirmed the findings in normal 
mice(Massberg et al. 2007).  For the first time I show that a similar phenomenon is observed 
with injected HSC, the findings at multiple timepoints using the HPC-7 cell line were 
confirmed with injection of KSL cells at a single timepoint.  This provides encouraging 
evidence for the concept of optimising the beneficial effects of this rare population of cells 
(Fig 7.2). 
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Figure 7.2 Proposed Mechanisms Mediating and Augmenting the Anti Fibrotic Effect of 
HSC 
(A)  The observed effects of injected HSC include a reduction in hepatic collagen, reduced 
myofibroblast activation and recruitment of F4/80+ and Ly6G+ cells.  Egress of HSC from the 
liver is mediated by migration across an S1P gradient between liver and draining lymphatics, 
followed by bone marrow homing and tissue recirculation (Massberg et al 2007). 
(B) FTY720 administration does not alter recruitment of injected HSC to the liver, however 
increased numbers of injected HSC accumulate within the liver as a result of reduced surface 
expression of S1P1 receptor rendering HSC less responsive to the S1P gradient meditating 
egress from the liver.  The increased numbers of injected HSC within the liver are associated 
with further reductions in hepatic collagen and myofibroblast activation. 
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When designing these studies, the dose of FTY720 administered was the same as that used 
in previous studies which involved normal mice rather than those with liver injury and the 
frequency of administration was chosen predominantly for practical purposes to allow 
consistency throughout treatments.  Given that this approach to FTY720 dosing resulted in 
no change in numbers of HSC within the peripheral blood during liver injury rather than the 
marked reduction seen in normal mice (Massberg et al. 2007; Juarez et al. 2012) it is possible 
that this did not represent an optimum strategy.   Further investigation of the effects of 
alternative FTY720 dosing strategies will determine whether this effect could be further 
enhanced. 
The ultimate aim of increasing the numbers of injected KSL cells within the liver was to 
improve upon the therapeutic effect.   In general these studies provide ‘proof of concept’ for 
this approach.  Although not all markers of fibrosis significantly improved, this may be in part 
due to insufficient sample sizes to allow confirmation of this effect.  As previously discussed 
the dosing regime for FTY720 could be examined in more detail.   I propose that the 
observations from these studies demonstrate that administration of FTY720 results in 
increased hepatic accumulation of injected KSL cells resulting in an enhanced anti fibrotic 
effect, particularly as administration of FTY720 alone had no effect on hepatic fibrosis. These 
findings suggest that there may be a relationship between the number of cells injected (and 
thus the number of cell engrafting the liver) and the therapeutic effect observed.   It remains 
unclear whether there is an optimum ‘dose’ of cells, above which no further effect is seen.  
Two studies using 1x106 KSL cells demonstrated a reduction in picosirius red staining (Cho et 
al. 2011, Li et al. 2013)whilst I demonstrated a reduction in this study using 5x104 KSL cells 
on 3 occasions.  Although the experimental design of all three studies varied and it is not 
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clear whether there is a continual relationship between number of cells injected and anti 
fibrotic effect observed, or whether a ‘plateau effect’ exists whereby any further increases in 
cell numbers does not increase the anti fibrotic effect.  Further studies utilising different 
experimental protocols are required to determine the optimum strategy for cell 
administration and the role of FTY720 in maximising this effect. 
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7.7 Proposed Future Work 
The work presented in this study has demonstrated the anti fibrotic effect of repeated 
injections of purified HSC, together with the observations that modulation of S1P receptor 
signalling with FTY720 increases the number of injected cells within the injured liver and 
augments the anti fibrotic effect.  These studies were designed to help inform and optimise 
the use of HSC as a therapy for liver disease, however I would propose that there are three 
key areas worthy of further study to understand better the therapeutic role of HSC in liver 
repair: i)an improved understanding of the molecular and cellular mechanisms responsible 
for the observed anti fibrotic effect, ii) determination of the optimum regime for cell therapy 
(numbers of cells to infuse and frequency of administration) and iii) further validation of the 
role of S1P receptor signalling in HSC trafficking during liver injury. 
This work was designed to demonstrate the anti fibrotic effect of HSC, and although not 
specifically designed to determine the mechanisms responsible has suggested that paracrine 
mechanisms are involved.   A greater understanding of the mechanism of action involved in 
liver repair after HSC injection will help with developing their use as a clinical therapy.   I 
would propose further in vitro experiments to investigate the profile of cytokines, 
chemokines and growth factors synthesised and secreted by HSC (for example,  IL-10 has 
been described as a potential anti fibrotic cytokine (Huang et al. 2006)).   
I have performed some initial experiments using qPCR to examine the gene expression 
profile of a panel of cytokines, chemokines and growth factors expressed by HSC, however 
this preliminary data requires replication and further validation. This approach could be 
followed by the quantitative analysis of such molecules secreted by HSC into conditioned 
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media, using a multiplex array approach.  Subsequent experiments would examine 
alterations in the expression profile following stimulation of HSC by cytokines, such as TGFβ, 
present during liver injury, with the aim of identifying potential targets for further study.   
Although the mechanisms underlying the anti fibrotic effect are likely to be multifactorial the 
role of individual molecules could be studied by repeating this experimental protocol using 
either HSC isolated from knockout mice deficient in the molecule of interest or by in vitro 
genetic manipulation of wild type HSC (eg viral transduction of shRNA coding for the gene of 
interest). 
Further in vitro investigation of the effects of HSC on myofibroblast activation using co-
culture models would be of value. In particular, determining whether the effect of HSC on 
myofibroblasts alters following stimulation of HSC.  The effect of HSC conditioned media 
alone, rather than direct cell contact, induces similar effects on myofibroblast activation 
could also be studied.    
This study demonstrated the beneficial anti fibrotic effect of three injections of 50,000 HSC, 
this experimental approach was selected for reasons of practicality and clinical applicability.  
There does remain uncertainty as to the optimum approach for cell administration, 
particularly the optimum number of cells to inject and the frequency and timing of injections 
to maximise the therapeutic effect.  I would propose similar experimental protocols as used 
in this work to examine the effect of varying concentrations of cells in injections on hepatic 
fibrosis and of alternative timings and frequency of cell delivery.  As I have previously 
described HSC are a rare population of cells, so significant benefits may be gained from 
seeking to maximise their therapeutic effect and avoiding superfluous use of cells.    
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It is also worth noting that in this study the injected HSC were harvested from mice without 
liver injury, however clinical applications of stem cell therapy rely on use of autologous cells 
harvested from patients with liver disease.  A recent animal study has suggested that 
injecting bone marrow cells harvested from animals with liver injury does not improve 
hepatic fibrosis(Mannheimer et al. 2011).   Future studies could address this in more detail 
by isolating HSC from mice with chronic carbon tetrachloride liver injury and determining 
whether the anti fibrotic effect is reduced or lost altogether. 
The findings from this work suggest that administration of FTY720 results in increased 
accumulation of injected cells within the injured liver through modulation of S1P signalling at 
the S1P1 receptor.  I would propose that further study of this is required to validate this 
proposed mechanism.   
Systemic injection of FTY720 may induce confounding effects, such as alterations in 
lymphocyte migration, that modulate the trafficking of HSC through alternative mechanisms.  
As the effect of FTY720 on HSC is to render the cells unresponsive to the effects of S1P, I 
questioned whether a similar effect would be observed in HSC that did not express S1P1 
receptors.  The S1P1 knockout mouse is embryonically lethal at day 14.5, and therefore I 
attempted to use a lentivirally delivered shRNA vector to knockdown S1P1 on HSC.  
Unfortunately I was unable to succeed with this approach although further optimisation may 
be possible. An alternative approach would be the use of HSC isolated from fetal liver of 
S1P1 knockout mice to study this in greater detail and clarify the role of S1P1 in the 
trafficking of injected HSC. 
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7.8 Implications for Clinical Studies 
There have been many reports of clinical studies describing the use of bone marrow stem 
cells and haematopoietic stem cells in patients with chronic liver disease (Fig 1.5).  These 
have predominantly involved small numbers of patients and made no comparisons with 
untreated controls.  The general message from these studies is that stem therapy appears to 
be a safe and feasible therapeutic option, however efficacy has yet to be proven.   There is a 
clear need for larger, randomised, controlled studies of stem cell therapy for liver disease. 
 The work performed in this study was designed to have some relevance to clinical 
applications, demonstrating the anti fibrotic effect of small numbers of purified HSC injected 
into a peripheral vein.  This approach is clinically relevant and is currently being studied in a 
large clinical trial which I helped design, set up and manage. 
The REALSTIC (Repeated Autologous Infusions of Stem cells In Cirrhosis) trial is the first 
phase II, randomised, controlled trial of autologous CD133 stem cells in patients with liver 
disease.  In this trial CD133+ haematopoietic stem cells are isolated from the peripheral 
blood of patients with cirrhosis by leukopheresis following administration of the mobilising 
cytokine Granulocyte Colony Stimulating Factor (G-CSF).  Using Good Manufacturing Practice 
(MHRA, UK) compliant immunomagnetic separation techniques, a population of CD133+ 
bone marrow cells which are highly enriched for haematopoietic stem cells is isolated.  
These cells are then injected back to the patient through a peripheral vein on 3 occasions at 
monthly intervals.   Patients enrolled in the trial are randomised to one of three treatment 
groups – a control group receiving standard care, a group receiving G-CSF alone and a group  
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Figure 7.3 Overview of the REALISTIC Trial 
Schematic representation of the REALISTIC trial design. Inclusion criteria for the trial include 
MELD score 12-15 and the presence of compensated cirrhosis, certain liver diseases such as 
autoimmune hepatitis and primary sclerosing cholangitis are excluded.  Recruited patients 
are randomised into one of three trial groups – a control group receiveing standard care 
alone, treatment group 1 receiving G-CSF treatment alone and treatment group 2 receving 
G-CSF followed by leukopheresis, CD133 cell isolation and repeated cell reinfusion.  The 
primary outcome measure of change in MELD score is determined at day 90, secondary 
outcome measures include non invasive markers of liver fibrosis (ELF, FIbroscan) and quality 
of life scores (CLDQ).(MELD Model for End stage Liver Disease, ELF Enhanced Liver Fibrosis 
test, QoL Quality of Life, GCSF Granulocyte Colony Stimulating Factor, SC Subcutaneous). 
 
 
 
 
Recruitment : MELD 12-15, Compensated Cirrhosis, Aetiology*
Randomisation : Stratified by Site
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receiving G-CSF and cell injections(Fig 7.1).  The inclusion of a group receiving G-CSF alone is 
to control for the effects of stem cell mobilisation alone being the beneficial mechanism.  
 The aim of this trial is to demonstrate the beneficial effects of CD133 stem cell therapy in 
liver disease compared with standard treatment which will be determined by the primary 
outcome measure at day 90 after enrolment.  The choice of primary outcome measure is 
vital as it is this which will determine the relative success or failure of a study.   Many of the 
small studies to date have reported biochemical data, such as improvements in serum 
albumin levels, and whilst these are encouraging give little indication of the effect of therapy 
on prognosis or survival.  Histological markers again provide useful quantitative data when 
analysing efficacy but are not validated as markers of liver related complications or survival.  
Transplant free survival is clearly the most definitive outcome measure, but patients with 
compensated cirrhosis have 1 and 2 year survival rates of 95 and 90%(D'Amico et al. 2006) 
and may require studies with large numbers of participants over long time periods to detect 
significant benefit.  Prognostic scoring systems, such as the Model for End stage Liver 
Disease (MELD) score, have been long established in hepatology for predicting 
survival(Malinchoc et al. 2000; Ripoll et al. 2007).  The MELD score is calculated from 
laboratory measurements of serum bilirubin, serum creatinine and international normalised 
ratio (INR) (http://optn.transplant.hrsa.gov/resources/MeldPeldCalculator). The MELD score 
represents a standardised, easily obtainable outcome measure that has been validated to 
predict survival.  Of particular relevance to clinical trials is emerging evidence that the 
change in MELD score (deltaMELD) between timepoints is of greater prognostic significance 
than the absolute MELD score(Bambha et al. 2004; Huo et al. 2005).  The primary outcome 
measure used in the REALISTIC trial is the change in MELD score between day 0 and day 90, 
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the trial is powered to detect a difference in change in MELD score between groups of 1.0 
thus requiring sample sizes of 27 participiants per treatment group.  Secondary outcome 
measures used include non invasive markers of hepatic fibrosis (transient elastography 
(Fibroscan) and serum markers (ELF test)), a further prognostic scoring system for liver 
disease (United Kingdom model for End stage Liver Disease, UKELD) and quality of life 
assessment (CLDQ questionnaire). 
The work in this thesis has demonstrated the dynamics of tissue distribution of injected cells 
following peripheral vein injection.  My work suggests that peripheral vein injection is a valid 
approach to cell delivery and that the need to inject cells via the hepatic artery or portal 
vein, which is technically difficult and carries significant risk, is not required.  There have 
been no studies in patients examining in detail the fate of injected cells and further clinical 
studies addressing this issue are required.  Techniques that could be utilised include 
radionucleotide labelling of cells with whole body nuclear imaging, or newer techniques such 
as magnetic resonance imaging (MRI), in conjunction with super paramagnetic iron oxide 
(SPIO) labelling of cells, which may provide the accuracy and definition to trace relatively 
small numbers of in injected cells. 
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7.9 Final Conclusions 
This thesis contains the novel findings that repeated injections of purified c-kit+ sca1+ 
lineage- haematopoietic stem and progenitor cells, delivered via a peripheral vein exert a 
significant anti fibrotic effect in a murine model of liver injury.  This provides encouraging 
evidence for their use in human studies.  Although not designed to investigate the 
mechanisms mediating this effect, these data would suggest that a paracrine mechanism 
stimulating endogenous repair is involved and propose further study in this area. 
Furthermore I also propose a mechanism by which the therapeutic efficacy of these cells can 
be enhanced.  Sphingosine 1-phosphate regulates both the egress of HSC from tissues into 
the draining lymphatics and also stimulates mobilisation of HSC from the bone marrow.  As 
demonstrated here, alterations seen in liver injury may be involved in liver injury induced 
HSC mobilisation.  FTY720 resulted in an increase in the number of injected HSC within the 
liver and improved the therapeutic effect.  I propose that this mechanism may warrant 
further investigation as a means of optimising cell therapy. 
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